

**SWOG
PUBLICATIONS LIST
LEUKEMIA COMMITTEE
2017**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
LEUKEMIA MANUSCRIPTS PUBLISHED/ACCEPTED (2017)			
S0333	Next-generation sequencing in adult B cell acute lymphoblastic leukemia patients. O Sala Torra, M Othus, D Williamson, B Wood, I Kirsch, H Robins, L Beppu, M O'Donnell, S Forman F Appelbaum, J Radich. <u>Biology of Blood and Marrow Transplantation</u> Apr;23(4):691-696; Epub 2017 Jan 3. PMID28062215; PMC5465962 https://www.ncbi.nlm.nih.gov/pubmed/28062215	4/15/05	11/01/09
S1117	A randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat vs. azacitidine monotherapy in higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia CMML): North American Intergroup Study SWOG S1117. MA Sekeres, M Othus, A List, O Odenike, R Stone, SD Gore, M Litzow, R Buckstein, M Fang, D Roulston, C Bloomfield, A Moseley, Y Zhang, M. Velasco, R Gaur, E Atallah, EC Attar, F Appelbaum, H Erba. <u>Journal of Clinical Oncology</u> Aug 20;35(24): 2745-2753, 2017. 2017 May 9. [Epub ahead of print]. PMID 28486043 https://www.ncbi.nlm.nih.gov/pubmed/28486043	3/1/12	11/14/14
C10603	Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. RM Stone, SJ Mandrekar, BL Sanford, K Laumann, S Geyer, CD Bloomfield, C Thiede, TW Prior, K Döhner , G Marcucci, F Lo-Coco, RB Klisovic, A Wei, J Sierra, MA Sanz, JM Brandwein, T de Witte, D Niederwieser, FR Appelbaum, BC Medeiros, MS Tallman, J Krauter, RF Schlenk, A Ganser, H Serve, G Ehninger, S Amadori, RA Larson, H Döhner. <u>New England Journal of Medicine</u> Aug 3;377(5):454-464, 2017. PMID: 28644114 https://www.ncbi.nlm.nih.gov/pubmed/28644114		
CALGB Multiple*	An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia. W Stock, B Diouf, KR Crews, D Pei, C Cheng, K Laumann, S Mandrekar, S Luger, A Advani, RM Stone, RA Larson MD, WE Evans. <u>Clinical Pharmacology and Therapeutics</u> 2017 Mar;101(3):391-395. doi: 10.1002/cpt.506. Epub 2016 Nov 16. *Studies C19802, C10403, C10102, C9862. PMID27618250; PMC5320866 https://www.ncbi.nlm.nih.gov/pubmed/27618250	n/a	n/a
Multiple*	Prognostic methylation markers for survival in cytogenetically normal AML patients treated on SWOG trials. X Qu, M Othus, J Davison, Y Wu, L Yan, E Estey, J Radich, H Erba, FR Appelbaum, M Fang. <u>Cancer</u> Jul 1;123(13):2472-2481, 2017. Feb 21 [Epub ahead of print]. PMID28222251 https://www.ncbi.nlm.nih.gov/pubmed/28222251 *studies: S8600, S9333, S9031, S9500, S9918, S0106, S0112.	n/a	n/a

Multiple* Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. S Mantha, DA Goldman, SM Devlin, J-W Lee, D Zannino, M Collins, D Douer, HJ Iland, MR Litzow, EM Stein, FR Appelbaum, RA Larson, R Stone, BL Powell, S Geyer, K Laumann, JM Rowe, H Erba, S Coutre, M Othus, JH Park, PH Wiernik, MS Tallman. Blood Mar 30;129(13):1763-1767, 2017. 2017 Jan 12 [Epub ahead of print]. PMID28082441; PMC5374291 [*studies S0521, E2496, C9710]
<https://www.ncbi.nlm.nih.gov/pubmed/28082441>

LEUKEMIA MANUSCRIPTS SUBMITTED (2017)

S0106_E1900 Higher clinical trial accrual volume improves outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN Study. BC Medeiros, M Othus, MS Tallman, Z Sun, HF Fernandez, JM Rowe, HM Lazarus, FR Appelbaum, SM Luger, MR Litzow, HP Erba. Haematologica, submitted.

S0919 Report of the relapsed/ refractory cohort of SWOG S0919: a phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia. AS Advani, Hongli Li, LC Michaelis, BC Medeiros, M Liedtke, AF List, K O'Dwyer, M Othus, HP Erba, FR Appelbaum. Blood Advances, submitted.

S1612 Title: Intergroup LEAP Trial (S1612): A Randomized Rolling- pending activation Arms Platform to Test Therapeutics in Less-Fit Older Adults with AML. RB Walter, LC Michaelis, M Othus, GL Uy, JP Radich, RF Little, S Hita, L Saini, JM Foran, AT Gerds, HD Klepin, AE Hay, JE Lancet, S Couban, MR Litzow, RM Stone, HP Erba. Blood, submitted 7/19/17.

Multiple* Impact of specimen heterogeneity on biomarkers in repository samples from patients with AML: a SWOG report. E Pogossova-Agadjanyan, A Moseley, M Othus, FR Appelbaum, T Chauncey, I-M L Chen, HP Erba, JE Godwin, M Fang, K Kopecky, AF List, GL Pogosso, JP Radich, CL Willman, BL Wood, S Meshinchi, DL Stirewalt. Biopreservation and Biobanking, submitted 8/16/17. [*S9031, S9333, S0106, S0112]

LEUKEMIA ABSTRACTS PUBLISHED/PRESENTED/ACCEPTED (2017)

C10404 A genetic risk-stratified, phase II study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): final results of Cancer and Leukemia Group B (CALGB) 10404. AS Ruppert, JC Byrd, NA Heerema, M Smith, J Godwin, S Couban, TA Fehniger, M Thirman, AE Halvorson, BL Peterson, MS Tallman, FR Appelbaum, RM Stone, Sumithra J. Mandrekar, Richard A. Larson. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral presentation. J Clin Oncol 35, 2017 (suppl; abstr 7503).
http://abstracts.asco.org/199/AbstView_199_192498.html

**SWOG
PUBLICATIONS LIST
LEUKEMIA COMMITTEE
2016**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
LEUKEMIA MANUSCRIPTS PUBLISHED (2016)			
S0106	Effect of measurable ("minimal") residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia. M Othus, BL Wood, EH Estey, SH Petersdorf, Frederick R. Appelbaum, HP Erba, RB Walter. <i>Leukemia</i> , Oct;30(10):2080-2083, 2016; 2016 May 2 [Epub ahead of print]. PMID27133827; PMC5053842 http://www.ncbi.nlm.nih.gov/pubmed/2713382	7/1/93	11/15/97
S0703	Association between early DNA methylation changes and outcome in older patients with acute myeloid leukemia treated on SWOG S0703. NJ Achille, M Othus, K Phelan, S Zhang, K Cooper, JE Godwin, FR Appelbaum, JP Radich, HP Erba, S Nand, NJ Zeleznik-Le. <i>Leukemia Research</i> , Mar;42:68-74, 2016. PMID: 26818573; PMC4779662 http://www.ncbi.nlm.nih.gov/pubmed/26818573	12/1/08	6/1/12
S0805	US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. F Ravandi, M Othus, SM O'Brien, SJ Forman, CS Ha, JY Wong, MS Tallman, E Paietta, J Racevskis, GL Uy, M Horowitz, N Takebe, R Little, U Borate, P Kebriaei, L Kingsbury, HM Kantarjian, JP Radich, HP Erba, FR Appelbaum. <i>Blood Advances</i> , Dec 27; 1(3):250-259, 2016. (pending posting on PubMed)	9/1/09	10/1/13
E1905	Azacitidine with or without entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. T Prebet, Z Sun, RP Ketterling, A Zeidan, P Greenberg, J Herman, M Juckett, MR Smith, L Malick, E Paietta, M Czader, M Figueroa, J Gabrilove, HP Erba, MS Tallman, M Litzow, SD Gore. 2016 Feb;172(3):384-91. <i>British Journal of Haematology</i> , Feb;172(3):384-391, 2016. PMID26577691; PMC4794257 http://www.ncbi.nlm.nih.gov/pubmed/26577691	10/1/06	n/a
E1908	A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). CS Zent, XV Wang, RP Ketterling, CA Hanson, EN Libby, JC Barrientos, TG Call, JE Chang, JJ Liu, AR Calvo, HM Lazarus, JM Rowe, SM Luger, MR Litzow, and MS Tallman. <i>American Journal of Hematology</i> Mar;91(3):308-312, 2016. PMID26662208; PMC4806550 http://www.ncbi.nlm.nih.gov/pubmed/26662208	11/15/10	10/31/13
Multiple*	Relation between event-free survival and overall survival in acute myeloid leukemia: A report from SWOG, HOVN/SAKK, and MRC/NCRI. M Othus, W van Putten, B Lowenberg, SH		

Petersdorf, S Nand, H Erba, F Appelbaum, R Hills, N Russell, A Burnett, E Estey. *includes other groups/institutions, as well as SWOG studies S0106, S0703. *Haematologica*, Jul;101(7): e284-286, 2016. 2016 Mar 24. [Epub ahead of print]. PMID27013652; PMC5004473
<http://www.ncbi.nlm.nih.gov/pubmed/27013652>

Multiple* Prediction of CR following a second course of "7+3" in patients with newly diagnosed acute myeloid leukemia not in CR after a first course. M Othus, S Mukherjee, MA Sekeres, J Godwin, S Petersdorf, F Appelbaum, H Erba, Eli Estey. *Leukemia*, Aug;30(8):1779-80, 2016. 2016 Feb 29 [Epub ahead of print]. PMID27055872; PMC4980556
 *Studies: S0106, S8600, S9031, S9333.
<http://www.ncbi.nlm.nih.gov/pubmed/27055872>

LEUKEMIA ABSTRACTS PUBLISHED/PRESENTED (2016)

S0106_other*	G-CSF, cladribine, cytarabine, and dose-escalated mitoxantrone (G-CLAM) in adults with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS): final results from a phase 1/2 study. AB Halpern, EH Estey, EM Huebner, M Othus, KF Orlowski, BL Scott, HA Smith, PS Becker, M-B M Percival, PC Hendrie, AM Perdue, TL Chen, SA Buckley, HP Erba, RB Walter. American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral; <i>Blood</i> 128:1068, 2016. http://www.bloodjournal.org/content/128/22/1068 *(FHCRC G-CLAM trial)	n/a	n/a
S0535	ATRA, arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO) is safe and highly effective in patients with previously untreated high-risk acute promyelocytic leukemia (APL): final results of the SWOG/Alliance/ECOG S0535 trial. JE Lancet, A Moseley, R Komrokji, SE Coutre, D DeAngelo, M Tallman, MR Litzow, M Othus, FR Appelbaum. American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral; <i>Blood</i> 128:896, 2016. http://www.bloodjournal.org/content/128/22/896	11/15/07	6/1/13
S1203	SWOG S1203: A randomized phase III study of standard cytarabine plus daunorubicin (7+3) therapy versus idarubicin with high dose cytarabine (IA) with or without vorinostat (IA+V) in younger patients with previously untreated acute myeloid leukemia (AML). G Garcia-Manero, M Othus, JM Pagel, JP Radich, M Fang, DA Rizzieri, G Marcucci, SA Strickland, MR Litzow, ML Savoie, BC Medeiros, MA Sekeres, TL Lin, G Uy, BL Powell, JE Kolitz, R. Larson, RM Stone, D Claxton, J Essell, SM Luger, SR Mohan, A Moseley, FR Appelbaum, HP Erba, American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral; <i>Blood</i> 128:901, 2016. http://www.bloodjournal.org/content/128/22/901	12/15/12	11/4/15
S1203	Feasibility of allogeneic hematopoietic cell transplantation among high-risk AML patients in first complete remission: results of the transplant objective from the SWOG (S1203) randomized phase III study of induction therapy using standard 7+3 therapy or idarubicin with high-dose cytarabine (IA) versus IA plus vorinostat. JM Pagel, M Othus, G Garcia-	12/15/12	11/4/15

	Manero, M Fang, JP Radich, DA Rizzieri, G Marcucci, SA Strickland, MR Litzow, ML Savoie, SR Spellman, DL Confer, JW Chell, M Brown, BC Medeiros, MA Sekeres, TL Lin, G Uy, BL Powell, JE Kolitz, RA Larson, RM Stone, D Claxton, J Essell, SM Luger, SR Mohan, A Moseley, HP Erba, FR Appelbaum. American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral; <u>Blood</u> 128:1166, 2016. http://www.bloodjournal.org/content/128/22/1166		
S1312	A Phase 1 trial of inotuzumab in combination with CVP (cyclophosphamide, vincristine, prednisone) for relapsed/refractory CD22+ acute leukemia (SWOG 1312). A Advani, A Moseley, M Liedtke, M O'Donnell, M Othus, M Mims, K O'Dwyer, HP Erba. American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster; <u>Blood</u> 128:1634, 2016. http://www.bloodjournal.org/content/128/22/1634	4/1/04	n/a
Multiple*	Improved prognostic significance genomic and transcriptional prognostic biomarkers by examining enriched populations of AML blasts: a SWOG report. EL Pogossova-Agadjanyan, A Moseley, B Wood, FR Appelbaum, TR Chauncey, HP Erba, J Godwin, M Fang, KJ Kopecky, AF List, M Othus, JP Radich, I-M Chen, CL Willman, S Meshinchi, DL Stirewalt.. American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster; <u>Blood</u> 128:2890, 2016. http://www.bloodjournal.org/content/128/22/2890 *Studies S9031-9333-0106-0112	n/a	n/a
Multiple*	Complete remissions (CRs) with azacitidine regimens compared to CRs with 7+3 induction chemotherapy and the effect on overall survival. M Othus, M Sekeres, S Nand, G Garcia-Manero, FR Appelbaum, HP Erba, Eli Estey. American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster. <u>Blood</u> 128:1613, 2016. http://www.bloodjournal.org/content/128/22/1613 *Studies: S0106, S0703, S1117, S1203.	n/a	n/a
Multiple*	Comparable outcomes of patients eligible versus ineligible for SWOG leukemia studies. A Statler, M Othus, H Erba, T Chauncey, J Radich, S Coutre, AS Advani, S Nand, F Ravandi, S Mukherjee, MA Sekeres. American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster; <u>Blood</u> 128:4002, 2016. http://www.bloodjournal.org/content/128/22/4002 *Studies: S0106, S0301, S0325, S0333, S0432, S0521, S0530, S0605, S0703, S0805, S0910, S0919, S1117	n/a	n/a
C10701	A phase II study of dasatinib and dexamethasone as primary therapy followed by hematopoietic cell transplantation for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: CALGB Study 10701 (Alliance). MJ Wieduwilt, J Yin, M Wetzler, G Uy, BL Powell, J Kolitz, M Liedtke, W Stock, JH Beumer, RJ Mattison, A Halvorson, S Devine, RM Stone, RA Larson. American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster; <u>Blood</u> 128:2782, 2016. http://www.bloodjournal.org/content/128/22/2782?sso-checked=true	6/1/12	11/14/14

COG_S0106	Genomic subtypes of nucleophosmin (NPM1) mutations are associated with clinical outcome in AML – A COG and SWOG intergroup collaboration. D Selim, T Alonzo, M Othus, R Gerbing, F Ostronoff, K Tarlock, EM Kutny, R Aplenc, A Kolb, JP Radich, FR Appelbaum, A Gams, D Stirewalt, S Meshinchi. American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral; <u>Blood</u> 128:285, 2016. http://www.bloodjournal.org/content/128/22/285		
E1912	Association between mutations, biological and clinical parameters in untreated CLL. Data from the ECOG-E1912, randomized phase II study. E Braggio, S Garcia, V Wang, L Bruins, C Lesnick, R Fonseca, N Kay, S O'Brien, T Shanafelt. American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster; <u>Blood</u> 128:4373, 2016. http://www.bloodjournal.org/content/128/22/4373	2/15/14	n/a

**SWOG
PUBLICATIONS LIST
LEUKEMIA COMMITTEE
2015**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
LEUKEMIA MANUSCRIPTS PUBLISHED/ACCEPTED (2015)			
S0106	The fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. M Othus, FR Appelbaum, SH Petersdorf, KJ Kopecky, M Slovak, T Nevill, J Brandwein, RA Larson, PJ Stiff, RB Walter, MS Tallman, L Stenke, HP Erba. <u>Biology of Blood and Marrow Transplantation</u> , Mar;21(3):559-564, 2015. PMID: 25536215; PMC4386840 http://www.ncbi.nlm.nih.gov/pubmed/?term=othus+m+the+fate	7/1/93	11/15/97
S0106/other	Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. RB Walter, M Othus, B Löwenberg, GJ Ossenkoppele, SH Petersdorf, T Pabst, M-C Vekemans, FR Appelbaum, HP Erba, EH Estey. <u>Haematologica</u> Oct;100(10):e409-11, 2015. 2015 Jul 9 [Epub ahead of print]. PMID26160876; PMC4591777 http://www.ncbi.nlm.nih.gov/pubmed/?term=walter+rb+empiric	7/1/93	11/15/97
E2997	Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997. DM Lucas, AS Ruppert, G Lozanski, GW Dewald, A Lozanski, R Claus, C Plass, IW Flinn, DS Neuberg, EM Paietta, JM Bennett, DF Jelinek, JG Gribben, MA Hussein, FR Appelbaum, RA Larson, DF Moore Jr, MS Tallman, JC Byrd, MR Grever. <u>Leukemia & Lymphoma</u> 2015 Mar 30:1-7 [Epub ahead of print]. PMID25721902; PMC pending http://www.ncbi.nlm.nih.gov/pubmed/25721902	10/15/02	3/19/04
Multiple*	Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia. A Cesano, C Willman, K Kopecky, U Gayko, S Putta, B Louie, M Westfall, N Purvis, D Spellmeyer, C Marimpiketri, J Hackett, J Shi, M Walker, Z Sun, E Paietta, M Tallman, L Cripe, S Atwater, F Appelbaum, J Radich. <u>PLOS ONE</u> 2015 Apr 17;10(4):e0118485. doi: 10.1371/journal.pone.0118485. PMID25884949; PMC4401549. *Studies: S9031, S9333, S0112, S0301; E3993, E3999 http://www.ncbi.nlm.nih.gov/pubmed/25884949	n/a	n/a

Multiple*	Prognostic significance of NPM1 mutations in the absence of FLT3-Internal Tandem Duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. F Ostronoff, M Othus, A Burnett, E Estey, F Appelbaum, A Evans, J Godwin, A Gilkes, K Kopecky, M Lazenby, A List, V Oehler, M Fang, S Petersdorf, E Pogossova-Agadjanyan, J Radich, C Willman, S Meshinchi, D Stirewalt. <u>Journal of Clinical Oncology</u> , Apr 1;33(10):1157-1164, 2015; Epub 2015 Feb 23.PMID25713434; PMC437285. *studies: S0106, S9031, S9333, S9500. http://www.ncbi.nlm.nih.gov/pubmed/25713434	n/a	n/a
Multiple*	Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia. BC Medeiros, M Othus, M Fang, FR Appelbaum, HP Erba. <u>Haematologica</u> Mar; 100(3):331-335, 2015. PMID25527568; PMC4349271 *studies: S9031, S9333, S9333A, S0106, S0112, S0301, S9126, S9500-A, S9500-B, S9918. http://www.ncbi.nlm.nih.gov/pubmed/25527568	n/a	n/a

LEUKEMIA MANUSCRIPTS SUBMITTED (2015)

S0703	Association between early DNA methylation changes and outcome in older patients with acute myeloid leukemia treated on SWOG S0703. NJ Achille, M Othus, K Phelan, S Zhang, K Cooper, JE Godwin, FR Appelbaum, JP Radich, HP Erba, S Nand, NJ Zeleznik-Le. <u>Leukemia Research</u> , under review.	12/1/08	6/1/12
Multiple*	Prognostic methylation markers for survival in cytogenetically normal AML patients treated on SWOG trials. X Qu, M Othus, J Davison, Y Wu, L Yan, E Estey, J Radich, H Erba, FR Appelbaum, M Fang. <u>Blood</u> , submitted 12-8-15. *studies: S8600, S9333, S9031, S9500, S9918, S0106, S0112.	n/a	n/a

LEUKEMIA ABSTRACTS PUBLISHED/ACCEPTED (2015)

S0106	Effect of minimal residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia (SWOG S0106). M Othus, BL Wood, EH Estey, SH Petersdorf, Frederick R. Appelbaum, HP Erba, RB Walter. American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), poster presentation; <u>Blood</u> 126(23):2569, 2015. http://www.bloodjournal.org/content/126/23/2569	7/1/93	11/15/97
S0106 & COG	Defining the genomic make up of acute myeloid leukemia in adolescents and young Adults (AYA) – report from COG AAML03P1, AAML531 and SWOG S0106. F Ostronoff, TA Alonzo, M Othus, M Kutny, RB Gerbing, JP Radich, HP Erba, FR Appelbaum, AS Gamis, EA Kolb, DL Stirewalt, S Meshinchi. American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), poster presentation; <u>Blood</u> 2015 126(23):2576, 2015. http://www.bloodjournal.org/content/126/23/2576	7/1/93	11/15/97

S0106/Other	Phase 1 Trial of G-CSF, cladribine, cytarabine, and dose-escalated mitoxantrone (G-CLAM) in adults with newly diagnosed AML or high-risk MDS. A Anwar, AB Halpern, BL Scott, PS Becker, M Othus, PC Hendrie, EM Ranker, A Perdue, TL Chen, SA Buckley, KF Orlowski, MA Powell, EH Estey, RB Walter. European Hematology Association Annual Meeting (June 11-14, 2015, Vienna, Austria), poster presentation. http://learningcenter.ehaweb.org/eha/2015/20th/100715/asma.anwar.phase.1.trial.of-g-csf.cladribine.cytarabine.and.dose-escalated.html?f=l5512p16m3	7/1/93	11/15/97
S0535	Safety and tolerability of the combination of ATRA + Arsenic Trioxide (ATO) + Gemtuzumab Ozogamicin (GO) in high-risk acute promyelocytic leukemia (APL): initial report of the SWOG/Alliance/ECOG S0535 trial (NCT00551460). JE Lancet, M Othus, R Komrokji SE Coutre, D DeAngelo, M Tallman, MR Litzow, FR Appelbaum. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster discussion. J Clin Oncol 33:5s, 2015 (suppl; abstr 7016). http://abstracts.asco.org/156/AbstView_156_150829.html	11/15/07	6/1/13
S0703	Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients treated on SWOG S0703 (NCT00658814). S Nand, NJ Achille, M Othus, K Phelan, S Zhang, K Cooper, JE Godwin, FR Appelbaum, JP Radich, HP Erba, NJ Zeleznik-Le. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session. J Clin Oncol 33:5s (suppl; abstr 7060), 2015. http://abstracts.asco.org/156/AbstView_156_150661.html	12/1/08	6/1/12
S0805	Multi-center US intergroup study of intensive chemotherapy plus dasatinib followed by allogeneic stem cell transplant in patients with Philadelphia chromosome positive acute lymphoblastic leukemia younger than 60. F Ravandi, M Othus, SM O'Brien, SJ Forman, CS Ha, JYC Wong, M Tallman, Elisabeth Paietta, J Racevskis, GL Uy, U Borate, Partow, L Kingsbury, JP Radich, H Kantarjian, HP Erba, F Appelbaum. American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), oral presentation; Blood 126(23):796, 2015. http://www.bloodjournal.org/content/126/23/796	9/1/09	10/1/13
S0919	Report of the relapsed/refractory cohort of SWOG S0919: phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). AS Advani, H Li, LC Michaelis, BC Medeiros, M Liedtke, AF List, KM O'Dwyer, M Othus, HP Erba, FR Appelbaum. American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), poster; Blood 126(23):3803, 2015. http://www.bloodjournal.org/content/126/23/3803	8/15/09	n/a

S1117	Additional analyses of a randomized phase II study of azacitidine combined with lenalidomide or with vorinostat vs. azacitidine monotherapy in higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML): North American Intergroup Study SWOG S1117. MA Sekeres, M Othus, AF List, O Odenike, RiM Stone, SD Gore, MR Litzow, R Buckstein, M Fang, D Roulston, CD Bloomfield, Y Zhang, MR Velasco, R Gaur, E Atallah, EC Attar, FR Appelbaum, HP Erba. American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), oral; <u>Blood</u> 126(23):908, 2015. http://www.bloodjournal.org/content/126/23/908	3/1/12	11/14/14
C10603	The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (mut): an international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]). M Stone, S Mandrekar, BL Sanford, S Geyer, CD Bloomfield, K Dohner, C Thiede, G Marcucci, F Lo-Coco, RB Klisovic, A Wei, J Sierra, MA Sanz, JM Brandwein, T de Witte, D Niederwieser, FR. Appelbaum, BC Medeiros, MS Tallman, J Krauter, F Schlenk, A Ganser, H Serve, G Ehninger, S Amadori, RA Larson, H Dohner. American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), oral presentation; <u>Blood</u> 126(23):6, 2015. http://www.bloodjournal.org/content/126/23/6	2/1/09	10/15/11
E2902	Tipifarnib as maintenance therapy In acute myeloid leukemia (AML) improves survival in women with high risk disease. Results of the phase III intergroup trial E2902. S Luger, X Yao, E Paietta, R Ketterling, W Rybka, MR Litzow, JM Rowe, R Larson, F Appelbaum, MS Tallman. American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), poster presentation; <u>Blood</u> 126(23):1308, 2015. http://www.bloodjournal.org/content/126/23/1308	10/1/04	6/1/07
E2906	Phase III randomized trial of clofarabine as induction and post-remission therapy vs. standard daunorubicin & cytarabine induction and intermediate dose cytarabine post-remission therapy, followed by decitabine maintenance vs. observation in newly-diagnosed acute myeloid leukemia in older adults (Age>=60 Years): A trial of the ECOG-ACRIN Cancer Research Group (E2906). JM Foran, Z Sun, MS Tallman, DF Claxton, HM Lazarus, ML Thomas, AM Melnick, RL Levine, E Paietta, D Arber, Y Zhang, Jacob M. Rowe, JE Godwin, JK Altman, SM Luger, A Al-Kali, ER Broun, BL Powell, KM O'Dwyer, M Litzow. American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), oral; <u>Blood</u> 126(23):217, 2015. http://www.bloodjournal.org/content/126/23/217	8/15/12	2/23/15
Multiple*	Prognostic methylation markers for survival in cytogenetically normal AML patients treated on SWOG trials. X Qu, M Othus, J Davison, L Yan, E Estey, J Radich, H Erba, FR Appelbaum, Min Fang. American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL),oral presentation; <u>Blood</u> 126(23):688, 2015. *studies: S8600, S9333, S9031, S9500, S9918, S0106, S0112. http://www.bloodjournal.org/content/126/23/688	n/a	n/a

**SWOG
PUBLICATIONS LIST
LEUKEMIA COMMITTEE
2014**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
LEUKEMIA MANUSCRIPTS PUBLISHED/ACCEPTED (2014)			
S0106B	Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia. R Walter, GS Laszlo, JM Lionberger, JA Pollard, KH Harrington, C Gudgeon, M Othus, S Rafii, S Meshinchi, F Appelbaum, ID Bernstein. <i>Leukemia</i> 28(10): 1969-1977, 2014. PMID24721792; PMC4167978 http://www.ncbi.nlm.nih.gov/pubmed/24721792	n/a	n/a
S0106/other	NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. F Ostronoff, M Othus, RB Gerbing, MR Loken, SC Raimondi, BA Hirsch, BJ Lange, S Petersdorf, J Radich, FR Appelbaum, AS Gamis, TA Alonzo, S Meshinchi. <i>Blood</i> 124(15):2400-2407, 2014; PMID:25145343; PMC4192751 http://www.ncbi.nlm.nih.gov/pubmed/25145343	n/a	n/a
S0325	Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an inter-group randomized phase II trial in newly diagnosed chronic phase chronic myeloid leukemia. M Deininger, K Kopecky, J Radich, S Kamel-Reid, W Stock, E Paietta, P Emanuel, M Wadleigh, R Larson, J Lipton, M Slovak, F Appelbaum, B Druker. <i>British Journal of Haematology</i> , 164(2):223-32, 2014. PMID24383843; PMC4127316 http://www.ncbi.nlm.nih.gov/pubmed/24383843	8/15/04	2/28/09
S0432	Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. H Erba, K Kopecky, R Walter, M Kirschbaum, M Tallman, RA Larson, M Slovak, M Othus, H Gundacker, FR Appelbaum. <i>Leukemia Research</i> 38(3):329-33, 2014. PMID24411921; PMC4247790 http://www.ncbi.nlm.nih.gov/pubmed/24411921	9/14/04	2/21/06
S0521	Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. S Coutre, M Othus, B Powell, C Willman, W Stock, E Paietta, D Levitan, M Wetzler, A Attar, J Altman, S Gore, T Maher, K Kopecky, M Tallman, L Larson, F Appelbaum. <i>British Journal of Haematology</i> , May;165(4):497-503, 2014. PMID24579885; PMC4064464 http://www.ncbi.nlm.nih.gov/pubmed/24528179	6/1/07	5/27/10

S0910	SWOG S0910: a phase 2 trial of clofarabine/cytarabine/ epratuzumab for relapsed/refractory acute lymphocytic leukemia. A Advani, S McDonough, S Coutre, B Wood, J Radich, M Mims, M O'Donnell, S Elkins, M Becker, M Othus, F Appelbaum. <u>British Journal of Haematology</u> , May;165(4):504-509, 2014. PMID24579885; PMC4209396 http://www.ncbi.nlm.nih.gov/pubmed/24579885	8/14/10	7/1/12
S0919	SWOG0919: a phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia. A Advani, S McDonough, E Copelan, C Willman, DA Mulford, AF List, MA Sekeres, M Othus, HP Erba, FR Appelbaum. <u>British Journal of Haematology</u> Oct;167(2):233-237, 2014; Epub 2014 Jul 18. PMID25039477; PMC4188732 http://www.ncbi.nlm.nih.gov/pubmed/25039477		
E1905	Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. T Prebet, Z Sun, ME Figueroa, R Kettering, A Melnick, P Greenberg, M Juckett, M Smith, L Malick, E Paietta, M Czader, J Gabilove, H Erba, S Gore, M Tallman. <u>Journal of Clinical Oncology</u> , Apr;32(12):1242-2348, 2014. PMID24663049;PMC3986386 http://www.ncbi.nlm.nih.gov/pubmed/24663049	10/1/06	n/a
E1905	Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. AM Zeidan, J-W Lee, T Prebet, P Greenberg, Z Sun, M Juckett, MR Smith, E Paietta, J Gabilove, HP Erba, MS Tallman, SD Gore. <u>British Journal of Haematology</u> Aug;166(3):352-359. PMID:24712482; PMC4299460 http://www.ncbi.nlm.nih.gov/pubmed/24712482	10/1/06	n/a
E1905	Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. AM. Zeidan, J-W Lee, T Prebet, P Greenberg, Z Sun, M Juckett, MR Smith, E Paietta, J Gabilove, HP Erba, RP Katterling, MS Tallman, SD Gore on behalf of the Eastern Cooperative Oncology Group (ECOG) and North American Leukemia Intergroup. <u>British Journal of Haematology</u> Oct;167(1):62-68, 2014; Epub 2014 Jul 4; PMID24995683; PMC4299466 http://www.ncbi.nlm.nih.gov/pubmed/24995683	10/1/06	n/a
Multiple*	Declining rates of treatment-related mortality in patients with newly-diagnosed AML given "intense" induction regimens: a report from SWOG and MD Anderson. M Othus, H Kantarjian, S Petersdorf, F Ravandi, J Godwin, J Cortes, S Pierce, H Erba, S Faderl, F Appelbaum, E Estey. <u>Leukemia</u> , Feb;28(2):289-292, 2014. PMID23760400. (retrospective review not in scope of Public AccessPolicy) *Studies:S0106,S0112,S8600,S9031,S9126, S9333,S9500,S9617,S9918. http://www.ncbi.nlm.nih.gov/pubmed/?term=Othus+M+declining	n/a	n/a

Multiple*	Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukemia. B Medeiros, M Othus, E Estey, M Fang, F Appelbaum. <u>British Journal of Haematology</u> . Jan;164(2):245-250, 2014. PMID24383844; PMC4117470;*Studies S8600, S9031, S9034, S9126, S9333, S9500, S9617, S9918, S0106, S0112] http://www.ncbi.nlm.nih.gov/pubmed/24383844	n/a	n/a
Multiple*	The addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in acute myeloid leukaemia by reducing relapse risk: A source data meta-analysis of randomised trials in adults. R Hills, S Castaigne, F Applebaum, J Delaunay, S Petersdorf, M Othus, E Estey, H Dombret, S Chevret, N Ifrah, J-Y Cahn, C Recher, L Chilton, A Moorman, A Burnett. <u>Lancet Oncology</u> Aug;15(9):986-996, 2014. *Multiple studies/groups pooled analysis, including SWOG S0106. PMID25008258; PMC4137593 http://www.ncbi.nlm.nih.gov/pubmed/25008258	n/a	n/a

LEUKEMIA ABSTRACTS PUBLISHED/PRESENTED/ACCEPTED (2014)

S0106/other	Empiric definition of eligibility criteria for clinical trials in relapsed/refractory AML: analysis of 2,314 patients from HOVON/SAKK and SWOG. RB Walter, M Othus, B Löwenberg, GJ Ossenkoppele, SH Petersdorf, T Pabst, M-Ch Vekemans, FR Appelbaum, HP Erba, EH Estey. American Society for Hematology (December 6-9, 2014, San Francisco, CA), poster presentation. <u>Blood</u> 124(21):3676, 2014. http://www.bloodjournal.org/content/124/21/3676	7/1/93	11/15/97
S1117	A randomized phase II study of azacitidine combined with lenalidomide or with vorinostat vs. azacitidine monotherapy in higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML): North American Intergroup study SWOG S1117. MA Sekeres, M Othus, AF List, O Odenike, RM Stone, SD Gore, MR Litzow, R Buckstein, MR Velasco, R Gaur, E Atallah, EC Attar, FR Appelbaum, HP Erba. American Society for Hematology (December 6-9, 2014, San Francisco, CA), oral presentation. <u>Blood</u> 124(21):LBA-5, 2014. http://www.bloodjournal.org/content/124/21/LBA-5	3/1/12	11/14/14
C10403	Favorable outcomes for adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of US intergroup trial CALGB 10403 (Alliance). W Stock, S Geyer, S Luger, A Advani, R Harvey, C Mullighan, C Willman, E August Parker, K Laumann, BL Sanford, G Marcucci, E Paietta, MS Tallman, FR Appelbaum, HP Erba, M Litzow, RM Stone, RA Larson. American Society for Hematology (December 6-9, 2014, San Francisco, CA), oral presentation. <u>Blood</u> 124(21):796, 2014. http://www.bloodjournal.org/content/124/21/796	1/15/08	9/14/12
E2491 (S9129):	Determinants of fatal bleeding during induction chemotherapy for acute promyelocytic leukemia in the ATRA era. S Mantha, DA Goldman, S Devlin, J-W Lee, D Zannino, D Douer, H Iland, MR Litzow, EM Stein, FR Appelbaum, RA Larson, JM Rowe, MS Tallman. American Society for Hematology (December 6-9, 2014, San Francisco, CA), poster presentation. <u>Blood</u> 124(21):948, 2014. http://www.bloodjournal.org/content/124/21/948	6/15/92	2/1/95

E2491 (S9129)/ C9710	Telomere length recovery strongly predicts overall survival in acute promyelocytic leukemia. M Baljevic, B Dumitriu, J-W Lee, E Paietta, J Racevskis, C Chen, E Stein, RE Gallagher, JM Rowe, F Appelbaum, BL Powell, RA Larson, NS Young, MS Tallman. American Society for Hematology (December 6-9, 2014, San Francisco, CA), poster presentation. <u>Blood</u> 124(21):2375, 2014. http://www.bloodjournal.org/content/124/21/2375?sso-checked=true	6/15/92 7/15/99	2/1/95 3/29/05
-------------------------	---	----------------------------	---------------------------

**SWOG
PUBLICATIONS LIST
LEUKEMIA COMMITTEE
2013**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
LEUKEMIA MANUSCRIPTS PUBLISHED (2013)			
S0106	A phase III study of the addition of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. SH Petersdorf, KJ Kopecky, M Slovak, C Willman, T Nevill, J Brandwein, RA Larson, HP Erba, PJ Stiff, RK Stuart, MD Tallman, L Stenke, FR Appelbaum. <u>Blood</u> 121(24):4854-4860, 2013. PMID23591789; PMC3682338 http://www.ncbi.nlm.nih.gov/pubmed/23591789	7/1/93	11/15/97
S0703	A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. S Nand, M Othus, JE Godwin, CL Willman, TH Norwood, DS Howard, SE Coutre, HP Erba, FR Appelbaum. <u>Blood</u> , submitted 5/31/13; resubmitted 7/18/13; Re-re-submitted 9/9/13; accepted 10/11/13; <u>Blood</u> 122(20):3432-3439, 2013. PMID24092933; PMC3829116 http://www.ncbi.nlm.nih.gov/pubmed/24092933	12/1/08	6/1/12
CALBG*	Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. JA Woyach, AS Ruppert, K Rai, TS Lin, S Geyer, J Kolitz, FR Appelbaum, MS Tallman, AR Belch, VA Morrison, RA Larson, JC Byrd. <u>Journal of Clinical Oncology</u> 31(4):440-447, 2013. PMID23233702; PMC3731920 *Studies: C9011, C9712, C19901, C10101. http://www.ncbi.nlm.nih.gov/pubmed/23233702	n/a	n/a
C9011	The impact of initial fludarabine therapy on transformation to Richter's syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). M Solh, KR Rai, BL Peterson, JE Kolitz, FR Appelbaum, MS Tallman, A Belch, RA Larson, VA Morrison. <u>Leukemia & Lymphoma</u> 54(2):252-254, 2013. PMID22897733 http://www.ncbi.nlm.nih.gov/pubmed/22897733	6/15/91	12/7/94
C19808/ Multiple	Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALBG and SWOG trials. WG Woods, AR Franklin, TA Alonzo, RB Gerbing, KA Donohue, M Othus, J Horan, FR Appelbaum, EH Estey, CD Bloomfield, RA Larson. <u>Cancer</u> , 119(23): 4170-4179, 2013. PMID:24104597; PMC3833872 [studies C19808, C8525, C9022, C9222, C9621, S0106, S8600, S9500] http://www.ncbi.nlm.nih.gov/pubmed/?term=woods+wg+Outcome+of+adolescents+and+young+adults	n/a	n/a

Multiple*	Mutations in the DNMT3A exon 23 independently predict poor outcome in older AML patients: a SWOG report. F Ostronoff, M Othus, P Ho, DE Geraghty, SH Petersdorf, J Anderson, J Godwin, C Willman, G Radich, F Appelbaum, K Kopecky, DL Stirewalt, S Meshinchi. <u>Leukemia</u> 27(1): 238-241, 2013. PMID22722750; note: letters to the editor are not within the scope of the Public Access Policy. [*studies: S9031, S9033]. http://www.ncbi.nlm.nih.gov/pubmed/22722750	n/a	n/a
Multiple*	Significance of the FAB subclassification of "acute myeloid leukemia, not otherwise specified" in the 2008 WHO classification: analysis of 5,848 newly diagnosed patients. R Walter, M Othus, AK Burnett, A Lowenberg, H Kantarjian, G Ossenkoppele, RK Hills, K van Montfort, F Ravandi, S Pierce, F Appelbaum, E Estey. <u>Blood</u> 121(13):2424-2431, 2013. PMID23325837; PMC3612855 *Studies: S0106, S0112, S8600, S9031, S9034, S9333, S9500, S9617. http://www.ncbi.nlm.nih.gov/pubmed/23325837	n/a	n/a
Multiple*	A model for prediction of FLT3-ITD and NPM1 (without FLT-3-ITD) positivity in patients with newly diagnosed acute myeloid leukemia. (correspondence) F Ostronoff, M Othus, HM Kantarjian, S Meshinchi, F Ravandi, P Hendrie, S Faderl, P Becker, JE Cortes, JM Pagel, SH Petersdorf, JE Godwin, C Willman, SA Pierce, AF List, RK Sandhu, R Walter, D Stirewalt, FR Appelbaum, EH Estey. <u>British Journal of Haematology</u> 163(1):130-132, 2013. PMID:23829510; (correspondence - not within scope of Public Access Policy). *Studies: S0106, S9031, S9333, S9500. http://www.ncbi.nlm.nih.gov/pubmed/23829510	n/a	n/a
Multiple	All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study 10129. D Douera, L Zicki, C Schiffer, F Appelbaum, J Feusnere, L Shepherd, C Willman, C Bloomfield, E Peietta, R Gallagher, J Park, J Rowe, P Wiernik, M Tallman. <u>Leukemia Research</u> 37(7):795-801 PMID23528262; PMC pending. http://www.ncbi.nlm.nih.gov/pubmed/23528262	n/a	n/a
Multiple*	Expression of novel IRF8 splice variants is associated with a significant decrease in relapse-free survival in adult AML patients. E Pogossova-Agadjanian, K Kopecky, S Meshinchi, F Appelbaum, J Anderson, J Godwin, H Lee, A List, V Oehler, S Petersdorf, J Radich, C Willman, D Stirewalt. <u>British Journal Haematology</u>, submitted 11/15/12; rejected; <u>PlosOne</u> 8(8): e70812, 2013. PMID23967110; PMC3743845 *Studies S9031, S9126, S9333 and S9500 http://www.ncbi.nlm.nih.gov/pubmed/23967110	n/a	n/a

LEUKEMIA ABSTRACTS PUBLISHED/PRESENTED (2013)

S0106/other*	The addition of gemtuzumab ozogamicin (GO) to induction chemotherapy reduces relapse and improves survival in patients without adverse risk karyotype: results of an individual patient meta-analysis of the five randomized trials. R Hills, M Othus, F Appelbaum, E Estey, AK Burnett, J Delaunay, S Castaigne, S Chevert.. American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), submitted 8/8/13; oral presentation. *Studies: pooled analysis of 5 trials, including S0106. <u>Blood</u> 122:356, 2013. http://bloodjournal.hematologylibrary.org/content/122/21/356.abstract?sid=a76a17d7-8204-48ec-b144-03986e3adf2d	7/1/93	11/15/97
S0106	Evaluation of which patients get a second course of 3+7 on cooperative group trials for newly diagnosed acute myeloid leukemia: a report from SWOG. M Othus, F Appelbaum, S Petersdorf, H Erba, E Estey. American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), submitted 8/8/13; poster presentation; <u>Blood</u> 122:3925, 2013. http://bloodjournal.hematologylibrary.org/content/122/21/3925.abstract?sid=a76a17d7-8204-48ec-b144-03986e3adf2d	7/1/93	11/15/97
S0106/COG	NUP98/NSD1 translocation further risk-stratifies patients with FLT3/ITD in acute myeloid leukemia: report from Children's Oncology Group and SWOG. F Ostronoff, M Othus, RB Gerbing, MR Koken, L Pardo, R Aplenc, L Sung, SC Raimondi, BA Hirsch, S Kahwash, A Heerema-McKenney, L Winter, K Glick, P Byron, RS Lavey, SM Davies, FO Smith, AS Gamis, S Petersdorf, J Radich, F Appelbaum, T Alonzo, S Meshinchi. American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), submitted 8/8/13; accepted, oral presentation; <u>Blood</u> 122:488, 2013. http://bloodjournal.hematologylibrary.org/content/122/21/488.abstract?sid=a76a17d7-8204-48ec-b144-03986e3adf2d	7/1/93	11/15/97
S0919	SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia (AML). AS Advani, S McDonough, EA Copelan, CL Willman, D Mulford, AF List, MA Sekeres, M Othus, HP Erba, FR Appelbaum. <i>American Society of Clinical Oncology Annual Meeting</i> (May 31-June 4, 2013, Chicago, IL), submitted 2/5/13; poster discussion. <u>Journal of Clinical Oncology</u> 31(suppl; abstr 7028),2013. http://abstracts2.asco.org/AbstView_132_111137.html	8/15/09	n/a
C10403	Front-line treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US inter-group trial CALGB 10403 (Alliance). AS Advani, B Sanford, S Luger, M Devidas, E Larsen, M Liedtke, M Foster, D Claxton, E Parker, K Coffan, W Carroll, N Winik, S Coutre, M Tallman, F Appelbaum, H Erba, R Stone, S Hunger, R Larson, W Stock. American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), submitted 8/8/13; accepted, poster presentation. <u>Blood</u> 122:1443, 2013. http://bloodjournal.hematologylibrary.org/content/122/21/3903.abstract?sid=fa83e123-2959-4a97-b5d8-4118c336458c	1/15/08	9/14/12

E1905	Azacitidine with or without entinostat for the treatment of therapy related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. T Prebet, Z Sun, R Ketterling, P Greenberg, A Zeidan, M Litzow, J Gabriolove, HP Erba, E Paietta, M Czader, SD Gord, MS Tallman. American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), poster presentation; <u>Blood</u> 122:3924, 2013. http://bloodjournal.hematologylibrary.org/content/122/21/2777.abstract?sid=138987df-eeed-4d21-931a-e4bead45f4a8	10/1/06	n/a
Multiple*	Deregulation of stem cell factor (SCF)-AKT-S6 pathway in diagnostic AML samples is associated with disease-free survival: results of a verification study. A Cesano, CL Willman, KJ Kopecky, S Putta, A Cohen, C Marimpietri, SK Atwater, FR Appelbaum, JP Radich. European Hematology Association 18th Congress (June 13-16, 2013, Stockholm, Sweden), poster presentation; <u>Haematologica</u> 98(suppl.1):abstr. #P956, p. 396. *Studies: S0112, S0301, S9031, S9333 http://www.haematologica.org/content/98/supplement_1/1.full.pdf+html	n/a	n/a
Multiple*	Prediction of CR on reinduction in patients with newly diagnosed acute myeloid leukemia given intensive induction regimens: A report from SWOG and Cleveland Clinic. M Othus, S Mukherjee, M Sekeres, J Godwin, J Anderson, S Petersdorf, F Appelbaum, H Erba, E Estey. American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), submitted 8/8/13; accepted, poster presentation. <u>Blood</u> 122:2686, 2013. *Studies: SWOG S0106, S9031, S9333, S9500. http://bloodjournal.hematologylibrary.org/content/122/21/2686.abstract?sid=a76a17d7-8204-48ec-b144-03986e3adf2d		
Multiple*	Impact of cytarabine dose in the induction regimen on the outcome of patients with newly diagnosed acute myeloid leukemia with or without NPM1 and/or FLT3 mutations: a SWOG and MD Anderson. M Othus, F Ravandi, S Faderl, D Stirewalt, S Pierce, G Borthakur, J Godwin, J Anderson, S Petersdorf, J Cortes, F Ostronoff, E Pogossova-Agadjanyan, F Appelbaum, H Kantarjian, E Estey. American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), submitted 8/8/13; poster; <u>Blood</u> 122:2686, 2013. *Studies: S0106, S9031, S9333, S9500 http://bloodjournal.hematologylibrary.org/content/122/21/2686.abstract?sid=a76a17d7-8204-48ec-b144-03986e3adf2d		
Multiple*	Prediction of therapeutic resistance in adult acute myeloid leukemia: analysis of 4,550 newly diagnosed patients from MRC/NCRI, Hovon, SWOG, and MD Anderson Cancer Center. R Walter, M Othus, AK Burnett, B Lowenberg, H Kantarjian, G Ossenkoppele, R Hills, K van Montfort, F Ravandi, A Evans, SA Pierce, HP Erba, EH Estey. American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), submitted 8/8/13; oral presentation; *Studies: S0106, S0112, S8600, S9031, S9034, S9333, S9500, S9617, S9918 http://bloodjournal.hematologylibrary.org/content/122/21/64.abstract?sid=a76a17d7-8204-48ec-b144-03986e3adf2d		

- Multiple* Prognostic significance of NPM1 mutations in the absence of FLT3-ITD in older patients with AML: a SWOG report. F Ostronoff, M Othus, S Meshinchi, J Godwin, K Kopecky, A List, V Oehler, S Petersdorf, E Pogossova-Agadjanyan, J Radich, C Willman, F Appelbaum, D Stirewalt. American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), submitted 8/8/13; poster presentation; *Blood* 122:1315, 2013. *Studies: SWOG S9333, S9031, S9500, S0106 <http://bloodjournal.hematologylibrary.org/content/122/21/1315.abstract?sid=a76a17d7-8204-48ec-b144-03986e3adf2d>
- Multiple* Alteration of cytogenetic risk stratification in new diagnosis of leukemia by FISH testing – the SWOG experience. M Fang, S McDonough, M Othus, L Zhuo, D Roulston, H Erba, F Appelbaum. American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), submitted 8/8/13; poster presentation; *Blood* 122:64, 2013. *Studies: S0106, S0112, S0301, S0325, S0333, S0432, S0521, S0530, S0535, S0605, S0703. <http://bloodjournal.hematologylibrary.org/content/122/21/1383.abstract?sid=7e8550d5-91ca-499b-a2bb-0e270fab237d>
- Multiple* Novel long-term co-culture approach identifies prognostically important heterogeneity of stem/progenitor cell involvement in human acute myeloid leukemia. Laszlo GS, Lionberger JM, Harrington BS, Gudgeon CJ, Othus M, Appelbaum FR, Bernstein ID, Walter RB. American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), poster presentation; *Blood* 122: 1318, 2013. *Studies: includes SWOG S8600, S9031, S9333, S9500, and S0106 <http://bloodjournal.hematologylibrary.org/content/122/21/1318.abstract?sid=7f2421c1-1644-4170-b269-54b23ab9c2ed>

**SWOG
PUBLICATIONS LIST
LEUKEMIA COMMITTEE
2012**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
LEUKEMIA MANUSCRIPTS PUBLISHED (2012)			
S0325	A randomized trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phase chronic myeloid leukemia. JP Radich, KJ Kopecky, FR Appelbaum, S Kamel-Reid, W Stock, G Mainassy, E Paietta, M Wadleigh, R Larson, P Emmanuel, M Tallman, J Lipton, R Turner, B Druker. <u>Blood</u> 120(19):3898-905, 2012]. PMID22915637;PMC3496952 http://www.ncbi.nlm.nih.gov/pubmed/22915637	8/15/04	2/28/09
C9011	The impact of initial fludarabine therapy on transformation to Richter's syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). M Solh, KR Rai, BL Peterson, JE Kolitz, FR Appelbaum, MS Tallman, A Belch, RA Larson, VA Morrison. <u>Leukemia & Lymphoma</u> 2012 Aug 17 [Epub ahead of print]. PMID22897733; (this is a published study of CALGB cooperative group; SWOG endorsed and participated in this study and its investigator, FR Appelbaum, was recognized with authorship; CALGB responsible for journal submission) http://www.ncbi.nlm.nih.gov/pubmed/22897733	6/15/91	12/7/94
C9710	Treatment-influenced associations of PML-RAR α mutations, FLT3 mutations and additional chromosome abnormalities in relapse acute promyelocytic leukemia. RE Gallagher, BK Moser, J Racevskis, X Poire, CD Bloomfield, AJ Carroll, RP Ketterling, D Roulston, E Schachter-Tokarz, DC Zhou, IM Chen, R Harvey, G Koval, DA Sher, JH Feusner, MS Tallman, RA Larson, BL Powell, FR Appelbaum, E Paietta, CL Willman, W Stock. <u>Blood</u> 120(10):2098-2108, 2012. PMID22734072; PMCID3437597 http://www.ncbi.nlm.nih.gov/pubmed/22734072	7/15/99	3/29/05
C10603	Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. RM Stone, T Fischer, R Paquette, G Schiller, CA Schiffer, G Ehninger, J Cortes, HM Kantarjian, DJ DeAngelo, A Huntsman-labed, C Dutreix, A del Corral, F Giles. <u>Leukemia</u> 26(9):2061-2068, 2012. PMID:22627678 http://www.ncbi.nlm.nih.gov/pubmed/22627678	2/1/09	10/15/11
Multiple	Impact of body-mass index in the outcome of adult patients with acute myeloid leukemia. BC Medeiros, M Othus, EH Estey, M Fang, FR Appelbaum. <u>Haematologica</u> 97(9):1401-1404, 2012 PMID22315487; PMCID3436242 [Studies: S8600, S9031, S9126, S9333, S9500, S9617, S9918, S0106] http://www.ncbi.nlm.nih.gov/pubmed?term=medeiros%20b%20body%20mass%20index	n/a	n/a

Multiple	Impact of residual normal metaphases in core binding factor acute myeloid leukemia cancer. B Medeiros, M Othus, M Fang, F Appelbaum, E Estey. <u>Cancer</u> , 118(9):2420-2423, 2012. PMID21928314; PMC3490403 [studies S8600, S9031, S9034, S9126, S9333, S9500, S9617, S9910, S9918, S0106, S0112] http://www.ncbi.nlm.nih.gov/pubmed?term=medeiros%20b%20impact%20of%20residual	n/a	
Multiple	Unsuccessful diagnostic cytogenetics is a poor prognostic feature in acute myeloid leukemia. [Letter to the Editor!]. B Medeiros, M Othus, M Fang, E Estey, F Appelbaum. <u>Leukemia</u> , accepted 5/21/12 (note: Letters to the Editor are not within the scope of the Public Access Policy). [Studies S8600, S9031, S9034, S9126, S9333, S9500, S9617, S9918, S0106, S0112]	n/a	n/a

LEUKEMIA ABSTRACTS PUBLISHED/PRESENTED (2012)

S0703	A phase II trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 acute myeloid leukemia (SWOG S0703): report on the good risk patients. S Nand, H Gundacker, JE Godwin, C Willman, T Norwood, H Erba, D Howard, S Coutre, M Othus, F Appelbaum. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation; <u>J Clin Oncol</u> 30, 2012 (suppl; abstr 6502). http://abstract.asco.org/AbstView_114_93704.html	12/1/08	n/a
S0703	A phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC0720568) as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 acute myeloid leukemia (SWOG S0703): report on the poor risk patients. S Nand, M Othus, J Godwin, C Willman, T Norwood, H Erba, D Howard, S Coutre, F Appelbaum. American Society of Hematology, Annual Meeting (December 8-11, 2012, Atlanta, GA), accepted, poster presentation. <u>Blood</u> 120(21):abst. 3584, 2012. http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/3584?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=NAND&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT	12/1/08	6/1/12
S0910	SWOG study S0910: a phase 2 trial of clofarabine/cytarabine/ epratuzumab for relapsed/refractory acute lymphocytic leukemia. A Advani, S McDonough, SE Coutre, B Wood, J Radich, M Mims, M O'Donnell, S Elkins, MW Becker, M Othus, F Appelbaum. American Society of Hematology, Annual Meeting (December 8-11, 2012, Atlanta, GA), accepted, poster presentation; <u>Blood</u> 120(21): abst. 2603, 2012. http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/2603?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=s0910&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT	8/14/10	7/1/12

C10403	Who participates in an adult cooperative group trial for adolescent and young adults (AYAs)? L Muffly, W Stock, A Breitenbach, F Mulkey, S Luger, A Advani, E Parker, MC Foster, M Liedtke, R Garcia, K Coffan, J Sipin- Sayno, J McNeer, M Tallman, F Appelbaum, R Stone, R Larson. Baseline demographic and psychosocial characteristics of AYAs enrolled on intergroup trial C10403 for acute lymphoblastic leukemia (ALL). American Society of Hematology, Annual Meeting (December 8-11, 2012, Atlanta, GA), poster presentation; <u>Blood</u> 120(21):abst. 3535, 2012. http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/3535?maxtoshow=&hits=25&RESULTFORMAT=&fulltext=swog&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT	1/15/08	9/14/12
Multiple*	Declining rates of treatment-related mortality recent in patients with newly diagnosed AML given "intense" induction regimens: a report from SWOG and MD Anderson. M Othus, K Kantarjian, S Petersdorf, F Ravandi, J Godwin, J Cortes, S Pierce, H Erba, S Faderl, F Appelbaum, E Estey. American Society of Hematology, Annual Meeting (December 8-11, 2012, Atlanta, GA), oral presentation; <u>Blood</u> 120(21):abst. 129, 2012. http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/129?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=othus&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT Studies: S 0106, S0112, S8600, S9031, S9126, S9333, S9500, S9617, S9918.	n/a	n/a
Multiple*	Prognostic significance of the French-American-British (FAB) morphologic subclassification of "acute myeloid leukemia, not otherwise specified" in the 2008 WHO classification: analysis of 5,848 newly diagnosed patients from HOVON, MRC, SWOG, and MD Anderson Cancer Center. R Walter, M Othus, AK Burnett, A Lowenberg, H Kantarjian, G Ossenkoppele, RK Hills, K van Montfort, F Ravandi, S Pierce, F Appelbaum, E Estey. American Society of Hematology, Annual Meeting (December 8-11, 2012, Atlanta, GA), oral presentation; <u>Blood</u> 120(21):abst. 540, 2012. http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/540?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=othus&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT *Studies: S0106, S0112, S8600, S9031, S9034, S9333, S9500, S9617.	n/a	n/a
Multiple*	A scoring system of prediction of FLT3-ITD positivity in patients with newly diagnosed acute myeloid leukemia: a SWOG, FHCRC and MDACC study. F Ostronoff, M Othus, S Meshinchi, F Appelbaum, E Estey. American Society of Hematology, Annual Meeting (December 8-11, 2012, Atlanta, GA), accepted, poster presentation. <u>Blood</u> 120(21):abst. 2590, 2012. http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/2590?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=FLT3ITD+positivity&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT *Studies: S0106, S9031, S9333, S9500	n/a	n/a

Multiple*	Single-cell network profiling (SCNP)-based classifier to predict response to induction therapy in elderly patients with acute myeloid leukemia (AML): validation in two independent sample sets from ECOG and SWOG trials. A Cesano, CL Willman, K Kopecky, U Gayko, S Putta, B Louie, M Westfall, N Purvis, D Spellmeyer, C Marimpietri, J Hackett, J Shi, E Paietta, M Tallman, L Crippe, S Atwater, F Appelbaum, J Radich. <i>American Society of Hematology Annual Meeting</i> (December 8-11, 2012, Atlanta, GA), poster presentation; <i>Blood</i> 120(21):abst.2489, 2012. http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/2489?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=cesano&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT *Studies: S0112, S0301, S9031, S9333, E3999.	n/a	n/a
-----------	---	-----	-----

**SWOG
PUBLICATIONS LIST
LEUKEMIA COMMITTEE
2011**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
LEUKEMIA MANUSCRIPTS PUBLISHED (2011)			
S0106/Mult.	Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype. B Xie, M Othus, B Medeiros, M Fang, FR Appelbaum, EH Estey. <i>Haematologica</i> 96(4):631-632, 2011. PMID21330329; PMC3069244 (studies:S0106,S0112, S8600, S9031, S9034, S9126, S9333, S9500, S9617, S9918) PMID21330329; PMC3069244 http://www.ncbi.nlm.nih.gov/pubmed/21330329	7/1/93	11/15/97
S0605	A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: SWOG study S0605. M Sekeres, H Gundacker, J Lancet, A Advani, S Petersdorf, J Liesveld, D Mulford, T Norwood, C Willman, A List, F Appelbaum. <i>Journal of Clinical Oncology, Blood</i> 118(3):523-528, 2011. PMID21551228; PMC3142897 http://www.ncbi.nlm.nih.gov/pubmed?term=sekeres%20M%20S0605	6/15/06	7/1/10
S9031	Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a Children's	11/15/91	1/15/95
S9033	Oncology Group and Southwest Oncology Group Study. PA Ho, KJ Kopecky, TA Alonzo, RB Gerbing, KL Miller, J Kuhn, R Zeng, RE Ries, SC Raimondi, BA Hirsch, V Oehler, CA Hurwitz, JL Franklin, AS Gamis, SH Petersdorf, JE Anderson, JE Godwin, GH Reaman, CL Willman, ID Bernstein, JP Radich, FR Appelbaum, DL Stirewalt, S Meshichi. <i>Blood</i> 118(17):4561-4566, 2011	1/15/95	12/1/98
S9500	PMID21873548; PMC3208275 http://www.ncbi.nlm.nih.gov/pubmed/21873548	12/15/95	4/1/97
Multiple	Cytarabine dose for acute myeloid leukemia. Letter to the editor. BC Medeiros, M Othus, FR Appelbaum. <i>New England Journal of Medicine</i> , 364(22):2167-2168, 2011. PMID21631340. (studies:S8600, S9031, S9126, S9333, S9500, S9617, S9918, S0106, S0112); PMID21631340; Letters to Editor/Correspondence not within scope of Public Access Policy. http://www.ncbi.nlm.nih.gov/pubmed/21631340	n/a	n/a
Multiple	Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. M Fang, B Storer, E Estey, M Othus, L Zhang, B Sandmaier, F Appelbaum. <i>Blood</i> 118(6):1490-1494, 2011. PMID21680797; PMC3156042 [S0106, S0112, S8600, S9126, S9333, S9500] http://www.ncbi.nlm.nih.gov/pubmed/21680797	n/a	n/a

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	-------------------------------	---

Multiple	Prediction of early death after induction therapy for newly diagnosed acute leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. R Walter, M Othus, G Borthakur, F Ravandi, J Cortes, S Pierce, F. Appelbaum, H Kantarjian, E Estey. <u>Journal of Clinical Oncology</u> , 29(33):4417-23, 2011. PMID21969499; PMC3221524 [studies S8600, S9031, S9034, S9126, S9333, S9500, S9617, S9918, S0106, S0112] http://www.ncbi.nlm.nih.gov/pubmed/?term=walter+r++predication+of+early+death	n/a	n/a
----------	--	-----	-----

E2997	Incidence of therapy-related myeloid neoplasia after initial therapy for CLL with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US intergroup study E2997. MR Smith, D Neuberg, IW Flinn, MR Grever, HM Lazarus, JM Rose, G Dewald, JM Bennett, EM Paietta, JC Byrd, MA Hussein, FR Appelbaum, RA Larson, MR Litzow, MS Tallman. <u>Blood</u> 118(13):3525-3527, 2011. PMID21803850; PMC3186330 http://www.ncbi.nlm.nih.gov/pubmed/21803850	10/15/02	3/19/04
-------	---	----------	---------

LEUKEMIA ABSTRACTS PRESENTED/PUBLISHED (2011)

S0106	Prognostic significance of FLT3 and NPM1 mutations in adults of age 18-60 with <i>de novo</i> acute myeloid leukemia (AML): a study by FHCRC and SWOG. EL Pogossova-Agadjanyan, KJ Kopecky, S Petersdorf, H Erba, R Stone, S Meshinchi, TJ Nevill, JP Radich, L Stenke, M Slovak, RK Stuart, MS Tallman, CL Willman, A Brumbaugh, M Cronk, C Cummings, J Engel, R Mortensen, A Suchanek, FR Appelbaum, DL Stirewalt. American Society of Hematology Annual Meeting (December 10-13, 2011, San Diego, CA), poster presentation. <u>Blood</u> 118(21): abst. 2520, 2011. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/2520?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=NPM1&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT	5/15/04	8/20/09
-------	--	---------	---------

S9030	Response to high dose cytarabine (HIDAC) as first salvage for relapsed acute lymphocytic leukemia is not affected by prior exposure to HIDAC. AS Advani, H Gundacker, N Nyatanga, PJ Rosen, M Sekeres, M Kalaycio, R Sobecks, E Copelan, F Appelbaum. American Society of Hematology, poster presentation, 2011. <u>Blood</u> 118(21):abstract 2594, 2011. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/2594?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=gundacker&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT	11/1/91	5/15/94
-------	--	---------	---------

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
S9031 S9033	KIT mutations are very uncommon among elderly AML patients: a SWOG report. F Ostronoff, M Othus, PA Ho, SH Petersdorf, JE Anderson, JE Godwin, CL Willman, JP Radich, FR Appelbaum, DL Stirewalt, S Meshinchi. American Society of Hematology, accepted, poster presentation. <u>Blood</u> 118(21):abstract 2510, 2011. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/2510?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=othus&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT	11/15/9 1/15/95	11/15/95 12/1/98
S9031 S9333 S9500	Prevalence and clinical implications of IDH1 R140 and R172 mutations in older adults with AML: a report from SWOG. PA Ho, M Othus KJ Kopecky, F Ostronoff, SH Petersdorf, JE Anderson, JE Godwin, CL Willman, JP Radich, FR Appelbaum, DL Stirewalt, S Meshinchi. American Society of Hematology, poster, 2011. <u>Blood</u> 118(21):abstract 3516, 2011. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/3516?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=othus&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT	11/14/91 1/15/95 12/15/95	1/15/95 12/1/98 4/1/97
S9031 S9333 S9500	DNMT3A mutations independently predict poor outcome in older AML patients: a SWOG report. F Ostronoff, M Othus, PA Ho, SH Petersdorf, JE Anderson, JE Godwin, CL WL Willman, JP Radich, FR Appelbaum, DL Stirewalt, S Meshinchi. American Society of Hematology, poster, 2011. <u>Blood</u> 118(21):abstract 3519, 2011. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/3519?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=othus&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT	11/15/9 1/15/95 12/15/95	11/15/95 12/1/98 4/1/97
S9031/ S9126/ S9333/ S9500	Expression of topoisomerase (topo) II in adult patients with acute myeloid leukemia (AML): relationship to immunophenotype and treatment outcome. A. Michelson, KJ Kopecky, E. Koegle, JE Anderson, JE Godwin, SH Petersdorf, AF List, CL Willman, FR Appelbaum, JP Radich, M Ganapathi, R Ganapathi, AS Advani. ASCO 2011 annual meeting (June 4-8, 2011, Chicago, IL), poster presentation, <u>Journal of Clinical Oncology</u> 29:(suppl; abstr 6564), 2011. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=79396	n/a	
S9031 S9333 S9918 S0112 S0106	Prognostic import of French-American-British (FAB) system as embedded in 2008 revision of World Health Organization classification of AML. L Newell, M Othus, R Walter, S Petersdorf, T Chauncey, J Anderson, J Godwin, K Kopecky, F Appelbaum, E Estey. American Society of Hematology, poster presentation, 2011. <u>Blood</u> 118(21):abst 1446, 2011. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/1446?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=%28FAB%29&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT	11/15/91 1/15/95 2/1/00 8/1/01 5/15/04	1/15/95 12/1/98 3/5/01 4/1/03 8/20/09

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
S9129 (ECOG INT0129)	Late relapses following ALL-trans retinoic acid for acute promyelocytic leukemia are uncommon, respond well to salvage therapy and occur independently of prognostic factors at diagnosis: longterm follow-up of North American Intergroup study 0129. D Douer, L Zickl, C Schiffer, FR Appelbaum, JH Feusner, L Shepherd, C Willman, CD Bloomfield, JM Rowe, PH Wiernik, MS Tallman. American Society of Hematology, oral presentation, 2011. <u>Blood</u> 118(21): abstract 83, 2011. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/83?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=north&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT	6/15/92	2/1/95
S9400 S0333	Outcome and incidence of hyperdiploidy and hypoploidy in adults with newly diagnosed acute lymphocytic leukemia. A Advani, H Gundacker, M Slovak, K Theil, S Forman, J Radich, F Appelbaum. American Society of Hematology, accepted, poster presentation. <u>Blood</u> 118: abstr. #2555, 2011. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/2555?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=gundacker&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT	7/15/95 4/5/05	5/1/00 11/1/09

**SWOG
PUBLICATIONS LIST
LEUKEMIA COMMITTEE
2010**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
LEUKEMIA MANUSCRIPTS PUBLISHED/PRESENTED (2010)			
S0112/ S0301	Sequential phase II Southwest Oncology Group studies (S0012 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with cyclosporine, in older patients with previously untreated acute myeloid leukemia (AML). TR Chauncey, H Gundacker, M Shadman, AF List, SR Dakhil, HP Erba, ML Slovak, I-M Chen, CL Willman, KJ Kopecky, FR Appelbaum. <u>British Journal of Haematology</u> 148(1):48-58, 2010. PMID19821823;PMC2967366 http://www.ncbi.nlm.nih.gov/pubmed?term=chauncey%20tr%20cytarabine	5/1/01 10/1/03	12/1/05 12/15/06
S0530	Southwest Oncology Group study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukemia. A Advani, H Gundacker, O Sala-Torra, J Radich, R Lai, ML Slovak, JE Lancet, S Coutre, RK Stuart, M Mims, P Stiff, F Appelbaum. <u>British Journal of Haematology</u> 151(5):430-434,2010.PMID21113977; PMC3058291 http://www.ncbi.nlm.nih.gov/pubmed?term=advani%20a%20S0530	10/1/06	8/1/08
S8819/Multiple	Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M.D. Anderson Cancer Center Study. RB Walter, HM Kantarjian, Huang X. SA Pierce, Z Sun, H Gundacker, F Ravandi, S Faderl, M Tallman, F Appelbaum. <u>Journal of Clinical Oncology</u> 28(10):1766-1771, 2010. PMC2849766; PMID20159819 http://www.ncbi.nlm.nih.gov/pubmed/20159819	02/15/89	07/01/11
S9031 S9333 S9500	Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group Study. PA Ho, TA Alonzo, KJ Kopecky, KL Miller, J Kuhn, R Gerbing, S Raimondi, B Hirsch, V Oehler, C Hurwitz, J Franklin, A Gamis, S Petersdorf, J Anderson, GH Reaman, LH Baker, C Willman, I Bernstein, G Radich, F Appelbaum, D Stirewalt, S Meshinchi. <u>Leukemia</u> 24(5):909-913, 2010. PMID20376086;PMC2944692 http://www.ncbi.nlm.nih.gov/pubmed/20376086	11/15/91 1/15/95 12/15/95	1/15/95 12/1/98 04/01/97

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	-------------------------------	---

S9129	Does microgranular variant morphology of acute promyelocytic leukemia independently predict for a less favorable outcome compared with classical Mc APL? A joint study of North American Intergroup and PETHEMA Group. Tallman MS, Haesook T, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH, Gonzalez M, Larson RA, Gonzalez-San Miguel JD, Ogden A, Milone G, Rowe JM, Rayon C, Shepherd L, Riva C, Schiffer CA, Vellenga E, Wiernik PH, Willman C, MA Sanz. <u>Blood</u> . 116(25):5650-5659,2010. PMID20858857;PMC3031411 http://www.ncbi.nlm.nih.gov/pubmed/20858857	6/15/92	2/1/95
-------	---	---------	--------

C9710	Arsenic trioxide improves event-free and over-all survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. BL Powell, W Stock, RE Gallagher, CL Willman, RM Stone, JM Rowe, S Coutre, JH Feusner, J Gregory, S Couban, FR Appelbaum, M Tallman, RA Larson. <u>Blood</u> 116(19):3751-3757, 2010.PMID20705755;PMC2981533 http://www.ncbi.nlm.nih.gov/pubmed/20705755	7/15/09	3/29/05
-------	--	---------	---------

Multiple	Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group experience. BC Medeiros, M Othus, M Fang, D Roulston, FR Appelbaum. <u>Blood</u> 116(13): 2224-2228, 2010. PMID: 20562328; PMC3709629 http://www.ncbi.nlm.nih.gov/pubmed?term=medeiros%20b%20prognostic%20impact	n/a	n/a
----------	---	-----	-----

LEUKEMIA ABSTRACTS PRESENTED/PUBLISHED (2010)

*S0325	A randomized phase II trial of dasatinib 100 mg vs. imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 intergroup trial. JP Radich, KJ Kopecky, S Kamel-Reid, W Stock, E Paietta, M Wadleigh, RA Larson, PD Emanuel, MS Tallman, J Lipton, S Couban, MW Deininger, FR Appelbaum, BJ Druker. American Society of Hematology 2010 Annual Meeting, "late breaking" abstract; oral presentation, <u>Blood</u> 116:abst. #6, 2010. http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/LBA-6?maxtoshow=&hits=25&RESULTFORMAT=&fulltext=radich&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT	8/15/04	2/28/09
--------	--	---------	---------

*S0333 S9400	Analysis of CRLF2/JAK expression and mutation status in adult ALL patients. O Sala-Torra, G Pogosov, E Pogosova-Agadjanyan, H Gundacker, S Forman, S O'Donnell, F Appelbaum, C Willman, JP Radich. American Society of Hematology 2010 Annual Meeting, oral presentation, <u>Blood</u> 116:abst.#758, 2010. http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/758?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=sala-torra&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT	04/15/05	11/01/09
-----------------	--	----------	----------

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*S0605	A phase II study of lenalidomide for previously untreated deletion (del) 5q acute myeloid leukemia (AML) patients age 60 or older who are not candidates for remission induction chemotherapy (Southwest Oncology Group study S0605). M Sekeres, H Gundacker, J Lancet, A Advani, S Petersdorf, J Liesveld, D Mulford, T Norwood, C Willman, A List, F Appelbaum. American Society of Hematology 2010 Annual Meeting, oral presentation, <u>Blood</u> 116:abst.#332, 2010. http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/332?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=sekeres&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT	06/15/06	7/01/10
*S8600 S9500 S0106	Outcome of adolescents and young adults (AYAs) with non-M3 acute myeloid leukemia 9AML) treated on Children's Oncology Group (COG) trials compared to Cancer and Leukemia Group B (CALGB) and Southwest Oncology Group (SWOG) trials. A Franklin, T Alonzo, RB Gerbing, K Donohue, M Othus, J Horan, EH Estey, RA Larson, WG Woods. <u>Blood</u> 116:Abstract 183, 2010 (oral presentation). http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/183?maxtoshow=&hits=25&RESULTFORMAT=&fulltext=franklin&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT	11/1/86 12/15/95 5/15/04	12/1/91 4/1/97 8/20/09
S9031 S9123 S9333 S9500	Over-expression of novel IRF8 splice variants is associated with a significant decrease in relapse-free survival in adult AML patients. E Pogosso-Agadjanyan, K Kopecky, H Lee, J Anderson, J Godwin, A List, S Meshinchi, V Oehler, S Petersdorf, C Willman, F Appelbaum, JP Radich, D Stirewalt. American Society of Hematology 2010 Annual Meeting, poster presentation, <u>Blood</u> 116:abst.#1679, 2010. http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/1679?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=kopecky&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT	11/15/91	02/15/94
S9031	Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a Children's Oncology Group and Southwest Oncology Group study. P Ho, T Alonzo, K Kopecky, K Miller, J Kuhn, R Zeng, R Ries, R Gerbing, W Fan, S Raimondi, B Hirsch, V Oehler, CA Hurwitz, J Franklin, A Gamis, S Petersdorf, J Anderson, J Godwin, GH Reaman, C Willman, LP Zhao, I Bernstein, J Radich, F Appelbaum, D Stirewalt, S Meshinchi. American Society of Hematology 2010 poster presentation, <u>Blood</u> 116:abst.#2737, 2010. http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/2737?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=kopecky&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT	11/15/91	02/15/94
Multiple	Influence of residual normal metaphases in patients with monosomal karyotype. B Xie, M Othus, B Medeiros, M Fang, F Appelbaum, E Estey. <u>Blood</u> 115:abst.#1671, 2010 (poster). (Studies:S0106, S0112, S8600, S9031,S9034, S9126, S9333, S9500, S9617, S9918) http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/1671?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=xie&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT	n/a	n/a

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
C9710	Clonal markers in relapsed acute promyelocytic leukemia (APL): clinicopathological associations and relation to all-trans retinoic acid (ATRA) treatment on intergroup phase III trial C9710. R Gallagher, B Moser, J Racevskis, X Poire, C Bloomfield, A Carroll, R Ketterling, D Ralston, E Schachter-Tokarz, D Zhou, I Chen, R Harvey, G Koval, D Sher, J Feusner, M Tallman, F Appelbaum, R Larson, B Powell, E Paietta, C Willman, W Stock. American Society of Hematology 2010 Annual Meeting, poster presentation, <u>Blood</u> 116:abst.#1038, 2010. http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/1038?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=gallagher&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT	7/15/99	3/29/05
*E1905	Prolonged administration of azacitidine with or without entinostat increases rate of hematologic normalization for myelodysplastic syndrome and acute myeloid leukemia with trilineage dysplasia: results of the E1905 trial. T Prebet, S Gore, Z Sun, P Greenberg, M Juckett, L Malick, M Smith, E Paietta, M Czader, J Gabrilove, H Erba, M Tallman. American Society of Hematology 2010 Annual Meeting, oral presentation, <u>Blood</u> 116:abst.#1038, 2010. http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/601?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=prebet&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT	10/01/06	n/a
*E1905	A 10 day schedule of azacitidine induces more complete cytogenetic remissions than the standard schedule: results of the E1905 study. T Prebet, Z Sun, R Ketterling, G Hicks, CL Beach, P Greenberg, E Paietta, M Czader, J Gabrilove, H Erba, M Tallman, S Gore. American Society of Hematology Annual Meeting, oral presentation, <u>Blood</u> 116:abst. #601,2010. http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/4013?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=prebet&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT	10/01/06	n/a
*Presented			

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
LEUKEMIA COMMITTEE
2009**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	-------------------------------	---

LEUKEMIA MANUSCRIPTS PUBLISHED/PRESENTED (2009)

S8124/25/26	Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. J Koreth, R Schlenk, KJ Kopecky, S Honda, J Sierra, B Djulbegovic, M Wadleigh, DJ DeAngelo, RM Stone, H Sakamaki, FR Appelbaum, H Dohner, JH Antin, RJ Soiffer, C Cutler. <u>Journal of the American Medical Association</u> 301(22): 2349-2361, 2009. PMID:19509382	5/11/82	9/27/85
S9706	Lin28 enhances tumorigenesis and is associated with advanced human malignancies. SR Viswanathan, JT Powers, W Einhorn, Y Hoshida, TL Ng, S Toffanin, M O'Sullivan, J Lu, LA Phillips, VL Lockhard, SP Shah, PS Tanwar, CH Mermel, R Beroukhim, M Azam, J Teixeira, M Meyerson, TP Hughes, JM Lovet, J Radich, GQ Daley. <u>Nature Genetics</u> 41:843-848, 2009. PMC2757943; PMID:19483683	9/15/97	3/1/99
Multiple	Very late antigen-4 (VLA-4) function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. PS Becker, KJ Kopecky, AN Hanks, AN Wilks, JM Harlan, CL Willman, S Petersdorf, T Papayannopoulou, FR Appelbaum. <u>Blood</u> 113(4):866-874, 2009. PMC2630271 PMID:18927435	n/a	n/a

LEUKEMIA ABSTRACTS PUBLISHED/PRESENTED

*S0106	Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 Randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to no additional therapy versus post-consolidation gemtuzumab ozogamicin for previously untreated acute myeloid leukemia. SH Petersdorf, KJ Kopecky, RK Stuart, TJ Nevill, R Larson, L Stenke, M Tallman, M Slovak, C Willman, H Erba, F Appelbaum. <u>Blood</u> 114:abst. #790, 2009.	5/15/04	8/20/09
S0530	Southwest Oncology Group S0530: A phase 2 trial of clofarabine/cytarabine for relapsed/refractory acute lymphocytic leukemia. A Advani, H Gundacker, L Sala-Torra, J Radich, R Lai, J Lancet, S Coutre, RK Stuart, MP Mims, P Stiff, FR Appelbaum. <u>Blood</u> 114:abst.#3094, 2009 (poster presentation ASH)	10/1/06	8/1/08

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*S9108	Long-term survival analysis of the North American Intergroup Study C9011 comparing fludarabine (f) and chlorambucil (c) In previously untreated patients with chronic lymphocytic Leukemia (CLL). KR Rai, BL Peterson, FR Appelbaum, MS Tallman, A Belch, VA Morrison, RA Larson. Blood 114: Abst. # 536, 2009 (ASH Annual Meeting, oral presentation).	6/15/91	12/7/94

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
LEUKEMIA COMMITTEE
2008**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE DATE PROTOCOL ACTIVATED	PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED (2008)				
9400 (2404)	Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group study SWOG-9400. V Pullarkat, ML Slovak, KJ Kopecky, SJ Forman, FR Appelbaum. <u>Blood</u> 111(5):2563-2572, 2008. PMID 18156492	Leukemia	7/15/95	5/11/00
Multiple (2542)	Identification of genes with abnormal expression changes in acute myeloid leukemia. DL Stirewalt, S Meshinchi, KJ Kopecky, W Fan, EL Pogossova-Agadjanyan, JH Engel, MR Cronk, KS Dorcy, AR McQuary, D Hockenbery, B Wood, S Heimfeld, JP Radich. <u>Genes Chromosomes Cancer</u> 47(1):8-20, 2008. PMID 17910043	Leukemia		
Multiple (2582)	Has gene expression profiling improved diagnosis, classification and outcome prediction in AML? CL Willman. <u>Best Practice & Research Clinical Hematology</u> 21(1):21-28, 2008. PMID: 18342809	Leukemia	n/a	
LEUKEMIA ABSTRACTS PUBLISHED (2008)				
S0432 (2476)	Phase II studies of different schedules and doses of the farnesyltransferase inhibitor tipifarnib (R11577, zarcesta) for patients age 70 or older with previously untreated acute myeloid leukemia (AML): North American Intergroup Study S0432. HB Erba, KJ Kopecky, MH Kirschbaum, MS Tallman, RA Larson, CL Willman, ML Slovak, HM Gundacker, FR Appelbaum, <u>Annals of Hematology</u> , 87(Suppl.1):S57-S59, 2008. http://abstracts.hematologylibrary.org/cgi/content/abstract/110/11/440?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&author1=Erba%2C+HP&andorexacttitle=and&andorexacttitleabs=and&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&fdate=11/1/2007&resourcetype=HWCIT	9/15/04	2/23/06	
C9710 (2507)	Arsenic trioxide consolidation improves event-free and overall survival among patients with newly diagnosed acute promyelocytic leukemia: North American Intergroup protocol C9710. BL Powell, B Moser, W. Stock, RE Gallagher, CL Willman, RM Stone, JM Rowe, S Coutre, JH Feusner, J Gregory, S Couban, FR Appelbaum MS Tallman, RA Larson. <u>Annals of Hematology</u> 87 (Suppl 1):87:S77-S-78, 2008. http://www.springerlink.com/content/j68u63275v24/?p=a25c478c6a524eb08a002ce8f779eb2f&pi=11	7/15/99	3/29/05	

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2007**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

9031/9333 (2432)	Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. N Kuptsova, KJ Kopecky, J Godwin, J Anderson, A Hoque, CL Willman, ML Slovak, CB Ambrosone. <u>Blood</u> 109(9):3936-3944, 2007. PMID: 17197435	Leukemia		
9400 (2388)	Connective tissue growth factor (CTGF) expression and Outcome in adult patients with acute lymphoblastic leukemia. O Sala-Torra, HM Gundacker, DL Stirewalt, PA Ladne, EL Pogossova-Agadjanyan, ML Slovak, CL Willman, S Heimfeld, DH Boldt, JP Radich. <u>Blood</u> 109(7):3080-3083, 2007.	Leukemia	1/1/97	5/1/00
9500 (2221)	Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500). SH Petersdorf, C Rankin, DR Head, HR Terebelo, CL Willman, SP Balcerzak, AB Karnad, SR Dakhil, FR Appelbaum. <u>American Journal of Hematology</u> 82:1056-1062, 2007.	Leukemia	12/15/95	04/01/97
Multiple (2543)	Regularization strategies for hyperplane classifiers: application to cancer classification with gene expression data. E Andries, T Hagstrom, C Willman. <u>Journal of Bioinformatics and Computational Biology</u> 5(1):79-104, 2007	Leukemia	n/a	n/a

ABSTRACTS PUBLISHED/PRESENTED

*S0432 (2416)	Phase II studies of different schedules and doses of the farnesyl transferase inhibitor tipifarnib (R115777, Zarnestra, NSC-702818) for patients of age 70 or older with previously untreated acute myeloid leukemia (AML): A North American Intergroup study (S0432). HP Erba, KJ Kopecky, MH Kirschbaum, MS Tallman, RA Larson, CL Willman, ML Slovak, HM Gundacker, FR Appelbaum. <u>Blood</u> 110(11):#440, 2007.	Leukemia	9/15/04	2/23/06
C19801 (2550)	Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. DJ DeAngelo, D Yu, JL Johnson, SE Coutre, RM Stone, AT Stopeck, JP Gockerman, BS Mitchell, FR Appelbaum, RA Larson. <u>Blood</u> 109(12):5136-5142, 2007.	Leukemia	6/15/00	9/12/01

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2006**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9129 (2332)	Relapse of acute promyelocytic leukemia with PML-RARx mutant subclones independent of proximate all-trans retinoic acid selection pressure. RE Gallagher, E Schachter-Tokarz, DC Zhou, W Ding, SH Kim, BJ Sankoorikal, W Bi, KJ Livak, JL Slack, CL Willman. <u>Leukemia</u> 20:556-562, 2006.	Leuk	6/15/92	2/1/95
Multiple Studies (2328)	A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. M Yan, E Kanbe, LF Peterson, A Boyapati, Y Miao, Y Wang, IM Chen, Z Chen, JD Rowley, CL Willman, DE Zhang. <u>Nature Medicine</u> 12(8):945-949, 2006.	Leuk		
Multiple Studies (2087)	Age and acute myeloid leukemia. FR Appelbaum, H Gundacker, DR Head, ML Slovak, CL Willman, JE Godwin, JE Anderson, SH Petersdorf. <u>Blood</u> 107(9):3481-3485, 2006.	Leuk		
Multiple Studies (2315)	The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. FR Appelbaum, KJ Kopecky, MS Tallman, ML Slovak, HM Gundacker, HT Kim, GW Dewald, HM Kantarjian, SR Pierce, EH Estey. <u>British Journal of Haematology</u> 135:165-173, 2006.	Leuk		
Multiple Studies (2325)	Gene expression changes associated with progression and response in chronic myeloid leukemia. JP Radich, H Dai, M Mao, V Oehler, J Schelter, B Druker, C Sawyers, N Shah, W Stock, CL Willman, S Friend, PS Linsley. <u>Proc of the National Academy of Sciences</u> 103(8):2794-2799, 2006.	Leuk		
Multiple Studies (2313)	Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. CS Wilson, GS Davidson, SB Martin, E Andries, J Potter, R Harvey, K Ar, Y Xu, KJ Kopecky, DP Ankerst, H Gundacker, ML Slovak, M Mosquera-Caro, IM Chen, DL Stirewalt, M Murphy, FA Schultz, H Kang, X Wang, JP Radich, FR Appelbaum, SR Atlas, J Godwin, CL Willman. <u>Blood</u> 108(2):685-696, 2006.	Leuk		
Multiple Studies (2327)	Letter to the editor: A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. ML Slovak, H Gundacker, CD Bloomfield, G Dewald, FR Appelbaum, RA Larson, MS Tallman, JM Bennett, DL Stirewalt, S Meshinchi, CL Willman, Y Ravindranath, TA Alonzo, AJ Carroll, SC Raimondi, NA Heerema. <u>Leukemia</u> 20:1295-1297, 2006.	Leuk		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
Multiple Studies (2326)	Letter to the editor: Glutathione S-transferase (GSTM1, GSTT1 and GSTA1) polymorphisms and outcomes after treatment for acute myeloid leukemia: pharmacogenetics in Southwest Oncology Group (SWOG) clinical trials. JR Weiss, KJ Kopecky, J Godwin, J Anderson, CL Willman, KB Moysich, ML Slovak, A Hoque, CB Ambrosone. <u>Leukemia</u> 20:2169-2171, 2006.	Leuk		
Multiple Studies (2331)	Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia. T Pabst, E Stillner, D Neuberg, S Nimer, CL Willman, AF List, JV Melo, DG Tenen, BU Mueller. <u>British Journal of Haematology</u> 133:400-402, 2006.	Leuk		
Multiple Studies (2314)	Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. DL Stirewalt, KJ Kopecky, S Meshinchi, JH Engel, EL Pogosova-Agadjanyan, J Linsley, ML Slovak, CL Willman, JP Radich. <u>Blood</u> 107(9):3724-3726, 2006.	Leuk		

ABSTRACTS PUBLISHED/PRESENTED

*9007 (2429)	Changes in the pattern of cytogenetic aberrations with advancing age in acute myeloid (non-APL) leukemia: a Southwest Oncology study (S9007). TH Norwood, HM Gundacker, ML Slovak, HP Erba, FR Appelbaum. Proc of the American Society of Hematology, <u>Blood</u> 108:#808, 2006.	Leuk
-----------------	--	------

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2005**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9108 (2324)	Addition of rituximab to fludarabine may prolong progression free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. JC Byrd, K Rai, BL Peterson, FR Appelbaum, VA Morrison, JE Kolitz, L Shepherd, JD Hines, CA Schiffer, RA Larson. <u>Blood</u> 105(1):49-53, 2005.	Leuk	6/15/91	12/7/94
S9706 (2138)	Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a Phase II SWOG trial 9706. MA Hussein, H Gundacker, DR Head, L Elias, KA Foon, DH Boldt, SM Dobin, SR Dakhil, GT Budd, FR Appelbaum. <u>Leukemia</u> 19:1880-1886, 2005.	Leuk	9/15/97	3/1/99
Multiple Studies (2330)	AML1-FOG2 fusion protein in myelodysplasia. EM Chan, EM Comer, FC Brown, KE Richkind, ML Holmes, BH Chong, R Shiffman, DE Zhang, ML Slovak, CL Willman, CT Noguchi, Y Li, DJ Heiber, L Kwan, RJ Chan, GH Vance, HC Ramsey, RA Hromas. <u>Blood</u> 105(11):4523-4526, 2005.	Leuk		
Multiple Studies (2329)	Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia. DA Sweetser, AJ Peniket, C Haaland, AA Blomberg, Y Zhang, ST Zaidi, F Dayyani, Z Zhao, NA Heerema, J Boultonwood, GW Dewald, E Paietta, ML Slovak, CL Willman, JS Wainscoat, ID Bernstein, SB Daly. <u>Genes, Chromosomes & Cancer</u> 44:279-291, 2005.	Leuk		
ABSTRACTS PUBLISHED/PRESENTED				
9129 (2321)	Phase III trial of all-trans retinoic acid (ATRA) vs daunorubicin (D) and cytosine arabinoside (A) as induction therapy and ATRA vs observation as maintenance therapy for children with newly diagnosed acute promyelocytic leukemia (APL). J Gregory, H Kim, T Alonzo, R Gerbing, A Ogden, W Woods, H Weinstein, L Shepherd, C Schiffer, F Appelbaum, C Willman, P Wiernik, J Rowe, M Tallman, J Feusner. <u>Blood</u> (ASH Annual Meeting Abstracts) 106(11): #894, 2005.	Leuk	6/15/92	2/1/95
9129 (2323)	Very poor survival of patients with AML who relapse after achieving a first complete remission: the Eastern Cooperative Oncology Group experience. JM Rowe, X Li, PA Cassileth, FR Appelbaum, CA Schiffer, PH Wiernik, MR Litzow, LD Cripe, HM Lazarus, E Paietta, GW Dewald, HJ Weinstein, AK Ogden, WG Woods, L Shepherd, JH Feusner, CD Bloomfield, MS Tallman. <u>Blood</u> (ASH Annual Meeting Abstracts) 106(11): #546, 2005.	Leuk	6/15/92	2/1/95

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*9400 (2212)	CTGF (CCN2) Predicts OS and DFS in adult acute lymphoblastic leukemia. O Sala-Torra, HM Gundacker, DL Stirewalt, PA Ladne, EL Pogossova-Agadjanyan, ML Slovak, CL Willman, S Heimfeld, DH Boldt, JP Radich. <u>Blood</u> (ASH Annual Meeting Abstracts) 106(11): #336, 2005.	Leukemia	7/15/95	5/11/00
E2997 (2318)	Cytogenetic studies of 539 chronic lymphocytic leukemia (CLL) patients. NA Heerema, G Lozanski, TS Lin, M Moran, MR Grever, JC Byrd. <u>Blood</u> 106(11):#1192, 2005.	Leuk	10/15/02	3/19/04
E2997 (2320)	Expression of T cell co-stimulator (ICOS) and its ligand and disease progression in B-cell chronic lymphocytic leukemia. T Fukuda, DS Neuberg, L Huynh, LZ Rassenti, TL Toy, KR Rai, MJ Keating JG Gribben, IW Flinn, JC Byrd, NE Kay, TJ Kipps. <u>Blood</u> 106(11):#2943, 2005.	Leuk	10/15/02	3/19/04
*Multiple Studies (2161)	The clinical spectrum of adult acute myeloid leukemia (AML) associated with core binding factor (CBF) translocations. FR Appelbaum, KJ Kopecky, ML Slovak, HM Gundacker, M Tallman, H Kim, GW Dewald, E Estey, H Kantarjian, S Pierce. <u>Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology</u> 23(16S):563s (#6513), 2005.	Leuk		
Multiple Studies (2216)	Very late antigen-4 (VLA-4) expression by AML blasts: correlation of VCAM-1 binding to overall survival. PS Becker, T Papayannopoulou, KJ Kopecky, AN Hanks, JM Harlan, CL Willman, FR Appelbaum. <u>Blood</u> (ASH Annual Meeting Abstracts) 106(11): #2365, 2005.	Leuk		
*Presented				

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2004**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9031 (1990)	Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukemia. DL Stirewalt, S Meshinchi, SJ Kussick, KM Sheets, E Pogossova-Agadjanyan, CL Willman, JP Radich. <u>British Journal of Haematology</u> 124:481-484, 2004.	Leukemia	11/15/91	1/15/95
Multiple Studies (2089)	Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. DE Banker, SJ Mayer, HY Li, CL Willman, FR Appelbaum, RA Zager. <u>Blood</u> 104(6):1816-1824, 2004.	Leuk		
ABSTRACTS PUBLISHED/PRESENTED				
*9129 (2148)	Microgranular variant (M3V) of acute promyelocytic leukemia (APL) does not have a worse prognosis than classical APL in the atra era: a report of 153 patients treated on Intergroup 0129 and pethema LPA96 and LPA99. MS Tallman, HT Kim, CA Schiffer, FR Appelbaum, JH Feusner, AK Ogden, L Shepherd, CL Willman, CD Bloomfield, JM Rowe, RA Larson, PH Wiernik, G Martin, C Rayon, J de la Serna, C Rivas, JD Gonzalez-San Miguel, G Deben, MA Sanz. <u>Blood</u> 104(11): #394, 2004.	Leuk	6/15/92	2/1/95
E2997 (2316)	Clinical, laboratory, and treatment outcome characteristics of chronic lymphocytic leukemia (CLL) patients with p53 mutations or del(17p) enrolled on a prospective phase III clinical trial: short progression free survival, irrespective of fludarabine-based treatment used. DM Lucas, GW Dewald, DS Neuberg, JC Byrd, G Lozanski, J Harbison, KD Cunningham, IW Flinn, MS Tallman, MR Grever. <u>Blood</u> 104(11):#949, 2004.	Leuk	10/15/02	3/19/04
E2997 (2317)	Critical molecular studies to strategically plan therapy in chronic lymphocytic leukemia (CLL): correlating cellular proteins with defined prognostic patient subsets and their response to treatment. S Kitada, JC Reed, DM Lucas, DS Neuberg, JG Gribben, GW Dewald, IW Flinn, MS Tallman, JC Byrd, MR Grever. <u>Blood</u> 104(11):#956, 2004.	Leuk	10/15/02	3/19/04
*E2997 (2224)	Fludarabine and cyclophosphamide produces a higher complete response rate and more durable remissions Than fludarabine in patients with previously untreated CLL: Intergroup trial E2997. IW Flinn, E Kumm, MR Grever, D Neuberg, GW Dewald, JM Bennett, EM Paietta, FR Appelbaum, RA Larson, MA Hussein, DF Moore Jr, MS Tallman. <u>Blood</u> 104(11): #475, 2004.	Leuk	10/15/02	3/19/04
E2997 (2319)	Outcome of treatment with fludarabine versus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) is adversely impacted by high risk genetic features:	Leuk	10/15/02	3/19/04

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

results from ECOG 2997. MR Grever, DM Lucas, GW Dewald, DS Neuberg, IW Flinn, MS Tallman, JC Gribben, JC Byrd. Blood 104(11):#3487, 2004.

*Multiple
Studies
(2135)

Acute myeloid leukemia (AML) with t(6;9)(p23;q34) defines a very poor risk leukemia subgroup with distinguishing Clinicopathological features: a United States (US) cytogenetics Intergroup study of 62 AML and MDS cases. ML Slovak, CD Bloomfield, H Gundacker, G Dewald, FR Appelbaum, RA Larson, MS Tallman, C Willman, Y Ravindranath, TA Alonzo, A Carroll, B Hirsch, S Raimondi, NA Heerema. Blood 104(11): #567, 2004.

Leuk

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2003**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

9108/9706 (1966)	Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. ED Hsi, KJ Kopecky, FR Appelbaum, D Boldt, T Frey, M Loftus, MA Hussein. <u>British Journal of Haematology</u> 120:1017-1025, 2003.	Leukemia		
Multiple Studies (1835)	Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with <i>ras</i> hotspot mutations or overexpression. DL Stirewalt, FR Appelbaum, CL Willman, RA Zager, DE Banker. <u>Leukemia Research</u> 27:133-145, 2003.	Leukemia		

ABSTRACTS PUBLISHED/PRESENTED

9400 (2022)	Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia (ALL): a Southwest Oncology Group (SWOG) study (S9400). ML Slovak, KJ Kopecky, H Gundacker, F Appelbaum, D Boldt, V Pullarkat, SJ Forman. <u>Blood</u> 102(11):#2223, 2003.	Leuk	7/15/95	5/11/00
Multiple Studies (2132)	Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters associated with clinical characteristics and outcome. C Wilson, M Mosquera-Caro, S Martin, G Davidson, Y Xu, K Ar, J Potter, IM Chen, D Pauler, H Gundacker, M Slovak, F Appelbaum, K Kopecky, C Willman. <u>Blood</u> 102(11): #602, 2003.	Leukemia		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2002**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9007 (1779)	21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop. ML Slovak, V Bedell, L Popplewell, DA Arber, C Schoch, R Slater. <u>Genes, Chromosomes & Cancer</u> 33:379-394, 2002.	Leuk/Cyto	7/15/91	OPEN
9007 (1806)	Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study. SR Wolman, H Gundacker, FR Appelbaum, ML Slovak. <u>Blood</u> 100(1):29-35, 2002.	Leukemia	7/15/91	OPEN
9032 (1778)	Cyclosporine inhibition of p-glycoprotein in chronic myeloid leukemia blast phase. AF List, KJ Kopecky, CL Willman, DR Head, ML Slovak, D Douer, SR Dakhil, FR Appelbaum. <u>Blood</u> 100(5):1910-1912, 2002.	Leukemia	6/1/92	3/1/98
9108 (1653)	Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated Intergroup study. RE Martell, BL Peterson, HJ Cohen, WP Petros, KR Rai, VA Morrison, L Elias, L Shepherd, J Hines, RA Larson, CA Schiffer, HI Hurwitz. <u>Cancer Chemotherapy and Pharmacology</u> 50:37-45, 2002.	Leukemia	6/15/91	12/7/94
9129 (1953)	All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. MS Tallman, JW Andersen, CA Schiffer, FR Appelbaum, JH Feusner, WG Woods, A Ogden, H Weinstein, L Shepherd, C Willman, DC Bloomfield, JM Rowe, PH Wiernik. <u>Blood</u> 100(13):4298-4302, 2002.	Leukemia	6/15/92	2/1/95
9333 (1804)	Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. JE Anderson, KJ Kopecky, CL Willman, D Head, MR O'Donnell, FW Luthardt, TH Norwood, IM Chen, SP Balcerzak, DB Johnson, FR Appelbaum. <u>Blood</u> 100(12):3869-3876, 2002.	Leukemia	1/15/95	12/1/98
Multiple Studies (1692)	PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents, by more than one mechanism. DE Banker, JJ Cooper, DA Fennell,	Leukemia Leuk Bio		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

CL Willman, FR Appelbaum, FE Cotter.
Leukemia Research 26:91-106, 2002.

ABSTRACTS PUBLISHED/PRESENTED

9400 (1952)	Analysis of multidrug resistance gene-1 (MDR1) expression and function in adult acute lymphoblastic leukemia (ALL). a Southwest Oncology Group study. DH Boldt, HM Gundacker, DY Lee, Y Gazitt, SJ Forman. <u>Blood</u> 100(11):756a (#2991), 2002.	Leuk Leuk Bio	7/15/95	5/11/00
C19801 (1967)	A phase II study of 2-amino-9-B-D-arabinosyl-6-methoxy-9H-purine (506U78) in patients with relapsed or refractory T-lineage acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): CALGB study 19801. DJ De Angelo, D Yu, RK Dodge, SE Coutre, BS Mitchell, RM Stone, AT Stopeck, RA Larson. <u>Blood</u> 100(11):198a (#743), 2002.	Leukemia	6/15/00	9/12/01

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2001**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8417/19 (1658)	Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/ L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group study. SH Petersdorf, KJ Kopecky, DR Head, DH Boldt, SP Balcerzak, T Wun, V Roy, RW Veith, FR Appelbaum. <u>Leukemia</u> 15:208-216, 2001.	Leukemia	6/14/85	11/15/91
8600 (1676)	Methylation profiling in acute myeloid leukemia. M Toyota, KJ Kopecky, MO Toyota, KW Jair, CL Willman, JPJ Issa. <u>Blood</u> 97(9):2823-2829, 2001.	Leukemia	11/1/86	12/1/91
9031 (1625)	Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial. CL Bennett, D Hynes, J Godwin, TJ Stinson, RM Golub, FR Appelbaum. <u>Cancer Investigation</u> 19(6):603-610, 2001.	Leukemia	11/15/91	1/15/95
9031 (1674)	FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. DL Stirewalt, KJ Kopecky, S Meshinchi, FR Appelbaum, ML Slovak, CL Willman, JP Radich. <u>Blood</u> 97(11):3589-3595, 2001.	Leukemia Leuk Bio Cytogenetics	11/15/91	1/15/95
9108 (1652)	Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: an Intergroup study Cancer and Leukemia Group B 9011. VA Morrison, KR Rai, BL Peterson, JE Kolitz, L Elias, FR Appelbaum, JD Hines, L Shepherd, RE Martell, RA Larson, CA Schiffer. <u>Journal of Clinical Oncology</u> 19(16):3611-3621, 2001.	Leukemia	6/15/91	12/7/94
9126 (1626)	Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia. A Southwest Oncology Group study. AF List, KJ Kopecky, CL Willman, DR Head, DL Persons, ML Slovak, R Dorr, C Karanes, HE Hynes, JH Doroshow, M Shurafa, FR Appelbaum. <u>Blood</u> 98(12):3212-3220, 2001.	Leukemia	3/1/93	3/1/98
9129 (1949)	Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARa mRNA using real-time reverse-transcription polymerase chain reaction. JL Slack, W Bi, KJ Livak, N Beaubier, M Yu, M Clark, SH Kim, RE Gallagher, CL Willman. <u>Journal of Molecular Diagnostics</u> 3(4):141-149, 2001.	Leukemia	6/15/92	2/1/95

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
Multiple Studies (1693)	Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). SM Garrido, FR Appelbaum, CL Willman, DE Banker. <u>Experimental Hematology</u> 29:448-457, 2001.	Leukemia		
Multiple Studies (1631)	Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture and drug-induced apoptosis. SM Garrido, JJ Cooper, FR Appelbaum, CL Willman, K Kopecky, DE Banker. <u>Leukemia Research</u> 25:23-32, 2001.	Leukemia		
Multiple Studies	Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific. DL Stirewalt, CL Willman, JP Radich. <u>Leukemia Research</u> 25:1085-1088, 2001.	Leukemia		
Multiple Studies (1951)	State-of-the-art mini-review: Targeted AML therapy: new biologic paradigms and therapeutic opportunities. CL Willman. <u>Leukemia</u> 15:690-694, 2001.	Leukemia		
Multiple Studies (1812)	Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. WT Bellamy, L Richter, D Sirjani, C Roxas, B Glinsmann-Gibson, Y Frutiger, TM Grogan, AF List. <u>Blood</u> 97(5):1427-1434, 2001.	Lymph Lymph Bio Leuk Leuk Bio		

ABSTRACTS PUBLISHED/PRESENTED

*9007 (1729)	Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in myeloid leukemia patients in Southwest Oncology Group (SWOG) trials. SR Wolman, HM Gundacker, ML Slovak, FR Appelbaum. <u>Proc of the American Society of Clinical Oncology</u> 20:282a (#1125), 2001.	Leukemia Cytogenetics	7/15/91	OPEN
9007 (1776)	Prognostic implication of additional cytogenetic aberrations in de novo acute myeloid leukemia (AML) with t(15;17), t(8;21) or inv(16). PH Wiernik, H Kim, H Gundacker, D Dewald, ML Slovak, E Paietta, FR Appelbaum, MS Tallman. <u>Blood</u> 98(11):457a, (#1913), 2001.	Leuk/Cyto	7/15/91	OPEN
9108/9706 (1917)	Prognostic significance of CD38 and CD20 expression in chronic lymphocytic leukemia (CLL) as assessed by quantitative flow cytometry. E Hsi, KJ Kopecky, FR Appelbaum, DH Boldt, M Loftus, T Frey, MA Hussein. <u>Blood</u> 98(11):357a (#1504), 2001.	Leukemia Leuk Bio		
S9706 (1717)	Encouraging response rate to sequential cyclophosphamide (Cy) followed by fludarabine phosphate (FI) in newly diagnosed B-cell chronic lymphocytic leukemia (B-CLL): a Southwest	Leukemia	9/15/97	3/1/99

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
	Oncology Group trial. MA Hussein, H Gundacker, L Elias, SR Dakhi, DR Head, F Appelbaum. <u>Proc of the American Society of Clinical Oncology</u> 20:305a (#1217), 2001.			
Multiple Studies (1777)	The significance of trisomy 8 in myeloid leukemia: a Southwest Oncology Group (SWOG) study. ML Slovak, H Gundacker, SR Wolman, FR Appelbaum. <u>American Journal of Human Genetics</u> , 69(4):232 (#285), 2001.	Leukemia		
Multiple Studies (1899)	Use of DNA microarrays to identify gene expression patterns associated with progression and response in chronic myeloid leukemia. M Mao, J Radich, C Roberts, M Biery, S Kobayashi, J Schelter, Y He, D Levine, H Dai, R Stoughton, E Coffrey, A Blanchard, S Friend, P Linsley. <u>Proc of the American Association for Cancer Research</u> 42:428 (#2303), 2001.	Leukemia Leuk Bio		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2000**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8326/9031/ 9126 (1594)	Microsatellite instability is not a defining genetic feature of acute myeloid leukemogenesis in adults: results of a retrospective study of 132 patients and review of the literature. LM Rimsza, KJ Kopecky, J Ruschulte, I-M Chen, ML Slovak, C Karanes, J Godwin, A List, CL Willman. <u>Leukemia</u> 14:1044-1051, 2000.			
8600/9031 9333 (1582)	Acute myelogenous leukemia and aging. Clinical Interactions. JE Lancet, CL Willman, JM Bennett. <u>Hematology/Oncology Clinics of North America</u> 14(1):251-267, 2000.	Leukemia	11/1/86	12/1/91
8691 (1629)	Long-term follow-up of remission duration, mortality and second malignancies in hairy cell leukemia patients treated with pentostatin. IW Flinn, KJ Kopecky, MK Foucar, D Head, JM Bennett, R Hutchison, W Corbett, P Cassileth, T Haberman, H Golomb, K Rai, E Eisenhauer, F Appelbaum, B Cheson, MR Grever. <u>Blood</u> 96(9):2981-2986, 2000.	Leukemia	12/15/86	10/1/91
9030 (1539)	A phase II study of high dose Ara-C and Mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia. PJ Rosen, C Rankin, DR Head, DH Boldt, FW Luthardt, T Norwood, RP Pugh, C Karanes, FR Appelbaum. <u>Leukemia Research</u> 24:183-187, 2000.	Leukemia	11/1/99	5/15/94
9031 (1580)	Twenty-four-color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia. FF Zhang, JL Murata-Collins, P Gaytan, SJ Forman, KJ Kopecky, CL Willman, FR Appelbaum, ML Slovak. <u>Gene, Chromosomes & Cancer</u> 28:318-328, 2000.	Leukemia Leuk Bio Cytogenetics	11/15/91	1/15/95
9034 (1641)	Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. ML Slovak, KJ Kopecky, PA Cassileth, DH Harrington, KS Theil, A Mohamed, E Paietta, CL Willman, DR Head, JM Rowe, SJ Forman, FR Appelbaum. <u>Blood</u> 96(13):4075-4083, 2000.	Leukemia	2/1/91	2/15/95
9108 (1654)	Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. KR Rai, BL Peterson, FR Appelbaum, JE Kolitz, L Elias, L Shepherd, JD Hines, GA Threatte, RA Larson, BD Cheson, CA Schiffer. <u>New England Journal of Medicine</u>	Leukemia	6/15/91	12/7/94

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
	343(24):1750-1757, 2000.			
9129 (1691)	Hypergranular promyelocytic leukemia: correlation between morphology and chromosomal translocations including t(15;17) and t(11;17). JM Bennett, D Catovsky, MT Daniel, G Flandrin, DAG Galton, HR Gralnick, CL Willman. <u>Leukemia</u> 14:1197-1200, 2000.	Leukemia	6/15/92	6/1/95
9129 (1598)	Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARa isoform: results from Intergroup protocol 0129. JL Slack, CL Willman, JW Andersen, YP Li, DS Viswanatha, CD Bloomfield, MS Tallman, RE Gallagher. <u>Blood</u> 95(2):398-403, 2000	Leukemia	6/15//92	2/1/95
9617 (1531)	A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a Southwest Oncology Group study. TR Chauncey, C Rankin JE Anderson, IM Chen, KJ Kopecky, JE Godwin, ME Kalaycio DF Moore Jr, MS Shurafa, SH Petersdorf, EH Kraut, CP Leith, DR Head, FW Luthardt, CL Willman, FR Appelbaum. <u>Leukemia Research</u> 24:567-574, 2000.	Leukemia	11/1/96	9/1/98
Multiple Studies (1597)	Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia. W Stock, T Tsai, C Golden, C Rankin, D Sher, ML Slovak, MG Pallavicini, JP Radich, DH Boldt. <u>Blood</u> 95(7):2364-2371, 2000.	Leukemia Leuk Bio Cytogenetics		
Multiple Studies (1581)	<i>Glutathione S-transferase theta 1</i> gene deletion and risk of acute myeloid leukemia. C Crump, C Chen, FR Appelbaum, KJ Kopecky, SM Schwartz, CL Willman, ML Slovak, NS Weiss. <u>Cancer Epidemiology, Biomarkers & Prevention</u> 9:457-460, 2000.	Leukemia Leuk Bio		
Multiple Studies (1628)	Three-color versus four-color multiparameter cell cycle analyses of primary acute myeloid leukemia samples. SM Garrido, C Willman, FR Appelbaum, DE Banker. <u>Communications in Clinical Cytometry</u> 42:83-94, 2000.	Leukemia Leuk Bio		
Multiple Studies (1636)	Trisomy 15 is frequently observed as a minor clone in patients with anemia/MDS/NHL and as a major clone in patients with AML. JR Batanian, ML Slovak, A Mohamed, S Dobin, FW Luthardt, EA Keitges. <u>Cancer Genetics & Cytogenetics</u> 121:186-189, 2000.	Leukemia Cytogenetics		
Multiple Studies (1860)	Tumor suppressor gene aberrations in acute myelogenous leukemia. DL Stirewalt, JP Radich. <u>Hematology</u> 5:15-25, 2000.	Leukemia		

ABSTRACTS PUBLISHED/PRESENTED

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*9129 (1679)	Predictive value of automated quantitative real-time RT-PCR performed at the end of consolidation of acute promyelocytic leukemia (APL): a SWOG, CALGB, and ECOG Intergroup study (INT-0129). CL Willman, B Yeap, W Bi, JL Slack, DP Harrington, KJ Livak, FR Appelbaum, CD Bloomfield, MS Tallman, RE Gallagher. <u>Proc of the American Society of Clinical Oncology</u> 19:5a (#9), 2000.	Leukemia Leuk Bio	6/15/92	2/1/95
*Multiple Studies (1632)	Blasts from elderly acute myeloid leukemia patients are characterized by low levels of spontaneous and drug-induced apoptosis. SM Garrido, JJ Cooper, FR Appelbaum, CL Willman, KJ Kopecky, DE Banker. <u>Proc of the American Society of Clinical Oncology</u> 19:11a (#35), 2000.	Leukemia Leuk Bio		
Multiple Studies (1670)	Increased incidence of mutations in the granulocyte-colony stimulating factor receptor in patients with acute myeloid leukemia and chromosome 7 abnormalities without antecedent severe congenital neutropenia. LJ Druhan, AC Lidral, CL Willman, ML Slovak, KJ Kopecky, BR Avalos. <u>Blood</u> 96(11):83a (#354), 2000.	Leukemia		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1999**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8326/27 (1295)	A phase III comparison of high dose ARA-C (HIDAC) vs HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia. A Southwest Oncology Group study. C Karanes, KJ Kopecky, DR Head, MR Grever, HE Hynes, EH Kraut, RH Vial, A Lichtin, S Nand, WE Samlowski, FR Appelbaum. <u>Leukemia Research</u> 23(9):787-794, 1999.	Leukemia	4/26/85	12/15/92
8600 (1396)	Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia. Q Li, KJ Kopecky, A Mohan, CL Willman, FR Appelbaum, JK Weick, JJ Issa. <u>Clinical Cancer Research</u> 5:1077-1084, 1999.	Leuk/Bio	11/1/86	12/1/91
8600 (1537)	Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-Glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group study. CP Leith, KJ Kopecky, IM Chen, L Eijdens, ML Slovak, TS McConnell, DR Head, J Weick, MR Grever, FR Appelbaum, CL Willman. <u>Blood</u> 94(3):1086-1099, 1999.	Leukemia	11/1/86	12/1/91
8600 (1587)	Methylation analysis of the human multidrug resistance 1 gene in normal and leukemic hematopoietic cells. KB Fryxell, SB McGee, DK Simoneaux, CL Willman, MM Cornwell. <u>Leukemia</u> 13:910-917, 1999	Leukemia	11/1/86	12/1/91
8600 (1592)	P73 mutations and expression in adult <i>de novo</i> acute myelogenous leukemia. DL Stirewalt, B Clurman, FR Appelbaum, CL Willman, JP Radich. <u>Leukemia</u> 13:985-990, 1999.	Leukemia	11/1/86	12/1/91
8691 (1687)	Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2'-deoxycofomycin and prediction of early relapse. MS Tallman, D Hakimian, KJ Kopecky, S Wheaton, E Wollins, K Foucar, PA Cassileth, T Habermann, M Grever, JM Rowe, LC Peterson. <u>Clinical Cancer Research</u> 5:1665-1670, 1999.	Leukemia	12/15/86	10/1/91
Multiple Studies (1593)	Acute leukemias: a paradigm for the integration of new technologies in diagnosis and classification. CL Willman. <u>Modern Pathology</u> 12(1):218-228, 1999.	Leukemia		
Multiple Studies	Cloning and chromosomal localization of the gene encoding human cyclin d-binding Myb-like protein (hDMP1). SM Bodner, Biology	Leukemia		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
(1515)	CW Naeve, KM Rakestraw, BG Jones, VA Valentine, MB Valentine, FW Luthardt, CL Willman, SC Raimondi, JR Downing, MF Roussel, CJ Sherr, AT Look. <u>Gene</u> 229:223-228, 1999.	Cytogenetics		
Multiple Studies (1950)	Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. WJ Song, MG Sullivan, RD Legare, S Hutchings, X Tan, D Kufrin, J Ratajczak, IC Resende, C Haworth, R Hock, M Loh, C Felix, DC Roy, L Busque, D Kurnit, C Willman, AM Gewirtz, NA Speck, JH Bushweller, FP Li, K Gardiner, M Poncz, JM Maris, DG Gilliland. <u>Nature Genetics</u> 23:166-175, 1999.	Leukemia Leuk Bio		
Multiple Studies (1596)	Lack of IRF-1 expression in acute promyelocytic leukemia and in a subset of acute myeloid leukemias with del(5)(q31). WB Green, ML Slovak, IM Chen, M Pallavicini, JL Hecht, CL Willman. <u>Leukemia</u> 13:1960-1971, 1999.	Leukemia Leuk/Biol		
Multiple Studies (1583)	Molecular evaluation of acute myeloid leukemias. CL Willman. <u>Seminars in Hematology</u> 36(4):390-400, 1999.	Leukemia Leuk Bio		
ABSTRACTS PUBLISHED/PRESENTED				
*8600 (1585)	CPG island methylator phenotype in acute myelogenous leukemia. M Toyota, K Kopecky, M Ohe-Toyota, C Willman, JPJ Issa. <u>Blood</u> 94(10)Suppl 1:491a (#2196), part 1 of 2, 1999.	Leukemia Leuk Biol	11/1/86	12/1/91
*9031 (1575)	24-color karyotyping (multiplex or M-fish) reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia (AML). ML Slovak, F Zhang, JL Murata-Collins, KJ Kopecky, CL Willman, SJ Forman, FR Appelbaum. <u>Blood</u> 94(10) Suppl 1: 657a (#2918), part 1 of 2, 1999.	Leukemia Cytogenetics		
9032 (1567)	A randomized phase III study of cyclosporine (CsA) modulation of anthracycline resistance in CML-blast phase: Southwest Oncology Group (SWOG) study 9032. AF List, KJ Kopecky, ML Slovak, CL Willman, DR Head, FR Appelbaum. <u>Blood</u> 94(10) Suppl 1:276b (#4445), part 2 of 2, 1999.	Leukemia	6/1/92	3/1/98
*9108 (1549)	Therapy-related myelodysplastic syndrome (T-MDS) or acute myeloid leukemia (T-AML) in patients with chronic lymphocytic leukemia (CLL) treated with chlorambucil (C), Fludarabine (F), or Fludarabine + Chlorambucil (F + C): An Intergroup study (Cancer and Leukemia Group B (CALGB) 9011). VA Morrison, KR Rai, B Peterson, JE Kolitz, L Elias, JD Hines, L Shepherd, RA Larson, CA Schiffer. <u>Proc of the American Society of Clinical Oncology</u> 18:9a (#29), 1999.	Leukemia	6/15/91	12/7/94
*9108	Transformation to Richter's syndrome or prolymphocytic	Leukemia	6/15/91	12/7/94

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
(1627)	leukemia (PLL), and other second hematologic malignancies in patients with chronic lymphocytic leukemia (CLL): an Intergroup study (CALGB 9011). VA Morrison, KR Rai, BL Peterson, JE Kolitz, L Ilias, JD Hines, L Shepherd, RA Larson, CA Schiffer. <u>Blood</u> 94(10) Suppl 1:539a (#2410), part 1 of 2, 1999.			
*9129 (1584)	All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome results and prognostic factor analysis from Intergroup Protocol 0129. MS Tallman, JW Andersen, CA Schiffer, FR Appelbaum, JH Feusner, A Ogden, L Shepherd C Willman, CD Bloomfield, JM Rowe, PH Wiernik. <u>Blood</u> 94(10) Suppl 1:698a (#3086), part 1 of 2, 1999.	Leukemia Leuk Biol	6/15/92	2/1/95
*9333 (1576)	A randomized, phase III trial of mitoxantrone (M) + etoposide (E) versus daunomycin (D) + cytarabine (A) as induction therapy in patients over age 55 with previously untreated acute myeloid leukemia (AML): Southwest Oncology Group Study 9333. JE Anderson, KJ Kopecky, D Head, MR O'Donnell, FW Luthardt, TH Norwood, CL Willman, SP Balcerzak, DB Johnson, FR Appelbaum. <u>Blood</u> 94(10) Suppl 1:383a (#1702), part 1 of 2, 1999.	Leukemia Cytogenics	1/15/95	12/1/98

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1998**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8600 (1395)	Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein. DE Hogge, CL Willman, RJ Kreitman, M Berger, PD Hall, KJ Kopecky, C McLain, EP Tagge, CJ Eaves, AE Frankel. <u>Blood</u> 92(2):589-595, 1998.	Leuk Biol	11/1/86	12/1/91
9007 (1314)	Report on workshop regarding leukemia studies by SWOG cytogenetic laboratories. G Kinzie. <u>The Journal of the Association of Genetic Technologists</u> 24(2):44-46, 1998.	Cytogenetics Leukemia	7/15/91	Open
9031 (1386)	AML in the elderly: a biologically distinct disease in which MDR1 expression and unfavorable cytogenetics contribute to poor clinical response. Studies of the Southwest Oncology Group. CP Leith, KJ Kopecky, I Chen, T McConnell, ML Slovak, DR Head, J Godwin, FR Appelbaum, CL Willman. In: <u>Hematology and Blood Transfusion 39, Acute Leukemias VII</u> , Hiddemann et. al. eds, Springer-Verlag Berlin Heidelberg 413-421, 1998.	Leukemia	11/15/91	1/15/95
9031 (1306)	A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study (9031). JE Godwin, KJ Kopecky, DR Head, CL Willman, CP Leith, HE Hynes, SP Balcerzak, FR Appelbaum. <u>Blood</u> 91(10):3607-3615, 1998.	Leukemia	11/15/91	1/15/95
9031 (1389)	Biological features of acute myeloid leukemia in the elderly. CP Leith, KJ Kopecky, CL Willman. <u>Blood</u> 92(2):697-699, 1998.	Leukemia	11/15/98	1/15/95
9034 (1475)	Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. PA Cassileth, DP Harrington, FR Appelbaum, HM Lazarus, JM Rowe, E Paietta, C Willman, DD Hurd, JM Bennett, KG Blume, DR Head, PH Wiernik. <u>New England Journal of Medicine</u> 339(23):1649-1656, 1998.	Leukemia	2/1/91	2/15/95
Multiple Studies (1311)	Cell cycle perturbations in acute myeloid leukemia samples following <i>in vitro</i> exposures to therapeutic agents. DE Banker, M Groudine, CL Willman, T Norwood, FR Appelbaum. <u>Leukemia Research</u> 22(3):221-239, 1998.	Leuk Biol		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
Multiple Studies (1391)	Characterization and use of an antibody detecting the CBFβ- SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias. DS Viswanatha, I Chen, PP Liu, ML Slovak, C Rankin, DR Head, CL Willman. <u>Blood</u> 91(6): 1882-1890, 1998.	Leuk Biol		
Multiple Studies (1493)	The t(8;21) translocation is not consistently associated with high Bcl-2 expression in <i>de novo</i> acute myeloid leukemias Of adults. DE Banker, J Radich, A Becker, K Kerkof, T Norwood, C Willman, FR Appelbaum. <u>Clinical Cancer Research</u> 4(12):3051-3062, 1998.	Leukemia Biology		
Multiple Studies (1393)	Trisomy 6 as a primary karyotypic aberration in hematologic disorders. AN Mohamed, ML Varterasian, SM Dobin, TS McConnell, SR Wolman, C Rankin, CL Willman, DR Head ML Slovak. <u>Cancer Genetics and Cytogenetics</u> , 106:152-155, 1998.	Cytogenetics Leuk Biol		

ABSTRACTS PUBLISHED/PRESENTED

8600/9031/ 9034/9129 (1514)	Cell cycle arrest and therapeutic sensitivity in <i>de novo</i> AML. D Banker, C Willman, M Groudine, F Appelbaum. <u>Blood</u> 90(10) (Suppl 1):67a (#290), 1998.	Leukemia		
*9031 (1484)	Economic analysis of granulocyte colony stimulating factor (G-CSF) as adjunct therapy for older patients with acute myelogenous leukemia (AML): Estimates from a Southwest Oncology Group (SWOG) clinical trial. CL Bennett, D Hynes, J Godwin, TJ Stinson, RM Golub, FR Appelbaum. <u>Blood</u> 92 (10) (Suppl 1):615a (#2538), 1998.	Leukemia	11/15/91	1/15/95
*9034 (1474)	Karyotypic analysis predicts outcome of pre- and post-remission therapy in adult acute myeloid leukemia (AML): A SWOG/ECOG intergroup study. ML Slovak, KJ Kopecky, PA Cassileth, DH Harrington, K Theil, A Mohamed, A Chung, E Paietta, C Willman, DR Head, SJ Forman, FR Appelbaum. <u>Blood</u> 92(10) (Suppl 1):678a (#2795), 1998.	Leukemia	2/1/91	2/15/95
*9126 (1471)	Benefit of cycloporine (CsA) modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group (SWOG) study. AF List, KJ Kopecky, CL Willman, C Spier, R Door, L Flaherty, H Hynes, F Appelbaum. <u>Blood</u> 92(10) (Suppl 1):312a (#1281), 1998.	Leukemia	3/1/93	3/1/98
*9400 (1487)	Functional MDR1 expression in adult acute lymphoblastic leukemia (ALL). Y Gazitt, D Lee, ME Wang, DH Boldt. <u>Blood</u> 92(10) (Suppl 1):676a (#2788), 1998.	Leukemia	7/15/95	OPEN

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*9500 (1380)	A phase II study of standard dose daunomycin and cytosine arabinoside (ARA-C) with high dose ARA-C induction therapy followed by sequential high dose ARA-C consolidation for adults with previously untreated acute myelogenous leukemia: A Southwest Oncology Group study (SWOG 9500). S Petersdorf, C Rankin, H Terebolo, D Head, F Appelbaum. <u>Proc of the American Society of Clinical Oncology</u> 17:15a (#55), 1998.	Leukemia	12/15/95	4/1/97
*9617 (1478)	A phase I dose-finding study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone (M), etoposide (E), and the MDR modulator PSC833: Southwest Oncology Group study #9617. TR Chauncey, C Rankin, JE Anderson, JA Godwin, M Kalaycio, DF Moore, SH Petersdorf, MS Shurafa, EH Kraut, DR Head, ML Slovak, CL Willman, FR Appelbaum. <u>Blood</u> 92(10) (Suppl 1):231a (#945), 1998.	Cytogenetics Leuk Biol	11/1/96	9/1/98
Multiple Studies (1513)	Influence of trisomy 8 on prognosis in APL: A SWOG study. SR Wolman, C Rankin, FR Appelbaum, B Harshbarger, M Slovak. <u>Proc of the American Association for Cancer Research</u> 39:229 (#1564), 1998.	Cytogenetics Leukemia		
Multiple Studies (1516)	P73 mutations and expression in adult <i>de novo</i> acute myelogenous leukemia. DL Stirewalt, B Clurman, FR Appelbaum, CL Willman, JP Radich. <u>Blood</u> 92(10) (Suppl 1):221a (#903), 1998.	Leuk Biol		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1997**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
*7823/8124 8600 (1292)	Long-term survival after chemotherapy for acute myeloid leukemia: The experience of the Southwest Oncology Group. FR Appelbaum, KJ Kopecky. <u>Cancer</u> 80:2199-2204, 1997.	Leukemia		
8600/9034 9007 (1262)	Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. DE Banker, M Groudine, T Norwood, FR Appelbaum. <u>Blood</u> 89(1):243-255, 1997.	Leuk Biol		
9031 (1109)	Development of a highly sensitive multiparameter flow cytometric assay correlating MDR1 expression and function: Clinical application to acute myeloid leukemia. CP Leith, KJ Kopecky, IM Chen, FR Appelbaum, DR Head, JE Godwin, CL Willman. In: <u>Drug Resistance in Leukemia and Lymphoma II</u> , R Pieters, GJL Kaspers, AJP Veerman eds, Harwood Academic Publishers, Amsterdam, Advances in Blood Disorders Series 3:307-314, Ch 37, 1997.	Leuk Biol	11/15/91	1/15/95
9031/9007 (1212)	Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. CP Leith, KJ Kopecky, J Godwin, T McConnell, ML Slovak, IM Chen, DR Head, FR Appelbaum, CL Willman. <u>Blood</u> 89(9):3323-3329, 1997.	Cytogenetics Leuk Biol		
9129 (1263)	Association of PML-RARa fusion mRNA type with pre-treatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study. RE Gallagher, CL Willman, JL Slack, JW Andersen, Y Li, D Viswanatha, CD Bloomfield, FR Appelbaum, CA Schiffer, MS Tallman, PH Wiernik. <u>Blood</u> 90(4):1656-1663, 1997.	Leuk Biol	6/15/92	2/1/95
9129 (1303)	All-trans retinoic acid in acute promyelocytic leukemia. MS Tallman, JW Andersen, CA Schiffer, FR Appelbaum, JH Feusner, A Ogden, L Shepherd, C Willman, CD Bloomfield, JM Rowe, PH Wiernik. <u>New England Journal of Medicine</u> 337: 1021-1028, 1997.	Leukemia	6/15/92	2/1/95

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
*8417/9030 (1254)	Detection of cancer cells with PCR-telomerase assay in human tumor biopsies. E Raymond, S Sharma, D Sun, RE Champlin, H Soda, DH Boldt, DD Von Hoff. <u>American Society of Clinical Oncology</u> 16:93a (#327), 1997.	Leuk Biol		
*8417/9030 (1255)	Inactivation of cell cycle regulatory genes occurs frequently in adult acute lymphoblastic leukemia (ALL): potential role for p16, p15, Rb, and p53 in leukemogenesis. W Stock, C Rankin, D Sher, P Eagan, T Tsai, D Boldt. <u>American Society of Clinical Oncology</u> 16:552a (#1993), 1997.	Leuk Biol		
*8600 (1256)	Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia (AML). Q Li, KJ Kopecky, A Mohan, F Appelbaum, SB Baylin, C Willman, J Issa. <u>American Society of Clinical Oncology</u> 16:4a (#11), 1997.	Leuk Biol	11/1/86	12/1/91
*8691 (1351)	Long-term results in hairy cell leukemia (HCL) treated with pentostatin. IW Flinn, KJ Kopecky, MK Foucar, D Head, JM Bennett, RE Hutchison, WEN Corbett, PA Cassileth, T Habermann, H Golomb, K Rai, E Eisenhauer, FR Appelbaum, BD Cheson, M Grever. <u>Blood</u> 90 (10) Suppl 1: 578a (#2575), 1997.	Leukemia	12/15/86	10/1/91
9031 (1385)	Frequency and clinical significance of expression of the multidrug resistance proteins, MDR1, MRP1, and LRP in acute myeloid leukemia patients less than 65 years old. A Southwest Oncology Group study. CP Leith, KJ Kopecky, IM Chen, M Slovak, DR Head, J Weick, FR Appelbaum, CL Willman. <u>Blood</u> 90 (10) Suppl 1: 389a (#1733), 1997.	Leukemia	11/15/91	1/15/95
9031/9126 (1464)	Trisomy 10 as the sole cytogenetic abnormality in hematologic neoplasia. K Theil, SM Dobin, T McConnell, ML Slovak, S Kahwash, M Brownell, A Chaudhury. <u>Blood</u> 90(10):223b (#3742), 1997.	Cytogenetics Leukemia		
*9034 (1257)	Comparison of autologous bone marrow transplant (AUTOBMT) with high-dose cytarabine (HDAC) in adult acute myeloid leukemia (AML) in first remission (CR1): an ECOG intergroup study. P Cassileth, D Harrington, E Paietta, H Lazarus, F Appelbaum, K Blume, J Bennett, D Hurd, C Willman, M. Slovak, P Wiernik. <u>American Society of Clinical Oncology</u> 16:89a (#311), 1997.	Leuk Biol	2/1/91	2/15/95
*Multiple Studies (1349)	Stem cell sorting and leukemogenesis in adult acute lymphoblastic leukemia (ALL): Alterations of the p16 cell cycle regulatory gene are present in the stem cell compartment. T Tsai, C Golden, L Macay, M Slovak, M Pallavicini, DH Boldt. <u>Blood</u> 90 (10) Suppl 1:491a (#2186), 1997.	Leukemia		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
Multiple Studies (1495)	The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: Studies of the Southwest Oncology Group leukemia research program. CL Willman. <u>Seminars in Hematology</u> 34(4) (Suppl 5):25-33, 1997.	Leukemia		
Multiple Studies (1463)	Trisomy 6 as a primary karyotypic aberration in hematological disorders. AN Mohamed, M Varterasian, S Dobin, T McConnell, SR Wolman, C Rankin, D Head, ML Slovak. <u>Blood</u> 90(10):219b (#3720), 1997.	Cytogenetics Leukemia		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1996**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8417/9030 (1214)	Tumor suppressor gene alteration in adult acute lymphoblastic leukemia (ALL). Analysis of retinoblastoma (Rb) and p53 gene expression in lymphoblasts of patients with de novo, relapsed, or refractory ALL treated in Southwest Oncology Group studies. T Tsai, S Davalath, C Rankin, JP Radich, D Head, FR Appelbaum, DH Boldt. <u>Leukemia</u> 10:1901-1910, 1996.	Leukemia		
8600 (515)	A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study. JK Weick, KJ Kopecky, FR Appelbaum, DR Head, LL Kingsbury, SP Balcerzak, JN Bickers, HE Hynes, JL Welborn, SR Simon, M Grever. <u>Blood</u> 88(8):2841-2851, 1996.	Leukemia	11/1/86	12/1/91
8600/9007 (1215)	Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukemia. T Nakamura, DA Largaespada, MP Lee, LA Johnson, K Ohyashiki, K Toyama, SJ Chen, CL Willman, IM Chen, AP Feinberg, NA Jenkins, NG Copeland, JD Shaughnessey Jr. <u>Nature Genetics</u> 12:154-158, 1996.	Leuk Biol		
8600/9034 (1217)	Identification of the chimeric protein product of the CBFB-MYH11 fusion gene in inv(16) leukemia cells. PP Liu, C Wijmenga, A Hajra, TB Blake, CA Kelley, RS Adelstein, A Bagg, J Rector, J Cotelingam, CL Willman, FS Collins. <u>Genes, Chromosomes & Cancer</u> 16:77-87, 1996.	Leuk Biol		
8600/9031 (1216)	Methods to detect p-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations. WT Beck, TM Grogan, CL Willman, C Cordon-Cardo, DM Parham, JF Kuttesch, M Andreeff, SE Bates, CW Berard, JM Boyett, NA Brophy, HJ Broxterman, HSL Chan, WS Dalton, M Dietel, AT Fojo, RD Gascoyne, D Head, PJ Houghton, DK Srivastava, M Lehnert, CP Leith, E Paietta, ZP Pavelic, L Rimsza, IB Roninson, BI Sikic, PR Twentyman, R Warnke, R Weinstein. <u>Cancer Research</u> 56:3010-3020, 1996.	Leuk Biol		
8600/9007 (1126)	Multidrug resistance-1 (MDR1) expression and functional dye/drug efflux is highly correlated with the t(8;21) chromosomal translocation in pediatric acute myeloid Leukemia. L Pearson, CP Leith, MH Duncan, IM Chen, T McConnell, K Trinkaus, K Foucar, CL Willman. <u>Leukemia</u> 10:1274-1282, 1996.	Leuk Biol		
8600/9034 (1260)	The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias. BJ Kuss, RG Deeley, SPC Cole, CL Willman, KJ Kopecky, SR Wolman, HJ Eyre, DF Callen. <u>Leukemia and Lymphoma</u> 20:357-364, 1996.	Leuk Biol		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
9031/9007 (1246)	A subgroup of elderly AML patients with a high complete remission rate can be defined. ML Slovak, KJ Kopecky, T McConnell, CP Leith, J Godwin, IM Chen, C Rankin, DR Head, F Appelbaum, CL Willman. <u>Trends in Onco-Hematology</u> 4(2):34-35, 1996.	Leuk Biol Cytogenetics		
9031/9007 (1224)	Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1). CL Willman. <u>Leukemia</u> 10(Suppl 1):S33-S35, 1996.	Leuk Biol		
Multiple Studies (1222)	Prognostic markers in acute leukemia. CP Leith, CL Willman. <u>Current Opinion in Hematology</u> 3(4):329-334, 1996.	Leuk Biol		
Multiple Studies (1261)	Revised classification of acute myeloid leukemia. DR Head <u>Leukemia</u> 10:1826-1831, 1996.	Leuk Biol		

ABSTRACTS PUBLISHED/PRESENTED

*8417/9030 (1140)	Comparison of tumor suppressor gene inactivation in <u>de novo</u> and relapsed adult acute lymphoblastic leukemia (ALL). T Tsai, S Davalath, C Rankin, F Appelbaum, DH Boldt. <u>American Society of Clinical Oncology</u> 15:358 (#1052), 1996.	Leukemia		
*8600/8706 (1164)	Estrogen receptor methylation is a favorable prognostic factor in AML. JJ Issa, KJ Kopecky, F Appelbaum, C Willman, SB Baylin. <u>American Society of Clinical Oncology</u> 15:357 (#1048), 1996.	Leuk Biol		
8600/9034 (1221)	Characterization and rapid diagnostic utility of a novel antibody detecting the CBF β /SMMHC fusion protein of inversion(16)/t(16;16) associated acute myeloid leukemia. DS Viswanatha, IM Chen, PP Liu, ML Slovak, C Rankin, CL Willman. <u>Blood</u> 88(10) Suppl 1:664a (#2646), 1996.	Leuk Biol		
8600/9034 (1219)	Spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. DE Banker, M Groudine, FR Appelbaum. <u>Blood</u> 88(10) Suppl 1:665a (#2649), 1996.	Leuk Biol		
*9031 (1144)	AML in the elderly: Stratification by MDR1 phenotype, secondary vs de novo status, and cytogenetics identifies patients with high complete remission (CR) rates. A Southwest Oncology Group study. CP Leith, KJ Kopecky, J Godwin, T McConnell, M Slovak, IM Chen, DR Head, F Appelbaum, CL Willman. <u>American Society of Clinical Oncology</u> 15:359 (#1058), 1996.	Leuk Biol	11/15/91	1/15/95
9031 (1161)	Cytogenetics, MDR1, and disease status in elderly AML identify a subgroup with a high complete remission (CR) rate: A Southwest Oncology Group study. ML Slovak, KJ Kopecky, T McConnell, CP Leith, J Godwin, IM Chen, C Rankin, DR Head, F Appelbaum, CL Willman. <u>British Journal of Haematology</u> 93 (Suppl 2):134 (#522), 1996.	Leuk Biol	11/15/91	1/15/95

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
9031/9007 (1220)	Acute myeloid leukemia in the elderly: High frequency of trilineage dyspoiesis suggests that elderly AML is biologically similar to AML arising secondary to myelodysplasia. CP Leith, KJ Kopecky, CL Willman, M Slovak, T McConnell, J Godwin, I Chen, FR Appelbaum, DR Head. <u>Blood</u> 88(10) Suppl 1:559a (#2225), 1996.	Leuk Biol		
9108 (1406)	A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG/NCI-C and ECOG Inter-group study. KR Rai, B Peterson, L Elias, L Shepherd, J Hines, D Nelson, B Cheson, J Kolitz, CA Schiffer. <u>Blood</u> 88(19): 141a (#552), 1996.	Leukemia		
9129 (1218)	Molecular characteristics and clinical features of adult APL patients with the type V PML-RARa ISOFORM: Results from intergroup protocol 0129. JL Slack, CL Willman, Y Li, D Viswanatha, CD Bloomfield, PH Wiernik, MS Tallman, RE Gallagher. <u>Blood</u> 88(10) Suppl 1:635a (#2528), 1996.	Leuk Biol	6/15/92	2/1/95
*9129/9007 (1127)	Correlation of PML-RARa mRNA transcript type with morphology, cytogenetics and clinical parameters in acute promyelocytic leukemia. D Viswanatha, KJ Kopecky, K Doss, C Rankin, DR Head, RE Magenis, FR Appelbaum, CL Willman. <u>International Academy of Pathology Book of Abstracts</u> 125A (#730), 1996.	Leuk Biol		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1995**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7984 (903)	Effects of vitamin A on survival in patients with chronic myelogenous leukemia: A SWOG randomized trial. FL Meyskens Jr, KJ Kopecky, FR Appelbaum, SP Balcerzak, W Samlowski, H Hynes. <u>Leukemia Research</u> 19(9):605-612, 1995.	Leukemia	7/10/80	4/1/87
8124/25/26 (910)	A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): A Southwest Oncology Group study. J Hewlett, KJ Kopecky, D Head, HJ Eyre, L Elias, L Kingsbury, SP Balcerzak, L Dabich, H Hynes, JN Bickers, FR Appelbaum. <u>Leukemia</u> 9:562-569, 1995.	Leukemia	5/11/82	9/27/85
8124/8522 8561/8600 8706 (900)	Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. D Head, KJ Kopecky, J Weick, JC Files, D Ryan, K Foucar, M Montiel, J Bickers, A Fishleder, M Miller, C Spier, C Hanson, M Bitter, R Brazier, G Mills, J Welborn, W Williams, J Hewlett, C Willman, FR Appelbaum. <u>Blood</u> 86(5):1717-1728, 1995.	Leuk Biol		
8561 (907)	Treatment of acute myelogenous leukemia in patients over 50 years of age with V-TAD: A Southwest Oncology Group study. CL Bigelow, K Kopecky, JC Files, D Head, DA Lipschitz, M Grever, FR Appelbaum. <u>American Journal of Hematology</u> 48:228-232, 1995.	Leukemia	7/26/85	11/1/87
8600 (1258)	Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group. EL Sievers, FO Smith, WG Woods, JW Lee, WA Bleier, CL Willman, ID Bernstein. <u>Leukemia</u> 9:2042-2048, 1995.	Leuk Biol	11/1/86	12/1/91
8600/9007 9031 (1059)	Amplification of the E2F-1 transcription factor gene in the HEL erythroleukemia cell line. M Saito, K Helin, MB Valentine, BB Griffith, CL Willman, E Harlow, AT Look. <u>Genomics</u> 25:130-138, 1995.	Leuk Biol		
8600/9031 (1040)	Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR ⁻ /efflux ⁺ and MDR1 ⁺ /efflux ⁻ cases. CP Leith, IM Chen, KJ Kopecky, FR Appelbaum, DR Head, JE Godwin, JK Weick, CL Willman. <u>Blood</u> 86(6):2329-2342, 1995.	Leuk Biol		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
8600/8750 (1064)	Cytogenetically aberrant cells in the stem cell compartment (CD34 ⁺ lin ⁻) in acute myeloid leukemia. B Mehrotra, TI George, K Kavanau, H Avet-Loiseau, D Moore II, CL Willman, ML Slovak, S Atwater, DR Head, MG Pallavicini. <u>Blood</u> 86(3):1139-1147, 1995.	Leuk Biol		
8600/9007 9031 (1060)	Heterogeneity in CBF β /MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia. SA Shurtleff, S Meyers, SW Hiebert, SC Raimondi, DR Head, CL Willman, S Wolman, ML Slovak, AJ Carroll, F Behm, MG Hulshof, TA Motroni, T Okuda, P Liu, FS Collins, JR Downing. <u>Blood</u> 85(12):3695-3703, 1995.	Leuk Biol		
8600/8326 9031/9034 (1069)	Trisomy 11: an association with stem/progenitor cell immunophenotype. ML Slovak, ST Traweek, CL Willman, DR Head, KJ Kopecky, RE Magenis, FR Appelbaum, SJ Forman. <u>British Journal of Hematology</u> 90:266-273, 1995.	Leuk Biol		
8612 (998)	Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post bone marrow transplantation: A Southwest Oncology Group study (SWOG-8612). ML Slovak, KJ Kopecky, SR Wolman, JP Henslee-Downey, FR Appelbaum, SJ Forman, KG Blume. <u>Leukemia Research</u> 19(6):381-388, 1995.	Leukemia	12/30/86	10/1/91
8691 (INT-0073) (1014)	Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An Intergroup study. M Grever, K Kopecky, MK Foucar, D Head, JM Bennett, RE Hutchison, WEN Corbett, PA Cassileth, T Habermann, H Golomb, K Rai, E Eisenhauer, F Appelbaum, BD Cheson. <u>Journal of Clinical Oncology</u> 13(4):974-982, 1995.	Leukemia	12/15/86	10/1/91
8828 (1003)	Carboplatin infusion in relapsed and refractory acute myeloid leukemia - A Southwest Oncology Group trial. JL Welborn, KJ Kopecky, FJ Meyers, R Veith, M Shurafa, JH Doroshow, SP Balcerzak, FR Appelbaum. <u>Leukemia</u> 9:1126-1129, 1995.	Leukemia	11/15/89	10/15/92
*9031 (1048)	Design and conduct of a double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: A Southwest Oncology Group Study. J Godwin. <u>Journal of the National Cancer Institute Monographs</u> 19:31-35, 1995.	Leukemia	11/15/91	Open
Multiple Studies (1225)	Advances in understanding the biology of acute myelogenous leukaemia and its treatment. The molecular basis of acute myelogenous leukaemia. J Downing, C Willman, FR Appelbaum. <u>Trends in Onco-Hematology</u> 3(4):67-71, 1995.	Leuk Biol		
Multiple Studies (1061)	Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). JD Licht, C Chomienne, A Goy, A Chen, AA Scott, DR Head, JL Michaux, Y Wu, A DeBlasio, WH Miller Jr, AD Zelenetz, CL Willman, Z Chen, S-J Chen, A Zelent, E Macintyre, A Veil, J Cortes, H Kantarjian, S Waxman. <u>Blood</u> 85(4):1083-1094, 1995.	Leuk Biol		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
*8417/19	Inactivation of tumor suppressor genes, Rb1 and p53, The Southwest Oncology experience. S Davalath, C Rankin, J Radich, K Kopecky, M Gulley, F Appelbaum, DH Boldt. <u>ASCO</u> 14:336 (#1008), 1995.	Leukemia	6/14/85	11/15/91 (1108)
8600/9007 9031 (1053)	Genetic heterogeneity of acute myeloid leukemia (AML) with FAB-AML M3 morphology. DR Head, F Behm, S Raimondi, A Carroll, M Slovak, E Magenis, C Willman, J Licht, A Scott, MV Gresik, J Downing, D Butler, T Motroni. <u>International Academy of Pathology Book of Abstracts</u> 112A (#651), 1995.	Leuk Biol		
8600/9007 9031 (1057)	Heterogeneity in CBF β /MYH11 fusion messages encoded by the inv(16) and the t(16;16) in acute myelogenous leukemia. J Downing, S Shurtleff, S Meyers, S Hiebert, S Raimondi, D Head, C Willman, S Wolman, A Carroll, F Behm, F Collins, P Liu. <u>International Academy of Pathology Book of Abstracts</u> 109A (#630), 1995.	Leuk Biol		
*8600/9007 (1124)	Multidrug resistance (MDR1) expression and function in acute myeloid leukemia (AML) in the elderly: MDR1 and secondary AML status are independent predictors of complete remission (CR). CP Leith, KJ Kopecky, IM Chen, JE Godwin, FR Appelbaum, DR Head, CL Willman. <u>Leukemia</u> 9(3):535 (#031), 1995.	Leuk Biol		
*9031 (1120)	MDR1 expression is highly predictive for achievement of complete remission (CR) in acute myeloid leukemia (AML) in the elderly: A Southwest Oncology Group study. CP Leith, KJ Kopecky, IM Chen, JE Godwin, FR Appelbaum, DR Head, CL Willman. <u>Blood</u> 86(10)(Suppl 1)(#1061):269a, 1995.	Leuk Biol	11/15/91	1/15/95
*9108 (1133)	Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia (CLL). A randomized inter-group study. KR Rai, B Peterson, J Kolitz, L Elias, L Shepherd, J Hines, B Cheson, C Schiffer. <u>Blood</u> 86(10)(Suppl 1)(#2414):607a, 1995.	Leukemia	6/15/91	12/7/94
9129 (1128)	Correlation of PML-RAR α mRNA type with pretreatment clinical characteristics and achievement of complete remission (CR) in acute promyelocytic leukemia (APL): An Intergroup laboratory study. R Gallagher, C Willman, J Slack, J Andersen, Y Li, D Viswanatha, C Bloomfield, F Appelbaum, C Schiffer, M Tallman, P Wiernik. <u>Blood</u> 86(10)(Suppl 1)(#2902):729a, 1995.	Leuk Biol	6/15/92	2/1/95
*9129 (1237)	Phase III randomized study of all-trans retinoic acid (ATRA) vs daunorubicin (D) and cytosine arabinoside (A) as induction therapy and ATRA vs observation as maintenance therapy for patients with previously untreated acute promyelocytic leukemia (APL). MS Tallman, J Andersen, CA Schiffer, FR Appelbaum, JE Feusner, WG Woods, A Ogden, H Weinstein, L Shepherd, JM Rowe, PH Wiernik. <u>Blood</u> 86(10)(Suppl 1)(#488):125a, 1995.	Leukemia	6/15/92	2/1/95

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1994**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8124/8522 8561/8600 8706 (1101)	Reply to comments by Fenaux and Warrell. DR Head, KJ Kopecky, C Willman, FR Appelbaum. <u>Leukemia</u> 8(Suppl 2):S62, 1994.	Leukemia		
8124/8522 8561/8600 8706 (974)	Treatment outcome with chemotherapy in acute promyelocytic leukemia: The Southwest Oncology Group (SWOG) experience. DR Head, KJ Kopecky, C Willman, FR Appelbaum. <u>Leukemia</u> 8(Suppl 2): S38-S41, 1994.	Leukemia		
8417/19 (933)	Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience. DH Boldt, KJ Kopecky, D Head, G Gehly, JP Radich, FR Appelbaum. <u>Leukemia</u> 8(12):2118-2126, 1994.	Leukemia CCR	6/14/85	11/15/91
8417/8750 (934)	Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction. JP Radich, KJ Kopecky, DH Boldt, D Head, ML Slovak, R Babu, J Kirk, A Lee, P Kessler, F Appelbaum, G Gehly. <u>Leukemia</u> 8(10):1688-1695, 1994.	Leukemia CCR		
8600/8750 (936)	Consistent loss of the D5S89 locus mapping telomeric to the interleukin gene cluster and centromeric to EGR-1 in patients with 5q- chromosome. L Nagarjan, J Zavadil, D Claxton, X Lu, J Fairman, JA Warrington, JJ Wasmuth, AC Chinault, CE Sever, ML Slovak, CL Willman, AB Deisseroth. <u>Blood</u> 83(1):199-208, 1994.	Leukemia CCR		
8600/8750 (1062)	Deletion of the gene for multidrug resistance in acute myeloid leukemia with inversion chromosome 16: Prognostic implications. BJ Kuss, RG Deeley, SP Cole, CL Willman, KJ Kopecky, SR Wolman, HJ Eyre, SA Lane, JK Nancarrow, SA Whitmore, DF Callen. <u>Lancet</u> 343:1531-1535, 1994.	Leukemia		
8600/8750 8828/9007 9031 (1000)	HLA-DR ⁺ , CD33 ⁺ , CD56 ⁺ , CD16 ⁺ myeloid/natural killer cell acute leukemia: A previously unrecognized form of acute leukemia potentially misdiagnosed as FAB AML-M3. AA Scott, DR Head, KJ Kopecky, FR Appelbaum, KS Theil, MR Grever, IM Chen, MH Whittaker, BB Griffith, JD Licht, S Waxman, MM Whalen, AD Bankhurst, LC Richter, TM Grogan, CL Willman. <u>Blood</u> 84(1):244-255, 1994.	Leukemia CCR		
Multiple Studies (1063)	Development of a sensitive PCR to detect allele loss in a model hematopoietic neoplasm. J Fairman, D Claxton, CL Willman, AB Deisseroth, L Nagarajan. <u>PCR Methods and Applications</u> 4:6-12, 1994.	Leukemia Biology		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
*8600/9007 9031 (1097)	Acute promyelocytic leukemia associated with t(11;17) is a discrete syndrome that fails to respond to retinoic acid. JD Licht, C Chomienne, A Goy, A Chen, AA Scott, DR Head, JL Michaux, Y Wu, A DeBlasio, WH Miller Jr, AD Zelenetz, CL Willman, Z Chen, SJ Chen, A Zelent, E Macintyre, A Veil, J Cortes, H Kantarjian, S Waxman. <u>Blood</u> 84(10)(Suppl 1) (#1500):379a, 1994.	Leukemia Biology		
*8600/8750 8828/9007 9031 (939)	CD56: A determinant of extramedullary and central nervous system (CNS) involvement in acute myeloid leukemia (AML). AA Scott, KJ Kopecky, TM Grogan, DR Head, FA Troy II, J Mullen, FR Appelbaum, KS Theil, CL Willman. <u>Lab Investigation</u> 70(1):120A(#695), 1994. <u>Modern Pathology</u> 7(1):120A(#695), 1994. <u>International Academy of Pathology Book of Abstracts</u> 120A(#695), 1994.	Leukemia Biology		
8600/9007 9031 (1054)	Comparative genomic hybridization (CGH) and cytogenetics provide complementary information to identify genetic abnormalities in AML. H Avet-Loiseau, K Theil, T McConnell, CL Willman, S Atwater, MG Pallavicini. <u>Blood</u> 84(10)(Suppl 1) (#2380):599a, 1994.	Leukemia Biology		
*8600/9031 (1056)	Correlation of functional efflux and multidrug resistance (MDR1) expression in acute myeloid leukemia (AML) in the elderly: MDR1 and secondary AML status are independent predictors of complete remission (CR). CP Leith, KJ Kopecky, IM Chen, JE Godwin, FR Appelbaum, DR Head, CL Willman. <u>Blood</u> 84(10)(Suppl 1) (#1493):377a, 1994.	Leukemia Biology		
8600/9007 (1055)	Multidrug resistance-1 (MDR1) expression and functional dye/drug efflux is highly correlated with the t(8;21) chromosomal translocation in pediatric acute myeloid leukemia (AML). L Pearson, CP Leith, IM Chen, MH Duncan, T McConnell, K Theil, K Foucar, CL Willman. <u>Blood</u> 84(10)(Suppl 1) (#172):46a, 1994.	Leukemia Biology		
8600/9007 9031 (1037)	Trisomy 8: A primary cytogenetic anomaly in leukemia? SR Wolman, ML Slovak, CL Willman, FR Appelbaum, RE Magenis. <u>Blood</u> 84(10)(Suppl 1) (#1219):308a, 1994.	Leukemia Biology		
*9007/9108 (946)	The detection of trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hybridization. PA Scalamogna, KS Theil. <u>American Journal of Clinical Pathology</u> 101(3):377 (#8), 1994.	Leukemia		
Multiple Studies (1065)	Analysis of non-clonal chromosome abnormalities observed in hematologic malignancies among Southwest Oncology Group patients. TS McConnell, SM Dobin. <u>American Society of Human Genetics</u> 55(3)(Suppl) (#1760):A301, 1994.	Leukemia		
Multiple Studies (966)	Trisomy II in acute myeloid leukemia: a non-random chromosomal aberration associated with a stem cell phenotype. ML Slovak, K Kopecky, RE Magenis, D Head, FR Appelbaum, C Willman. <u>American Association for Cancer Research</u> 35:194 (#1160), 1994.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1993**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8032 (429)	Mitoxantrone (dihydroxyanthracenedione) in acute leukemia: An evaluation of two treatment schedules by the Southwest Oncology Group. JH Saiki, WJ Stuckey, JW Athens, BL Trantum, E Van Slyck, DD Von Hoff. <u>IND</u> 11:197-200, 1993.	Leukemia Dev Ther	10/22/80	09/10/82
8600/8750 9007/9031 9034 (926)	An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the t(8;21) (q22;q22). JR Downing, DR Head, AM Curcio-Brint, MG Hulshof, TA Motroni, SC Raimondi, AJ Carroll, HA Drabkin, CL Willman, KS Theil, CI Civin, P Erikson. <u>Blood</u> 81(11):2860-2865, 1993.	Leukemia CCR		
8600/9007 9031/9034 (927)	HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities. SP Hunger, DC Tkachuk, MD Amylon, MP Link, AJ Carroll, JL Welborn, CL Willman, ML Cleary. <u>Blood</u> 81(12):3197-3203, 1993.	Leukemia CCR		
8612 (792)	A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with recurrent leukemia who were not in first remission: A Southwest Oncology Group study. KG Blume, KJ Kopecky, JP Henslee-Downey, SJ Forman, PJ Stiff, CF LeMaistre, FR Appelbaum. <u>Blood</u> 81(8):2187-2193, 1993.	Leukemia	12/20/86	10/01/91
8833 (797)	A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: A Southwest Oncology Group study. L Elias, D Stock-Novack, DR Head, MR Grever, JK Weick, RA Chapman, JE Godwin, EN Metz, FR Appelbaum. <u>Leukemia</u> 7(3):361-365, 1993.	Leukemia Dev Ther	05/15/89	04/15/91
9023/9126 (987)	Multidrug resistance: Clinical relevance in acute leukemia. AF List. <u>Oncology</u> 7(10):23-32, 1993.	Leukemia		
Multiple Studies (800)	Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. CL Willman, CE Sever, MG Pallavicini, H Harada, N Tanaka, ML Slovak, H Yamamoto, K Harada, TC Meeker, AF List, T Taniguchi. <u>Science</u> 259:968-971, 1993.	Leukemia		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
8417/19 (1058)	A comparison of two consolidation regimens in the treatment of adult acute lymphoblastic leukemia (ALL): The results of the Southwest Oncology Group studies (SWOG) 8417/19. S Petersdorf, KJ Kopecky, D Head, D Boldt, F Appelbaum. <u>Blood</u> 82(10)(Suppl):193a (#759), 1993.	Leukemia Biology		
8600/8750 (942)	Development of a highly sensitive polymerase chain reaction to detect allele loss in the 5q-chromosome. J Fairman, D Claxton, C Willman, A Deisseroth, L Nagarajan. <u>Blood</u> 82(10) (Suppl 1) (#123), 1993.	Leukemia CCR		
*8600/8750 8828/9007 9031 (931)	Identification and characterization of a previously unrecognized form of acute leukemia co-expressing myeloid and natural killer (NK) cell-associated antigens (CD56). AA Scott, DR Head, K Theil, LM Chen, MH Whittaker, CL Willman. <u>International Academy of Pathology</u> 68:100A (#575), 1993.	Leukemia CCR		
*8600/9007 (941)	Clinical and molecular characterization of the acute promyelocytic leukemia (APL) associated with the t(11;17) and PLZF-RAR fusion. Z Chen, JD Licht, A Zelenet, SJ Chen, A Chen, Y Wu, WH Miller Jr, A Zelenetz, A Goy, A DeBlasio, A Scott, C Willman, D Head, C Chomienne, F Guidez, S Waxman. <u>Blood</u> 82(10) (Suppl 1) (#432), 1993.	Leukemia CCR		
*8600/9031 (932)	Clinical significance and functional analysis of the expression of the multidrug resistance gene (MDR1) in acute myeloid leukemia (AML). CP Leith, LM Chen, BB Griffith, DR Head, AF List, FR Appelbaum, CL Willman. <u>International Academy of Pathology</u> 68:94A (#544), 1993.	Leukemia CCR		
*8600/9031 9126 (940)	Functional assessment of the multidrug (MDR1) resistance efflux pump in acute myeloid leukemia (AML): Identification of CD34-, CD33+, MRK16+ (MDR1+) cases lacking functional dye efflux. CP Leith, KJ Kopecky, IM Chen, BB Griffith, FR Appelbaum, CL Willman. <u>Blood</u> , 82(10) (Suppl 1) (#1754), 1993.	Leukemia CCR		
8612 (944)	Cytogenetic correlation with disease status and treatment outcome in poor prognosis leukemia post bone marrow transplantation: A Southwest Oncology Group study (SWOG-8612). ML Slovak, KJ Kopecky, SR Wolman, JP Henslee-Downey, SJ Forman, KG Blume. <u>Blood</u> 82(10) (Suppl 1) (#1150), 1993.	Leukemia	12/20/86	10/01/91
*9126	Non-P-glycoprotein (PGP) mediated multidrug resistance (MDR): Identification of a novel drug resistance phenotype with prognostic relevance in acute myeloid leukemia (AML). AF List, CS Spier, M Abbaszadegan, TM Grogan, JP Greer, SN Wolff, RJ Scheper, WS Dalton. <u>Blood</u> 82(10) (Suppl 1) (#1755), 1993.	Leukemia	3/1/93	

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
Multiple Studies (1245)	Interferon regulatory factor-1 (IRF-1): A new candidate tumor suppressor gene deleted in 5q-hematopoietic disorders. CE Sever, M Pallavacini, H Harada, N Tanaka, M Slovak, H Yamamoto, K Harada, A List, T Taniguchi, C Willman. <u>Lab Investigations</u> 68:100A (#576), 1993.	Leukemia Cytogenetics		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1992**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7823/24/ 25/26 (507)	Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia-results of a Southwest Oncology Group study of rubidazone vs adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and levamisole maintenance. FS Morrison, KJ Kopecky, D Head, JW Athens, SP Balcerzak, C Gumbart, L Dabich, JJ Costanzi, CA Coltman, Jr, JH Saiki, KK Hussein, CJ Fabian, FR Appelbaum. <u>Leukemia</u> 6(7):708-714, 1992.	Leukemia	08/04/78	09/20/82
8522 (445)	Analysis of treatment failure in acute non-lymphocytic leukemia patients over fifty years of age. A Southwest Oncology Group study. DH Ryan, KJ Kopecky, D Head, MR Grever, SM Shlaer, DA Lipschitz, HE Hynes, RH Vial, RW Veith, CH Gumbart. <u>AJCO</u> 15(1):69-75, 1992.	Leukemia	02/17/86	11/01/87
8592 (524)	Phase III evaluation of low-dose cytosine arabinoside versus supportive care in the treatment of adults with myelodysplastic syndrome: An Intergroup study of the Eastern Cooperative Oncology Group and the Southwest Oncology Group - preliminary results. JM Bennett, KB Miller, K Kim, S Morrison, JN Winter, P Cassileth, RS Neiman, D Head. In: <u>Myelodysplastic Syndrome</u> , Schmalzl & Mufti, Springer-Verlag, 253-258, 1992.	Leukemia	07/84	07/01/88
8592 (523)	The evaluation of low dose cytarabine in the treatment of the myelodysplastic syndromes: A phase III intergroup study. KB Miller, K Kyungmann, F Morrison, JN Winter, JM Bennett, RS Neiman, DR Head, PA Cassileth, MJ O'Connell. <u>Annals of Hematology</u> 65:162-168, 1992.	Leukemia	07/84	07/01/88
8600 (527)	False positive flow cytometric platelet glycoprotein IIb/IIIa expression in myeloid leukemias secondary to platelet adherence to blasts. S Betz, K Foucar, DR Head, IM Chen, CL Willman. <u>Blood</u> 79:2399-2403, 1992.	Leukemia	11/01/86	12/01/91
8600/8750 (447)	N-ras mutations in acute myelogenous leukemia: A review of the current literature and an update of the Southwest Oncology Group experience. JP Radich, KJ Kopecky, F Appelbaum, CL Willman, SJ Collins. <u>Leukemia and Lymphoma</u> 6:325-334, 1992.	Leukemia		
8600/8750 (528)	Activation of EVI-1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. K Morishita, E Paraganas, CL Willman, MH Whittaker, H Drabkin, J Oval, R Taetle, MB Valentine, JN Ihle. <u>Proc Natl Acad Sci</u> 89:3937-3941, 1992.	Leukemia		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
*8124/8522 (816)	Background dysplasia in acute myeloblastic leukemia (AML). D Head, K Kopecky, G Snow, F Appelbaum, CL Willman. <u>U.S. Canadian Academy of Pathology Lab Investigation</u> 66:79A, 1992.	Leukemia		
*8326/27 (819)	The relationship of the stem cell phenotype and lineage commitment to the multidrug resistance phenotype in acute leukemia. C Spier, A List, C Karanes, T Grogan, C Willman, F Appelbaum. <u>U.S. Canadian Academy of Pathology Lab Investigation</u> 5(1):88A, 1992.	Leukemia		
8326/27 (672)	Evaluation of combination chemotherapy using high dose ARA-C with and without mitoxantrone in the treatment of first relapse acute myeloid leukemia. A Southwest Oncology Group study. C Karanes, K Kopecky, M Grever, F Appelbaum. <u>Blood</u> 80:114A, 1992.	Leukemia	04/26/85	05/15/92
*8417/19 (821)	Expression of myeloid antigens in adult acute lymphoblastic leukemia: The Southwest Oncology Group experience. DH Boldt, K Kopecky, D Head, G Gehly, J Radich, F Appelbaum. <u>ASCO</u> 11:263 (#863), 1992.	Leukemia CCR	06/14/84	11/15/91
*8600 (830)	A randomized investigation of high-dose (HDAC) versus standard dose (SDAC) cytosine arabinoside with daunorubicin (DNR) in patients with acute myelogenous leukemia. J Weick, K Kopecky, F Appelbaum, D Head, L Elias, L Kingsbury, D Daniels, SP Balcerzak, GM Mills, HE Hynes, CA Coltman, Jr, M Grever. <u>ASCO</u> 11:261 (#856), 1992.	Leukemia CCR	11/01/86	12/01/91
*8600 (831)	Biologic parameters that predict treatment response in de novo acute myeloid leukemia (AML): CD34, but not multidrug resistance (MDR) gene expression, is associated with a decreased complete remission (CR) rate and CD34 ⁺ patients more frequently achieve CR with high dose cytosine arabinoside. CL Willman, KJ Kopecky, J Weick, F Appelbaum, MR Grever, DR Head, L Elias, SP Balcerzak, GM Mills, HE Hynes. <u>ASCO</u> 11:262 (#857), 1992.	Leukemia CCR	11/01/86	12/01/91
*8600 (832)	Biochemical modulation of anthracycline resistance (MDR) in acute leukemia with cyclosporin-A (CSA). AF List, C Spier, J Greer, C Azar, J Hutter, S Wolff, S Salmon. <u>ASCO</u> 11:264 (#866), 1992.	Leukemia CCR	11/01/86	12/01/91
8600/8750 (920)	Chromosomal rearrangements 3' of the EV1 myeloid transforming gene activate expression in human acute myelogenous leukemia. A Gajjar, E Parganas, CL Willman, K Morishita, J Ihle. <u>Blood</u> 80(10) Suppl 1:256a, 1992.	Leukemia CCR		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*8600/9007 (921)	Interferon regulatory factor-1 (IRF-1): A candidate tumor suppressor gene on chromosome 5q31-1 deleted in leukemia and myelodysplasia (MDS) with del (5q) or translocation of 5q31. CL Willman, C Sever, M Pallavicini, H Harada, N Tanaka, M Slovak, A List, H Yamamoto, K Harada, T Taniguchi. <u>Blood</u> 80:74a (#286), 1992.	Leukemia CCR		
8600/9007 (922)	The human cell cycle gene CDC25C maps to chromosome 5q31.1 within 100 KB of interferon regulatory factor-1 (IRF-1) in the critical region deleted in myelodysplasia (MDS) and leukemia with 5q abnormalities. C Sever, CL Willman, H Harada, T Taniguchi, W Kuo, M Pallavicini, M Slovak, T Meeker. <u>Blood</u> 80(10) Suppl 1:195a (#769), 1992.	Leukemia CCR		
8600/9007 (923)	Evaluation of the proliferative fraction of cytogenetically normal and aberrant hemopoietic subpopulations in acute myeloid leukemia (AML and myelodysplasia (MDS). TI George, B Mehrotra, CL Willman, PI Greenberg, MG Pallavicini. <u>Blood</u> 80(10) Suppl 1:30a, 1992.	Leukemia CCR		
8600/9007 (924)	Variable frequency of cytogenetically aberrant cells in the stem cell compartment and hemopoietic lineages in acute myeloid leukemia (AML) and myelodysplasia (MDS). B Mehrotra, C Mar, WL Kuo, CL Willman. <u>Blood</u> 80(10) Suppl 1:30a, 1992.	Leukemia CCR		
8600/9007 (925)	Precise localization of the long arm breakpoint of the inv(16) of ANNL M4Eo and progress towards cloning this breakpoint. D Callen, B Kuss, CL Willman, H Eyre, J Nancarrow, N Lapsys, RI Richards, GR Sutherland. <u>Am J Human Genetics</u> 51(4):57A, 1992.	Leukemia CCR		
*8691 (0073) (835)	A randomized comparison of deoxycoformycin (DCF) versus alpha-2a interferon (IFN) in previously untreated patients with hairy cell leukemia (HCL): An NCI-sponsored intergroup study. (SWOG, ECOG, CALGB, NCIC-CTG). M Grever, K Kopecky, D Head, P Cassileth, H Golomb, T Habermann, K Rai, E Eisenhauer, B Cheson. <u>ASCO</u> 11:264 (#868), 1992.	Leukemia Dev Ther	12/15/86	10/01/91
None (850)	Enhancement by c-kit ligand of leukemic colony formation in acute myelogenous leukemia. CH Park, BF Kimler, Z Estrov, AB Deisseroth, DE Williams, S Gillis. <u>AACR</u> 33:81 (#483), 1992.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS
1991**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8124/8600 (486)	Expression of the c-fgr and hck protein-tyrosine kinases in acute myeloid leukemic blasts is associated with early commitment and differentiation events in the monocytic and granulocytic lineages. CL Willman, CC Stewart, TL Longacre, DR Head, R Habbersett, SF Zeigler, RM Perlmutter. <u>Blood</u> 77(4):726-734, 1991.	Leukemia Biology		
8326/27 8600/8750 (550)	Multiparameter analysis of acute mixed lineage leukemia: Correlation of a B/Myeloid immunophenotype and immunoglobulin and T-cell gene rearrangements with the presence of the Philadelphia chromosome translocation in acute leukemias with myeloid morphology. IA Saikevych, DP Kerrigan, TS McConnell, DR Head, FR Appelbaum, CL Willman. <u>Leukemia</u> 5(5):373-382, 1991.	Leukemia		
8750 (552)	Do random (non-clonal) chromosome abnormalities in bone marrow predict a clone to come? TS McConnell, MH Duncan, K Foucar, and the Southwestern Oncology Group Leukemia Cytogenetics Subcommittee. <u>Cancer Genetics and Cytogenetics</u> 53:257-263, 1991.	Leukemia	04/15/87	10/15/91
ABSTRACTS PUBLISHED/PRESENTED				
*8124/8522 8561 (499)	Survival with cytotoxic therapy in acute promyelocytic leukemia. A Southwest Oncology Group report. DR Head, K Kopecky, J Hewlett, J Weick, D Ryan, J Files, J Bickers, K Foucar, M Montiel, A Fishleder, J Welborn, G Mills, E Billeter, C Willman, F Appelbaum. <u>Blood</u> 78: 268a, 1991.	Leukemia		
*8326/27 8600 (502)	Multidrug resistance in CD34 ⁺ acute leukemia correlates with non-lymphoid lineage. C Spier, A List, CL Willman, F Appelbaum, C Karanes, D Head. <u>Blood</u> 78:175a, 1991.	Leukemia		
8417/8750 (500)	Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction. G Gehly, K Kopecky, D Boldt, D Head, M Slovak, F Appelbaum, J Radich. <u>Blood</u> 78:266a, 1991.	Leukemia		
*8600 (501)	Multiparameter analysis of the expression of the multidrug resistance genes MDR1 and MDR2 (MDR3) in de novo AML by polymerase chain reaction (PCR) and multicolor flow cytometry: Identification of a biological subset of CD34 ⁺ , MDR1 + AML cases. CL Willman, K Kopecky, B Griffith, IM Chen, K Noonan, I Roninson, DR Head, T Tsuruo, J Weick, M Grever, F Appelbaum. <u>Blood</u> 78:172a, 1991.	Leukemia	11/01/86	12/01/91

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*8833 (413)	A phase I trial of combination fludarabine and chlorambucil in chronic lymphocytic leukemia. A Southwest Oncology Group study. L Elias, D Stock-Novack, M Grever, J Weick, R Chapman, JE Godwin, S Balcerzak, F Appelbaum. <u>ASCO</u> 10:221 (#745), 1991.	Leukemia	05/15/89	04/15/91

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1990**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8326/8327 8600/8750 (448)	Multiparameter analysis of acute mixed lineage leukemia: Correlation of a B/myeloid immunophenotype and immunoglobulin and T-cell receptor gene rearrangements with the presence of the Philadelphia chromosome translocation in acute leukemias with myeloid morphology. IA Saikevych, DP Kerrigan, TS McConnell, DR Head, FR Appelbaum, CL Willman. <i>Leukemia</i> 5(5):373-382, 1990.	Leukemia		
8417/19	An outpatient (OP) approach to the delivery of intensive consolidation chemotherapy (CT) to adults with acute lymphoblastic leukemia (ALL). P Palmer, FJ Meyers. <i>Oncology Nursing Forum</i> 17(4):553-558, 1990.	Leukemia	06/14/85	11/15/91
8600 (336)	Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. KE Noonan, C Beck, TA Holzmayer, JE Chin, JS Wunder, IL Andrulis, AF Gazdar, CL Willman, BB Griffith, DD Von Hoff, IB Roninson. <i>Proceedings National Academy of Sciences, USA</i> 87:7160-7164, 1990.	Leukemia Biology	11/01/86	12/01/91
8600/8750 (338)	Cloning and characterization of the t(15;17) t ranslocation breakpoint region in acute promyelocytic leukemia. RS Lemons, D Eilender, RA Waldmann, M Rebentisch, AK Frej, DH Ledbetter, C Willman, T McConnell, P O'Connell. <i>Genes, Chromosomes & Cancer</i> 2:79-87, 1990.	Leukemia Biology		
8600/8750 (349)	The molecular biology of acute myeloid leukemia: Proto-oncogene expression and function in normal and neoplastic myeloid cells. CL Willman, MH Whittaker. <i>Clinics in Laboratory Medicine</i> 10(4): 769-796, 1990.	Leukemia Biology		
8600/8750 (337)	N-ras mutations in adult de novo acute myelogenous leukemia: Prevalence and clinical significance. JP Radich, KJ Kopecky, CL Willman, J Weick, D Head, F Appelbaum, SJ Collins. <i>Blood</i> 75(4):801-807, 1990.	Leukemia		
Multiple Studies	Report of the National Cancer Institute-Sponsored Workshop on definitions of diagnosis and response in acute myeloid leukemia. BD Cheson, PA Cassileth, DR Head, CA Schiffer, JM Bennett, CD Bloomfield, R Brunning, RP Gale, MR Grever, MJ Keating, A Sawitsky, S Stass, H Weinstein, WG Woods. <i>JCO</i> 8(5):813-819, 1990.	Leukemia		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

ABSTRACTS PUBLISHED/PRESENTED

8600 (364)	Analysis of MDR1 gene expression in clinical tumor samples by polymerase chain reaction (PCR). KE Noonan, C Beck, TA Holzmeyer, J Wunder, I Andrulis, C Willman, B Griffith, DD Von Hoff, IB Roninson. <u>AACR</u> 31:361 (#2140), 1990.	Leukemia Biology	11/01/86	12/01/91
8600/8750 (365)	Expression of the EVI-1 gene encoding a DNA-binding protein in AMLs with karyotypic abnormalities of chromosome 3q. M Whittaker, K Morishita, C Willman, T McConnell, JP Lewis, J Ihle. <u>Laboratory Investigation/Modern Pathology</u> 626:106a, 1990.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1989**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8001	Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation and maintenance chemotherapy. KK Hussein, S Dahlberg, D Head, CC Waddell, L Dabich, JK Weick, F Morrison, JH Saiki, E Metz, SE Rivkin, MR Grever, D Boldt. <u>Blood</u> 73(1):57-63, 1989.	Leukemia	07/10/80	03/22/85
8124/25/26	Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission. MS Tallman, KJ Kopecky, D Amos, S Dahlberg, JS Hewlett, JC Files, CA Coltman, Jr, ED Thomas, FR Appelbaum. <u>JCO</u> 7(3):326-337, 1989.	Leukemia		
8161	Phase II evaluation of bisantrene in acute leukemia. A Southwest Oncology Group study. GM Mills, S Dahlberg, J Cowan, BA Neilan, CH Gumbart, K Hussein, CA Coltman, Jr. <u>AJCO</u> (CCT) 12(6):507-510, 1989.	Leukemia	02/22/82	04/20/84
8592	Pathogenetic implications of internuclear bridging in myelodysplastic syndrome. An Eastern Cooperative Oncology Group/Southwest Oncology Group Cooperative study. DR Head, K Kopecky, JM Bennett, K Grenier, FS Morrison, KB Miller, MR Grever. <u>Cancer</u> 64(11):2199-2202, 1989.	Leukemia	07/26/85	07/01/88
ABSTRACTS PUBLISHED/PRESENTED				
7984	A stratified, randomized trial of busulfan (B) or busulfan plus vitamin A (BVA) for the management of chronic myelogenous leukemia (CML). FL Meyskens, Jr, K Kopecky, M Grever. <u>ASCO</u> 8:203 (#790), 1989.	Leukemia	07/10/80	04/01/87
*8124/25/26	Significance of HLA-DR and FC receptor expression in acute non-lymphoblastic leukemia (ANLL). L Elias, DE Van Epps, JS Hewlitt, FR Appelbaum, DP Head, KJ Kopecky, MR Grever. <u>ASCO</u> 8:200 (#776), 1989.	Leukemia		
*8326/27	Increased risk of early death (ED) with high dose ara-C (HDAC) and m-AMSA compared to HDAC alone or HDAC and mitoxantrone (MITOX) in high risk nonlymphocytic leukemia (ANL). C Karanes, KJ Kopecky, BGM Durie, MR Grever. <u>ASCO</u> 8:201 (#783), 1989.	Leukemia	04/26/85	

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
8522	Analysis of treatment failure in acute non-lymphocytic leukemia (ANLL) patients over fifty years of age: A Southwest Oncology Group (SWOG) study. D Ryan, M Grever, K Kopecky. <u>ASCO</u> 8:206 (#800), 1989.	Leukemia	02/17/86	11/01/87
*8600	Biological parameters associated with therapeutic non-responsiveness in acute myeloid leukemia (AML). C Willman, L Elias, B Griffith, L Dressler, E Erickson-Ford, D Head, K Kopecky, D Stock-Novack, J Weick, M Grever. <u>ASCO</u> 8:200 (#777), 1989.	Leukemia	11/01/86	Open
8600/8326/27 8750	Philadelphia chromosome positive (ph+) leukemias with P210 BCR-ABL or P185 BCR-ABL may be distinct disorders: A clinical, immunophenotypic, and molecular study. I Saikevych, L Timson, C Denny, O Witte, B Griffith, D Kerrigan, K Kopecky, CL Willman. Submitted to <u>The American Society of Hematology</u> 74:79a, 1989.	Leukemia		
8600/8750	Cell surface phenotype in acute monocytic leukemia associated with t(8;16)(p11; p13). KS Theil, CL Willman, D Head, M Grever. <u>AACR</u> 30:37 (#143), 1989.	Leukemia	10/15/86	open

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1988**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8378	Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. MR Grever, KJ Kopecky, CA Coltman, JC Files, BR Greenberg, JJ Hutton, R Talley DD Von Hoff, SP Balcerzak. <u>Nouv Rev Fr Hematol</u> 30: 457-459, 1988.	Leukemia	12/05/83	06/15/87
ABSTRACTS PUBLISHED/PRESENTED				
*8124/25/26	Prognostic factor analysis of the outcome of marrow transplantation or further chemotherapy for acute nonlymphocytic leukemia. MS Tallman, FR Appelbaum, K Kopecky, D Amos, S Dahlberg, M Grever, C Coltman, Jr, ED Thomas. <u>ASCO</u> 7:178 (#689), 1988.	Leukemia		
8592	Evaluation of low dose ara-C versus supportive care in the treatment of myelodysplastic syndromes: An Intergroup study by the Eastern Cooperative Oncology Group and the Southwest Oncology Group. KB Miller, K Kim, FS Morrison, JN Winter, JM Bennett, PA Cassileth, M Grever, M Oken, D Head. <u>Blood</u> 72:215A, 1988.	Leukemia	07/26/85	07/01/88
8600/8750	Identification of new biological subtypes of acute leukemia co-expressing NK (LEU19) and myeloid cell surface antigens: A Southwest Oncology Group study. CL Willman, CC Stewart, L Elias, J Potter, K Kopecky, D Stock-Novack, D Head, JK Weick, MR Grever. <u>Blood</u> 72:235A, 1988.	Leukemia	11/01/86	12/1/91

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1987**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8243	Phase II evaluation of teniposide and ifosfamide in refractory adult acute lymphocytic leukemia: A Southwest Oncology Group study. DH Ryan, KJ Kopecky, D Head, CH Gumbart, MR Grever, C Karanes, JK Weick, CA Coltman, Jr. <u>Cancer Treat Rep</u> 71(7-8):713-716, 1987.	Leukemia	02/17/86	04/01/87
8378	Pulmonary toxicity associated with fludarabine monophosphate. PG Hurts, MP Habib, H Garewal, M Bluestein, M Paquin, BR Greenberg. <u>IND</u> 5:207-210, 1987.	Leukemia	12/05/83	06/15/87
ABSTRACTS PUBLISHED/PRESENTED				
8243	Southwest Oncology Group (SWOG) trial: VM-26 and ifosfamide (IF) in refractory adult lymphocytic leukemia (ALL). DH Ryan, KJ Kopecky, CH Gumbart, JN Bickers. <u>ASCO</u> #C-561 1987.	Leukemia	02/18/83	03/20/86
8694	Current cancer and leukemia group B (CALGB) trials in the treatment of active hairy cell leukemia (HCL): A status report. KR Rai, R Mick, H Ozer, CD Bloomfield. <u>Proc. Fourth International Symposium on Therapy of Acute Leukemia, Rome</u> 250:(223), 1987.	Leukemia	02/25/87	

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1986**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

8262	Phase II evaluation of Aclarubicin in refractory adult leukemia: A Southwest Oncology Group study. L Dabich, FE Bull, G Beltran, JW Athens, CA Coltman Jr., JK Weick, EJ Van Slyck, M Amare. <u>Cancer Treat Rep</u> 70(8):967-969, 1986.	Leukemia	04/26/82	12/05/83
------	---	----------	----------	----------

ABSTRACTS PUBLISHED/PRESENTED

*8124	Prospective comparative study of bone marrow transplantation (BMT) versus continued chemotherapy for adult acute nonlymphocytic leukemia (ANL): A Southwest Oncology Group study. FR Appelbaum, J Hewlett, K Kopecky, C Angle, CA Coltman Jr. Presented <u>ASH</u> , December 1986.	Leukemia	05/11/82	09/27/85
-------	---	----------	----------	----------

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1985**

NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7315/16	High rate of long-term survival in adult acute leukemia following ten-day chemotherapy (OAP) induction. Maintenance with chemotherapy or chemotherapy plus BCG vaccine. JS Hewlett, T Chen, SP Balcerzak, JU Gutterman, JJ Costanzi, M Amare. <u>Arch Intern Med</u> 145:1006-1012, 1985.	Leukemia	07/06/73	01/77
7823	Institutional performance in application of the FAB classification of acute leukemia: the Southwest Oncology Group experience. DR Head, L Cerezo, RA Savage, CM Craven, JN Bickers, R Hartsock, TA Hosty, JH Saiki, HE Wilson, FS Morrison, CA Coltman Jr., JJ Hutton. <u>Cancer</u> 55(9):1979-1985, 1985.	Leukemia	08/04/78	09/10/82
7823	Reproducibility of the French-American-British classification of acute leukemia. A Southwest Oncology Group experience. DR Head, RA Savage, L Cerezo, CM Craven, JN Bickers, R Hartsock, TA Hosty, JH Saiki, HE Wilson, FS Morrison, CA Coltman Jr., JJ Hutton. <u>Amer J Hem</u> 18:47-57, 1985.	Leukemia	08/04/78	09/10/82
8091	Concurrent chemoradiotherapy for limited small cell acute nonlymphocytic leukemia (ANLL). CH Park, BF Kimler, M Amare, PH Wiernik, JP Dutcher, FS Morrison, TR Maloney. <u>Stem Cells</u> 1:297-298, 1985.	Leukemia	10/23/80	
None	Specific esterase positivity in acute monocytic leukemia. DM Craven, DR Head, J Pullen, RD Logorsky. <u>Blood</u> 66:172a, 1985.	Leukemia		
ABSTRACTS PUBLISHED/PRESENTED				
8243	Phase II of VM-26 and ifosfamide in refractory adult acute lymphocytic leukemia (ALL). A Southwest Oncology Group study. D Ryan, J Bickers, J Athens C Coltman Jr. <u>ASCO</u> , #C-599, 1985.	Leukemia	02/18/83	03/20/86
8276	m-AMSA, 5-azacytidine and etoposide in acute non-lymphocytic leukemia (ANLL) in relapse. MR Grever, D Gray, CA Coltman Jr., H Hynes, SP Balcerzak. <u>AFCR</u> 33(2):341A, 1985.	Leukemia	05/27/83	01/11/85

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1984**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

None	The incidence of hand-mirror cells in acute myeloblastic and lymphoblastic leukemia. L Cerezo, DR Head, J Pullen, W Crist. <u>Am J Clin Path</u> 81:355-357, 1984.	Leukemia		
7522	Response of chronic myelogenous leukemia patients to COAP-splenectomy. A Southwest Oncology Group study. JP Hester, CC Waddell, CA Coltman Jr, FS Morrison, RL Stephens, SP Balcerzak, LH Baker, TT Chen. <u>Cancer</u> 54:1977-1982, 1984.	Leukemia		
7823/24 25/26	The prevalence of hand-mirror cells in acute myeloblastic and lymphoblastic leukemia. L Cerezo, DR Head, J Pullen, B Humphrey. <u>Am J Clin Path</u> 81:355-357, 1984.	Leukemia		

ABSTRACTS PUBLISHED/PRESENTED

*8091	In vitro drug sensitivity of leukemic colony-forming cells in acute nonlymphocytic leukemia: Clinical correlation update with various drug exposure methods. CH Park, M Amare, PH Weirnick, FS Morrison, JP Dutcher, TR Maloney. <u>4th Conference on Human Tumor Cloning</u> (Tucson, January 8-10, 1984).	Leukemia		
8243	VM-26 and ifosfamide in refractory adult acute lymphocytic leukemia. D Ryan. <u>ASCO</u> , #C-599, 1984.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1983**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7416/17	Management of adult acute leukemia. A Southwest Oncology Group study. KB McCredie, EA Gehan, EJ Freireich, JS Hewlett, CA Coltman Jr, KK Hussein, SP Balcerzak, TT Chen. <u>Cancer</u> 52:958-966, 1983.	Leukemia		
7510	Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). JD Boice Jr, MH Greene, JY Killen Jr, SS Ellenberg, RJ Keehn, E McFadden, TT Chen, JF Fraumeni Jr. <u>N Engl J Med</u> 309:1079-1084, 1983.	Leukemia		
7720	Smoldering acute granulocytic leukemia: Observations on its natural history and morphologic characteristics. EJ Van Slyck, JW Rebusck, CC Waddell, N Janakiraman. <u>Arch Intern Med</u> 143:37-40, 1983.	Leukemia		
*8005/8032	Mitoxantrone hydrochloride in hematologic malignancies: Southwest Oncology Group Phase II studies. CA Coltman Jr, JH Saiki, FJ Panettiere, SP Balcerzak, RL Stephens, FS Morrison, DO Dixon, DD Von Hoff. In: <u>3rd NCI-EORTC Symposium on New Drugs in Cancer Therapy</u> (Brussels, October 15-17, 1981). M Rozenzweig, DD Von Hoff, MJ Staquet, eds. <u>New Anticancer Drugs: Mitoxantrone and Bisantrene</u> . New York: Raven Press, 115-124, 1983.	Leukemia, Lymphoma		
8014	Colchicine in refractory chronic lymphocytic leukemia. JK Weick, RB Livingston, EJ Van Slyck. <u>Investigational New Drugs</u> 1:335-338, 1983.	Leukemia		
8051	The treatment of acute leukemia with continuous infusion L-Alanosine. JK Weick, BL Trantum, FS Morrison. <u>Investigational New Drugs</u> 1:249-252, 1983.	Leukemia		
8091	Clinical correlations of leukemic clonogenic cell chemosensitivity assessed by in vitro continuous exposure to drugs. CH Park, PH Wiernick, FS Morrison, M Amare, K Van Sloten, TR Maloney. <u>Cancer Research</u> 43:2346-2349, 1983.	Leukemia		
*8108/16/ 17/18/19/ 20/61/ 8214	Southwest Oncology Group studies with Bisantrene. CA Coltman Jr, D Cowan, DD Von Hoff, GM Durie, TP Miller, E Surwit, DS Alberts, RA Shildt, F Panettiere, GM Mills, PB Wasserman, TM McDaniel. In: <u>13th International Congress of Chemotherapy</u> (Vienna, August 28-September 2, 1983). KH Spitzzy, K Karrer, eds. <u>Symposium Bisantrene</u> 213:1-4, 1983.	Myeloma, Lymphoma, GYN, GI, Melanoma, Leukemia, Sarcoma		

None	Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). JD Boice Jr, MH Greene, JY Killen Jr, SS Ellenberg, RJ Keehn, E McFadden, TT Chen, JF Fraumeni Jr. <u>N Engl J Med</u> 309:1079-1084, 1983.	Leukemia
None	Therapy of secondary acute nonlymphocytic leukemia. (Letter to the Editor). G Beltran, WJ Stuckey. <u>N Engl J Med</u> 308:1295, 1983.	Leukemia

ABSTRACTS PUBLISHED/PRESENTED

8001	Treatment of acute lymphoblastic leukemia (ALL) in adults using intensive induction, consolidation and maintenance chemotherapy. CC Waddel, KK Hussein, DR Head. <u>AACR</u> , #457, 1983.	Leukemia
8032	Two-dose schedules of Dihydroxyanthracenedione (DHAD) in acute leukemia - A Southwest Oncology Group study. J Saiki, W Stuckey, B Trantum, R O'Bryan, S Rivkin, J Athens. <u>ASCO</u> , #C-675, 1983.	Leukemia
8091	Versatile drug exposure times for improved clinical chemotherapy correlation by cloning assay in acute nonlymphocytic leukemia. CH Park, M Amare, PH Wiernik, FS Morrison, JP Dutcher, JA Myers. <u>ASCO</u> , #C-108, 1983.	Leukemia

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1982**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

?	CNS prophylaxis in acute lymphoblastic leukemia: comparison of two methods. A Southwest Oncology Group study. DM Komp, CH Fernandez, JM Falletta, AH Ragab, GB Humphrey, J Pullen, T Moon, J Shuster. <u>Cancer</u> 50(6): 1031-1036, 1982.	Leukemia		
427/555/ 556/557/ 560/7315/ 7416/17	Adult acute leukemia studies utilizing Cytarabine: Early Southwest Oncology Group trials. CA Coltman Jr, EJ Freireich, O Pendleton, JN Bickers, GP Bodey, JS Hewlett, KB McCredie. <u>Med & Ped Onc Suppl</u> 1:173-183, 1982.	Leukemia		
7626	Rubidazone in combination with Ara-C, vincristine and prednisone (ROAP) in the treatment of adult acute leukemia. A Southwest Oncology Group study. FS Morrison, R Benjamin, M Amare, JJ Costanzi, K Hussein, DH Ryan, S Balcerzak, OJ Pendleton. <u>Am J Clin Oncol</u> 5:645-648, 1982.	Leukemia		
7762	Adriamycin combined with 10-day Ara-C, vincristine, and prednisone (10-day ADOAP) in the treatment of adult acute leukemia patients under fifty years of age. A Southwest Oncology Group study. SL Schreiter, M Amare, WJ Stuckey, N Oishi, JH Saiki, R Vial, O Pendleton, FS Morrison. <u>Am J Clin Oncol</u> 5:641-643, 1982.	Leukemia		

ABSTRACTS PUBLISHED/PRESENTED

?	Adriamycin, cytosine arabinoside, vincristine and prednisone in the treatment of adults with acute leukemia. KB McCredie, EA Gehan, EJ French, JS Hewlett, CA Coltman Jr, KK Hussein, SP Balcerzak. ?? (Rome, December 10-14, 1982). Rome: University of Rome, 537, 1982.	Leukemia		
7823	Nonspecific esterase cytochemistry in acute myeloblastic leukemia: alpha-naphthyl acetate versus alpha-naphthyl butyrate. L Cerezo, DR Head. <u>AJCP</u> , 248, February 1982.	Leukemia		
8091	Clinical correlation of in vitro chemotherapy sensitivity on leukemic colony forming cells. CH Park, M Amare, PH Wiernik, K Van Sloten, FS Morrison, TR Maloney. <u>Conference on Human Tumor Cloning</u> (Tucson, January 1982).	Leukemia		
*8091	Drug sensitivity of acute nonlymphocytic leukemia-colony forming cells (L-CFC) and clinical correlations. CH Park, M Amare, PH Wiernik, K Van Sloten, FS Morrison, TR Maloney. <u>ASCO</u> , #C-536, 1982.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1981**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7603	Effect of schedule on activity and toxicity of 5-Azacytidine in acute leukemia: A Southwest Oncology Group study. JH Saiki, GP Bodey, JS Hewlett, M Amare, FS Morrison, HE Wilson, JW Linman. <u>Cancer</u> 47(7):1739-1742, 1981.	Leukemia		
7633	Rubidazole (NSC-164011) in adults with previously treated acute leukemia and blast phase of chronic myelocytic leukemia: A Southwest Oncology Group study. J Bickers, R Benjamin, H Wilson, H Eyre, J Hewlett, K McCredie. <u>Cancer Treat Rep</u> 65:427-430, 1981.	Leukemia		

ABSTRACTS PUBLISHED/PRESENTED

7823/24/ 25/26	The effect of lumbar puncture in the incidence of meningeal leukemia. A Southwest Oncology Group study. FS Morrison, JC Files. <u>Clinical Research</u> 29:829A, 1981.	Leukemia		
7823/24/ 25/26	A comparison of Rubidazole and Adriamycin used in a multidrug regimen for remission induction in acute leukemia. A Southwest Oncology Group study. FS Morrison, JC Files. <u>Clinical Research</u> 29:719A, 1981.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1980**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Radiotherapy (2500 rad) for testicular leukemia: local control and subsequent clinical events: a Southwest Oncology Group study. MP Sullivan, CA Perez, J Herson, M Silva-Sausa, V Land, et al. <u>Cancer</u> 46(3): 508-15, 1980.	Leukemia		
7723	The treatment of advanced adult acute leukemia with diglycoaldehyde. M Shaw, FS Morrison, WJ Stuckey, A Trowbridge. <u>Cancer Treat Rep</u> 64:985-986, 1980.	Leukemia		
7768	Doxorubicin-Ifosfamide combination chemotherapy in previously treated acute leukemia in adults: A Southwest Oncology Group pilot study. D Ryan, J Bickers, R Vial, K Hussein, R Bottomley, J Hewlett, H Wilson, WJ Stuckey. <u>Cancer Treat Rep</u> 64:869-872, 1980.	Leukemia		
7835	Clonal changes in chronic granulocytic leukemia in blastic transformation and during remission. G Beltran, M Varela. <u>Cancer</u> 46:1590-1593, 1980.	Leukemia		
ABSTRACTS PUBLISHED/PRESENTED				
7603	Effect of schedule on activity of 5-Azacytidine in acute leukemia. J Saiki, J Hewlett, G Bodey, M Amare, FS Morrison. <u>ASCO</u> , #C-484, 1980.	Leukemia		
7762	Adriamycin combined with 10 day Ara-C, vincristine and prednisone in the treatment of adult acute leukemia patients. FS Morrison, SL Schreiter, JC Files. <u>Clinical Research</u> 28:825A, 1980.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1979**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Cycloctidine in the treatment of refractory acute childhood leukemia: a Southwest Oncology Group Phase I-II study. T Miale, E Hvizdala, A Ragab, J Pullen, P O'Brien, C McMillan. <u>Cancer Treat Rep</u> 63(11-12):1913-1915, 1979.	Leukemia		
?	Streptozotocin (NSC-85998) in children with acute lymphocytic leukemia: a Southwest Oncology Group study. PG Dymont, RV Iger, SK Morgan, CL Sexauer. <u>JCO</u> 19(7):390-391, 1979.	Leukemia		
425/426	Combination 6-Mercaptopurine and 6-Methylmercaptopyrine Riboside in the treatment of adult acute leukemia: a Southwest Oncology Group study. JS Hewlett, GP Bodey, HE Wilson, WJ Stuckey. <u>Cancer Treat Rep</u> 63(1):156-158, 1979.	Leukemia		
7401	Reinduction therapy for adult acute leukemia with adriamycin, vincristine and prednisone: A Southwest Oncology Group study. L Elias, MT Shaw, SO Raab. <u>Cancer Treat Rep</u> 63(8):1413-1415, 1979.	Leukemia		
7507	5-Fluorouracil in the treatment of acute leukemia: A Southwest Oncology Group study. JJ Costanzi, R Gagliano, CA Coltman, Jr, JN Bickers. <u>Cancer Treat Rep</u> 63(11-12):2126-2128, 1979.	Leukemia		
ABSTRACTS PUBLISHED/PRESENTED				
?	Beta-microglobulin in chronic lymphatic leukemia and myelomatosis. EH Cooper, JA Child, S Kerrush, B Spati. <u>Medical Oncology: Abstracts of the 5th Annual Meeting of the Medical Oncology Society</u> held in Nice, France, December 1-13, 1979. Medical Oncology Society, Nice, France. 52, 1979.	Leukemia		
?	Second remission maintenance therapy for acute lymphoblastic leukemia: is chemotherapy a rational alternative to bone marrow transplantation? GB Humphrey, S Culbert, E Hvizdala, D Komp. <u>Exp Hemat</u> 7(Suppl. 6):139, 1979.	Leukemia		
?	The value of protected environment (PE) in the management of acute leukemia (AL) in adults. R Vial, D Ryan, W Williams, J Bickers. <u>Clin Res</u> 27(2): 393(A), 1979.	Leukemia		
?	Salvage protocols for leukemic children who relapse. GB Humphrey, E Hvizdala, S Culbert, D Komp. <u>Proc AACR</u> 20:443, 1979.	Leukemia		

?	Acute non-lymphocytic leukemia (ANLL) in adults: remission reinduction with adriamycin, cytosine arabinoside, oncovin and prednisone (ADOAP). <u>Proc AACR</u> 20:380, 1979.	Leukemia
?	Treatment of adult acute myeloblastic leukemia. KB McCredie, MJ Keating, KA Dicke, GP Bodey, JP Hester, T Smith, EJ Freireich. <u>Modern Trends in Human Leukemia II, Proceedings of a Meeting Held in Wilsede, W. Germany, 19-23 June 1978</u> , Berlin, Springer. 1979.	Leukemia
560/561	Long term survival of adults with acute leukemia. CA Coltman, Jr, E Freireich, R Savage, E Gehan. <u>ASCO</u> , #C-405, 1979.	Leukemia
7209	Azacytidine in acute leukemia. J Saiki, K McCredie, T Vietti, J Hewlett, F Morrison, J Costanzi, W Stuckey, J Whitecar, B Hoogstraten. <u>Cancer Therapy Abstracts</u> 19:11, 1979.	Leukemia
7401	Successful remission reinduction of adult acute leukemia (ALL) with a combination of adriamycin, vincristine, and prednisone. L Elias, M Shaw, S Raab. <u>AACR</u> , #99, 1979.	Leukemia
7420	Therapeutic maneuvers and the prolongation of remission in childhood acute lymphocytic leukemia with poor prognostic factor. Dymont et al. 1979.	Leukemia
7422	"Late" overt or occult testicular leukemia - incidence and prognosis. Land et al. 1979.	Leukemia
7502	Addition of vincristine and prednisone to 5-Azacytidine in children with acute lymphocytic leukemia (ANLL). Nitschke et al. 1979.	Leukemia
None	Acute leukemia in New Mexico 1970-1978: A review of Southwest Oncology Group study results. J Saiki, H Saiers, W Hardy, B Wimer, A Rembe, R Weiler, M Shaw. <u>ASCO</u> , #C-438, 1979.	Leukemia

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1978**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
557	Chemotherapy of acute leukemia: Comparison of vincristine, cytarabine, and prednisone (OAP) alone and in combination with cyclophosphamide (COAP) or daunorubicin (DOAP). CA Coltman, Jr, GP Bodey, JS Hewlett, A Haut, J Bickers, S Balcerzak, J Costanzi, E Freireich, K McCredie, C Groppe, T Smith, E. Gehan. <u>Arch Intern Med</u> 138:1342-1348, 1978.	Leukemia		
7209	5-azacytidine in acute leukemia. JH Saiki, KP McCredie, TJ Vietti, JS Hewlett, FS Morrison, JJ Costanzi, WJ Stuckey, J Whitecar, B Hoogstraten. <u>Cancer</u> 42(5): 2111-2114, 1978.	Leukemia		
7211	Remission induction in myelogenous leukemia using cytosine arabinoside/synchronization. CP Steuber, CB Humphrey, CW McMillan, TJ Vietti. <u>Med Ped Onc</u> 4(4):337-42, 1978.	Leukemia		
7315/16	Remission maintenance in adult acute leukemia with and without BCG: A Southwest Oncology Group study. JS Hewlett, SP Balcerzak, JU Gutterman, EJ Freireich, EA Gehan, A Kennedy. In: <u>Immunotherapy of Cancer: Present Status of Trials in Man</u> . WD Terry and D Windhorst, eds, New York: Raven Press, pp. 383-391, 1978.	Leukemia		
7324	Toxicity study of cytosine arabinoside and methotrexate in the maintenance therapy of childhood leukemia. R Nitschke, T Vietti, D Komp, GB Humphrey, K Starling. 1978.	Leukemia		
7605	Baker's antifol in children with late-stage acute leukemia. Nitschke et al. 1978.	Leukemia		
Multiple Studies	Early deaths in newly diagnosed cases of pediatric acute leukemia. A Southwest Oncology Group study. SL George, DJ Fernbach, ET Lee. <u>Cancer</u> 42(2):781-786, 1978.	Leukemia		

ABSTRACTS PUBLISHED/PRESENTED

7315/17	Chemotherapy versus chemoimmunotherapy remission maintenance for acute leukemia. S Murphy, J Hewlett, S Balcerzak, J Gutterman, E Friereich, E Gehan. <u>ASCO</u> (#C-316), 1978.	Leukemia
7410	Cytosan, adriamycin, prednisone (CAP) chemotherapy for chronic lymphocytic leukemia (CLL). JP Hester, EA Gehan. <u>AACR</u> 19:214 (#853), 1978.	Leukemia
7416/17	Leukemia in pregnancy: Successful delivery after cytarabine and adriamycin. FS Morrison, L Balducci, M Newcomb, JT Thigpen. <u>Proc. 17th Congress ISH</u> , Paris, France, p. 758, 1978.	Leukemia
7626	The use of rubidazone in combination with vincristine Ara-C and prednisone for remission induction in acute leukemia. FS Morrison, R Benjamin. <u>Proc. 17th Congress ISH</u> , Paris, France, p. 41, 1978.	Leukemia

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1977**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

?	Combination intrathecal therapy for meningeal leukemia: two versus three drugs. MP Sullivan, TE Moon, R Trueworthy, TJ Vietti, GE Humphrey, D Komp. <u>Blood</u> 50 (3):471-479, 1977.	Leukemia		
448	Adriamycin therapy in previously treated adult acute leukemia. HE Wilson, GP Bodey, TE Moon, M Amare, RJ Bottomley, A Haut, JS Hewlett, FS Morrison and JH Saiki. <u>Cancer Treat Rep</u> 61:905-907, 1977.	Leukemia		
7401	Adriamycin in combination chemotherapy of adult acute lymphoblastic leukemia: a Southwest Oncology Group study. MT Shaw and SO Raab. <u>Med Ped Onc</u> 3(3):261-266, 1977.	Leukemia		

ABSTRACTS PUBLISHED/PRESENTED

150	Remission induction in adults with acute leukemia. WJ Stuckey, G Beltran, A Haut, SO Raab, BL Trantum and F Padilla. <u>ASCO</u> , #336, 1977.	Leukemia		
7209	5-azacytidine in acute leukemia. JH Saiki, K McCredie, T Vietti, J Hewlett and FS Morrison. <u>ASCO</u> , #C-290, 1977.	Leukemia		
7401	Treatment of adult acute myeloblastic leukemia (AML) unresponsive to or relapsing following ARA-C therapy. SO Raab and MT Shaw. <u>AACR</u> , #196, 1977.	Leukemia		
7416/17	Chemoimmunotherapy of adult acute leukemia (CIAL). KB McCredie, JS Hewlett, EA Gehan and EJ Freireich. <u>AACR</u> , #506, 1977.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1976**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

690	Cyclophosphamide-asparaginase vincristine-prednisone induction therapy in childhood leukemia. DM Komp, SL George, VJ Lang, KA Starling, GB Humphrey, J Lowman. <u>Cancer</u> 37:1243-1247, 1976.	Leukemia		
-----	--	----------	--	--

ABSTRACTS PUBLISHED/PRESENTED

?	Growth hormone and somatomedin in children with acute lymphocytic leukemia. DH Berry, JA Lee, BS Kilgore, MJ Elders. <u>ASCO</u> 17:298, 1976.	Leukemia		
*7375	Clinical and cytochemical correlations with response and survival in acute leukemia. MT Shaw, ET Lee and EA Gehan. <u>ASCO</u> 17:237 (#C-3), 1976.	Leukemia		
*7416/7	The chemoimmunotherapy of acute leukemia (CIAL): a cooperative group study. KB McCredie, JS Hewlett and A Kennedy. <u>ASCO</u> , #C-11, 1976.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1975**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
663/4	Long-term results of reinforcement therapy in children with acute leukemia. DJ Fernbach, SL George, WW Sutow, AH Ragab, DM Lane, ME Haggard and D Lonsdale. <u>Cancer</u> 36:1552-1559, 1975.	Leukemia		
666/9	Interrupted versus continued maintenance therapy in childhood acute leukemia. D Lonsdale, EA Gehan, DJ Fernbach, MP Sullivan, DM Lane and AH Ragab. <u>Cancer</u> 36:341-352, 1975.	Leukemia		
675	Evaluation of daunorubicin and methotrexate (NSC-740) in combination as a remission maintenance regimen in the treatment of acute leukemia. GB Humphrey, DJ Fernbach, AA Razek, WJ Stuckey, D Komp and A George. <u>Cancer Chemotherapy Reports</u> , Part I, Vol. 59: 395-399, 1975.	Leukemia		
680/3/4/6	Superiority of conventional intrathecal methotrexate therapy with maintenance over intensive intrathecal methotrexate therapy, unmaintained, or radiotherapy (2000-2500 rads tumor dose) in treatment for meningeal leukemia. MP Sullivan, GB Humphrey, TJ Vietti, ME Haggard and E Lee. <u>Cancer</u> 35:1066-1073, 1975.	Leukemia		
7203	Three dose regimens of adriamycin for induction of remission in acute leukemia in children. KA Starling, DH Berry, HA Britton, GB Humphrey, T Vats and AH Ragab. <u>Medical and Pediatric Oncology</u> 1:271-276, 1975.	Leukemia		
7220	Evaluation of POMP induction therapy in childhood acute leukemia. DH Berry, J Pullen, S George, TJ Vietti, MP Sullivan and D Fernbach. <u>Cancer</u> 36:98-102, 1975.	Leukemia		
ABSTRACTS PUBLISHED/PRESENTED				
*156	Adriamycin in the treatment of childhood acute leukemia and solid tumors. AH Ragab, WW Sutow, DM Komp, KA Starling and GM Yon Jr. <u>ASCO</u> , #1030, 1975.	Leukemia		
*684/6	Combination intrathecal (IT) therapy for meningeal leukemia: two versus three drugs. MP Sullivan, GB Humphrey, TJ Vietti, D Komp and R Trueworthy. <u>AACR</u> , #340, 1975.	Leukemia		
689	Remission induction in childhood non-lymphoblastic leukemia with l-asparaginase, vincristine and prednisone. VJ Land, WW Sutow, PG Dymont, JM Falletta, SK Morgan and JW Bryan. <u>ASCO</u> , #1057, 1975.	Leukemia		
*690/1	Is cranial radiation necessary for central nervous system prophylaxis in acute lymphoblastic leukemia of childhood? K Komp, J Falletta, A Ragab and GB Humphrey. <u>ASCO</u> , #1046, 1975.	Leukemia		

*7202	Radiotherapy for testicular leukemia 2500 rads: local control and relationship to subsequent disease. MP Sullivan and C Fernandez. <u>ASCO</u> , #1023, 1975.	Leukemia
7307	Vincristine and prednisone versus vincristine, prednisone and l-asparaginase for second remission induction in acute leukemia in children. KS Starling, GB Humphrey, J Pullen, TS Vats and P Dymont. <u>ASH</u> , #289, 1975.	Leukemia
7375	Significant prognostic indicators in acute leukemia. MT Shaw. <u>ASH</u> , #284, 1975.	Leukemia
7401	Successful induction therapy in adults with acute lymphocytic leukemia. MT Shaw. <u>ASCO</u> , #1031, 1975.	Leukemia

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1974**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
148	Therapy of adult acute leukemia with daunorubicin and l-asparaginase. GP Bodey, JS Hewlett, CA Coltman, Jr, V Rodriguez and EJ Freireich. <u>Cancer</u> 33:626-650, 1974.	Leukemia		
229	Dibromomannitol in the treatment of blastic transformation and refractory chronic granulocytic leukemia. WC Levin, CH Mims and A Haut. <u>Cancer Chemotherapy Reports</u> 58: 223-228, 1974.	Leukemia		
383	Pyrimethamine in CNS leukemia. AH Ragab. Lancet, letter to the editor.	Leukemia		
427	Arabinosyl cytosine (NSC-63878) (ARA-C) in acute leukemia in adults: effects of schedule on therapeutic response. JN Bickers, EA Gehan, CA Coltman, Jr, HE Wilson, JS Hewlett, WJ Stuckey and EJ Van Slyck. <u>Arch Intern Med</u> 133:251-259, 1974.	Leukemia		
555/6	Chemotherapy of acute leukemia. Comparison of cytarabine alone and in combination with vincristine/ prednisone and cyclophosphamide. GP Bodey, CA Coltman, Jr, EJ Freireich, JD Bonnet, EA Gehan, AB Haut. <u>Arch Intern Med</u> 133:260-266, 1974.	Leukemia		
7301	Guanazole (NSC-1895) in the treatment of childhood leukemia. VJ Land, JC Falletta and CW McMillan. <u>Cancer Chemotherapy Reports</u> 58:715-717, 1974.	Leukemia		
7375	Cytochemical staining with oil red O and B-glucuronidase in the diagnosis of acute leukemia. MT Shaw and VA Klemp. <u>Amer J Clin Path</u> 61:169-172, 1974.	Leukemia		
ABSTRACTS PUBLISHED/PRESENTED				
689	Daunomycin-vincristine-l-asparaginase-prednisone study in childhood acute leukemia. WW Sutow. <u>ASCO</u> , 1974.	Leukemia		
7375	Classification of acute leukemia by cytochemical staining. MT Shaw. <u>AACR</u> , 1974.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1973**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
132	Hexamethylmelamine (NSC-13875) for acute leukemia and solid tumors in children. PG Dymont, DJ Fernbach, WW Sutow. <u>J Clin Pharm</u> 13:111-113, 1973.	Leukemia		
367/77	5-fluorouracil (NSC-19893) and actinomycin D (NSC-3053) in the treatment of acute leukemia in children. VJ Land, PG Dymont, D Komp, GB Humphrey, MP Sullivan, KA Starling. <u>Cancer Chemo Rep</u> 57:335-339, 1973.	Leukemia		
444	Intermittent guanazole therapy in adult acute leukemia. JS Hewlett, GP Bodey, CA Coltman, Jr, EJ Freireich, AB Haut, KB McCredie. <u>Clin Pharm and Therapeutics</u> 14:271-276, 1973.	Leukemia		
7310	An evaluation of procarbazine in acute leukemia. GB Humphrey, D Komp, S Morgan. <u>Cancer Chemo-therapy Reports</u> 57:371, 1973.	Leukemia		
ABSTRACTS PUBLISHED/PRESENTED				
448	Adriamycin in adult acute leukemia. HE Wilson, GP Bodey, CA Coltman, Jr, JA Gottlieb, JS Hewlett. <u>ASCO</u> , 1973.	Leukemia		
671	Continuous maintenance therapy following either continuous or discontinuous maintenance therapy in childhood leukemia. DM Lane, SL George, D Komp, D Lonsdale, J Pullen, A Ragab, KA Starling. <u>AACR</u> , 1973.	Leukemia		
675	An evaluation of daunomycin and methotrexate in combination for remission maintenance phase of acute lymphoblastic leukemia. GB Humphrey, DJ Fernbach, AA Razek, WJ Stuckey, D Komp, S George. <u>AACR</u> , 1973.	Leukemia		
680	Superiority of intrathecal (IT) methotrexate (MTX) with maintenance over intensive MTX or neuroaxis radiation in treating meningeal leukemia. MP Sullivan, TJ Vietti, B Humphrey, ME Haggard. <u>ASCO</u> , 1973.	Leukemia		
690/1	Response and toxicity in childhood leukemia when cyclophosphamide and l-asparaginase are added to vincristine-prednisone induction. K Komp, S George, V Land, D Fernbach, GB Humphrey, J Lowman. <u>ASCO</u> , 1973.	Leukemia		
7203	Adriamycin for induction of remission in acute leukemia in children. KA Starling, DH Berry, HA Britton, GB Humphrey, T Vats, AH Ragab. <u>ASH</u> , 1973.	Leukemia		

7220/1	Comparison of prednisone, vincristine, methotrexate and 6-mercaptopurine (POMP) versus vincristine and prednisone (V-P) induction in childhood acute leukemia. D Berry, J Pullen, T Vietti, M Sullivan, D Fernbach. <u>AACR</u> , 1973.	Leukemia
7375	The importance of cytochemical differentiation of acute leukemias. MT Shaw. <u>AACR</u> , 1973.	Leukemia

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1972**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Survival of hematopoietic and leukemic colony-forming cells <u>in vivo</u> following the administration of daunorubicin or adriamycin. A Razek, F Valeriote and T Vietti. <u>Cancer Research</u> 32:1496-1500, 1972.	Leukemia		
?	6-azauridine in combination chemotherapy in childhood acute myelocytic leukemia. TR Walters, JA Aur, D Hernandez, T Vietti and D Pinkel. <u>Cancer</u> 29(4): 1057-1060, 1972.	Leukemia		
688	Toxicity of l-asparaginase in children with advanced leukemia. VJ Land, WW Sutow, DJ Fernbach, DM Lane and TW Williams. <u>Cancer</u> 30(2):339-347, 1972.	Leukemia		
967	Cyclophosphamide, vincristine, arabinosyl cytosine and prednisone (COAP) combination chemotherapy for adult acute leukemia. JP Whitecar, GP Bodey, KB McCredie, JS Hart and EJ Freireich. <u>Cancer Chemo-therapy Reports</u> 56:543-550, 1972.	Leukemia		
ABSTRACTS PUBLISHED/PRESENTED				
?	The growth of colon-forming units (CFU) from bone marrows of normal and leukemic children in culture. AH Ragab, E Gilkerson and TJ Vietti. <u>CSCR</u> :1972.	Leukemia		
?	Quantitation and optimization of the time sequence for combination therapy of a transplantable murine leukemia. T Vietti and K Dale. <u>AACR</u> 13:78, 1972.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1971**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Vincristine, prednisone and daunomycin in acute leukemia of childhood. TJ Vietti, KA Starling, JR Wilbur, D Lonsdale and DM Lane. <u>Cancer</u> 27(3):602, 1971.	Leukemia		
680/3	Remission maintenance therapy for meningeal leukemia. Intrathecal methotrexate versus intravenous bis-nitrosourea. MP Sullivan, TJ Vietti, ME Haggard, MH Donaldson, JM Drall and EA Gehan. <u>Blood</u> 38(6):680-688, 1971.	Leukemia		
688	L-asparaginase therapy in children with advanced leukemia. WW Sutow, G Florentina, KA Starling, TE Williams, DM Lane and EA Gehan. <u>Cancer</u> 28(4):1971.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1970**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Therapy of acute leukemia with the combination of arabinosyl cytosine and cyclophosphamide. GP Bodey, V Rodriguez, J Hart, EJ Freireich. <u>Cancer Chemo Rep</u> , Part I, 54: 255-262, 1970.	Leukemia		
?	The treatment of acute leukemia in adults. GP Bodey, V Rodriguez, JP Whitecar Jr., J Hart, EJ Freireich. In: <u>Leukemia-Lymphoma, 14th Annual Clinical Conference on Cancer</u> , 1969, the M.D. Anderson Hospital and Tumor Institute. Year Book Medical Publishers, Inc., Chicago, IL:333-346, 1970.	Leukemia		
?	Perspectives in leukemia-lymphoma research. E Frei III. In: <u>Leukemia-Lymphoma (Collection of Papers Presented at the Fourteenth Annual Clinical conference on Cancer</u> , 1969, at the M.D. Anderson Hospital) Chicago, IL, Year Book Medical Publishers:365-373, 1970.	Leukemia Lymphoma		
?	Advances in the chemotherapy of acute leukemia. E Frei III, GP Bodey, JP Whitecar Jr., J Hart, EJ Freireich. In: RM Dutcher, Ed. <u>Proceedings of the IVth International Symposium on Comparative Leukemia Research, 1969</u> , Karger, Basel. Bibl Haemat 36:689-700, 1970.	Leukemia		
?	Advances in the chemotherapy of acute leukemia. E Frei III, GP Bodey, J Whitecar, J Hart, E Freireich. <u>Brit J Haemat</u> 36:589-700, 1970.	Leukemia		
?	Remission induction in adults with acute myelogenous leukemia. EJ Freireich, GP Bodey, JS Hart, V Rodriguez, JP Whitecar Jr., E Frei III. In: <u>Recent Results in Cancer Research</u> , Vol. 30, P. Rentchnick (ed), Springer-Verlag, Berlin:85-91, 1970.	Leukemia		
?	Potential for eradication of the cellular phase of acute leukemia. EJ Freireich, GP Bodey, JS Hart, J Trujillo, EM Hersh, JE Curtis, JP Whitecar Jr., E Frei III. In: <u>Progress in Antimicrobial and Anticancer Chemotherapy. Proceedings of the 6th International Chemotherapy Congress</u> , University of Tokoyo Press, Tokoyo, Japan: 645-649, 1970.	Leukemia		
?	Supportive therapeutic measures for patients under treatment for leukemia-lymphoma. EJ Freireich, GP Bodey, DS de Jongh, JE Curtis, EM Hersh. In: <u>Leukemia-Lymphoma (A collection of papers presented at the Fourteenth Annual Clinical Conference on Cancer</u> , 1969, at the M.D. Anderson Hospital and Tumor Institute, Houston, TX). Year Book Medical Publishers, Chicago, IL:275-284, 1970.	Leukemia Lymphoma		

?	Host defense mechanisms in lymphoma and leukemia. EM Hersh, JE Curtis, JE Harris, C McBride, R Alexanian, R Rossen. In: <u>Leukemia-Lymphoma. 14th Annual Clinical Conference on Cancer</u> , 1969, the M.D. Anderson Hospital and Tumor Institute, Houston, TX. Year Book Medical Publishers, Inc.:149-167, 1970.	Leukemia Lymphoma
?	L-asparaginase requirement and the effect of L-asparaginase on the normal and leukemic bone marrow. DHW Ho, JP Whitecar, Jr, JK Luce, E Frei III. <u>Cancer Research</u> 30: 466-472, 1970.	Leukemia
?	Remission induction in childhood leukemia with second course vincristine (NSC-67574) and prednisone (NSC-10023) therapy. DM Lane, ME Haggard, D Lonsdale, K Starling, MP Sullivan. <u>Cancer Chemotherapy Reports</u> , Part I, 54(2):113-118, 1970.	Leukemia
?	Chemotherapy for lymphoma. Current status. JK Luce. In: <u>Leukemia-Lymphoma, A collection of papers presented at the Fourteenth Annual Clinical conference on Cancer</u> , 1969, the M.D. Anderson Hospital and Tumor Institute, Houston, TX. Year Book Medical Publishers, Chicago, IL: 265-304, 1970.	Leukemia Lymphoma
?	Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission. AH Ragab, RS Frech, TJ Vietti. <u>Cancer</u> 25(3):580-584, 1970.	Leukemia
?	Immunoglobulin pattern in childhood leukemia. AH Ragab, JL Lindquist, TJ Vietti, SC Choe, CK Osterland. <u>Cancer</u> 26(4):890-894, 1970.	Leukemia
?	Comparative effects of the antitumor agents 5-(dimethyl-triazeno) imidazole-4-carboxamide and 1,3-bis(2-chloroethyl)-1-nitrosourea on cell cycle of L-1210 leukemia cells <u>in vivo</u> . S Shirakawa, E Frei III. <u>Cancer Research</u> 30:2173-2179, 1970.	Leukemia
?	Third and fourth remission induction with prednisone + vincristine in children with acute leukemia. K Starling, DM Lane, WW Sutow, RW Monto, WG Thurman. Letter to the Editor, <u>Cancer Chemotherapy Reports</u> , Part I, Vol. 54, No. 5:293-300, 1970.	Leukemia
?	Typhlitis: A complication of leukemia in childhood. ML Wagner, HS Rosenberg, DJ Fernbach, ES Singleton. <u>American J Roentgenology</u> 109:341-350, 1970.	Leukemia
?	Prolonged induction of arabinosyl cytosine in childhood leukemia. JJ Wang, OS Selawry, TJ Vietti, GP Bodey Sr. <u>Cancer</u> , Vol. 25, No. 1:1-6, 1970.	Leukemia
?	Cytogenetic studies in acute myelocytic leukemia with special emphasis on the occurrence of Ph' chromosome. J Whang-Peng, ES Henderson, T Knutsen, EJ Freireich, JJ Gart. <u>Blood</u> 36(4):448-457, 1970.	Leukemia
?	Treatment for acute leukemia in children. JR Wibur, WW Sutow, MP Sullivan, DM Mumford. <u>Leukemia-Lymphoma. A collection of papers presented at the 14th Annual Clinical Conference on Cancer</u> , 1969, the M.D. Anderson Hospital & Tumor Institute, Houston, TX. Year Book Medical Publishers, Chicago, IL:347-363, 1970.	Leukemia

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1969**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Cytosine arabinoside (NSC-63878) therapy for acute leukemia in adults. GP Bodey, EJ Freireich, RW Monto, JW Hewlett. <u>Cancer Chemotherapy Reports</u> 52:59-66, 1969.	Leukemia		
?	Hyperplenism due to disseminated candidiasis in a patient with acute leukemia. GP Bodey, D De Jongh, A Isassi, EJ Freireich. <u>Cancer</u> 24(2):417-429, 1969.	Leukemia		
?	Continuous analysis of acute leukemia data. EA Gehan, EJ Freireich. <u>Proceedings of the 37th Session of the International Statistical Institute</u> :213-215, 1969.	Leukemia		
?	The mechanism of induction of complete remission in acute myeloblastic leukemia in man. JS Hart, S Shirakawa, J Trujillo, E Frei III. <u>Cancer Research</u> 29:2300-2307, 1969.	Leukemia		
?	Clinical study of daunomycin and prednisone for induction of remission in children with advanced leukemia. CP Holton, TJ Vietti, AH Nora, MH Donaldson, WJ Stuckey Jr., WL Watkins, DM Lane. <u>New England Journal of Medicine</u> 280: 171-174, 1969.	Leukemia		
?	Clinical investigations in the treatment of meningeal leukemia: Radiation therapy regimens vs. conventional intrathecal methotrexate. MP Sullivan, TJ Vietti, DJ Fernbach, KM Griffith, TB Haddy, WL Watkins. <u>Blood</u> 34(3): 301-319, 1969.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1968**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Vincristine (NSC-67574) in the treatment of children with acute leukemia. AE Evans. <u>Cancer Chemotherapy Reports</u> 52(4):469-471, 1968.	Leukemia		
?	Vincristine in acute leukemia of childhood. ME Haggard, DJ Fernbach, TM Holcomb, WW Sutow, TJ Vietti, J Windmiller. <u>Cancer</u> 22(2):438-444, 1968.	Leukemia		
?	Vincristine (NSC-67574) therapy for acute leukemia in children. ME Haggard. <u>Cancer Chemotherapy Reports</u> 52(4):477-479, 1968.	Leukemia		
?	Clinical study of daunomycin (NSC-82151) in children with acute leukemia. CP Holton, D Lonsdale, A Nora, WG Thurman, TJ Vietti. <u>Cancer</u> 2(5):1014-1017, 1968.	Leukemia		
?	Effectiveness of vincristine (NSC-67574) against refractory leukemia in children. M Karon. <u>Cancer Chemotherapy Reports</u> 52(4):473-476, 1968.	Leukemia		
?	Combination of vincristine and prednisone in therapy of acute leukemia in children. WW Sutow, TJ Vietti, DJ Fernbach, DM Lane, MH Donaldson, DH Berry. <u>J Pediatrics</u> 73(3):426-430, 1968.	Leukemia		
ABSTRACTS PUBLISHED/PRESENTED				
?	Cytosine arabinoside therapy for acute myelogenous leukemia (AML). GP Bodey, JS Hart, EJ Freireich. <u>AACR</u> , Atlantic City, NJ, 1968.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1967**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Chemotherapy for acute leukemia in children: Comparison of cyclophosphamide (NSC-26271) and 6-mercaptopurine (NSC-755). DJ Fernbach. <u>Cancer Chemotherapy Reports</u> 51:381-387, 1967.	Leukemia		
?	Cyclophosphamide (NSC-26271) in the treatment of acute leukemia in children. T Holcomb. <u>Cancer Chemotherapy Reports</u> 51:389-392, 1967.	Leukemia		
?	Clinical studies of 6-methymercaptopurine riboside (NSC-40774) in acute leukemia. JK Luce, EP Frenkel, TJ Vietti, AA Isassi, KW Hernandez, JP Howard. <u>Cancer Chemotherapy Reports</u> 51(7):535-546, 1967.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1966**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Chemotherapy of acute leukemia in childhood. Comparison of cyclophosphamide and mercaptopurine. DJ Fernbach, KM Griffith, ME Haggard, TM Holcomb, WW Sutow, TJ Vietti, J Windmiller. <u>New England J Med</u> 275: 451-456, 1966.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1965**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	L-sarcosyn (NSC-8806) therapy for acute leukemia in children. TM Holcomb, DH Berry, ME Haggard, MP Sullivan, WL Watkins, J Windmiller. <u>Cancer Chemo-therapy Reports</u> 48:45-48, 1965.	Leukemia		
?	The response of acute childhood leukemia to an initial and second course of prednisone. TJ Vietti, MP Sullivan, DH Berry, TB Haddy, ME Haggard, RJ Blattner. <u>J Pediatrics</u> 66(1):18-26, 1965.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1964**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

?	Antileukemic activity of hydroxyurea (NSC-32065) and other urea derivatives. A Goldin, JM Venditti, JAR Mead, JP Glynn. <u>Cancer Chemotherapy Reports</u> 40:57-74, 1964.	Leukemia		
?	Phase II studies of hydroxyurea (NSC-32065) in adults: Leukemia. CC Shullenberger. <u>Cancer Chemotherapy Reports</u> 40:49-50, 1964.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1962**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Clinical evaluation of cyclophosphamide. A new agent for the treatment of children with acute leukemia. DJ Fernbach, WW Sutow, WG Thurman, TJ Vietti. <u>JAMA</u> 182(1):30-37, 1962.	Leukemia		
?	Clinical trials with cyclophosphamide in the treatment of acute leukemia in children. DJ Fernbach, WW Sutow, WG Thurman, TJ Vietti. <u>Cancer Chemotherapy Reports</u> 16:175-176, 1962.	Leukemia		
?	Actinomycin P2 therapy for acute leukemia in children. FS Porter, WG Thurman, TM Holcomb. <u>Cancer Chemotherapy Reports</u> 25:97-99, 1962.	Leukemia		
?	Uracil mustard therapy in acute leukemia in children. FS Porter, J Holowach, WG Thurman. <u>Cancer Chemotherapy Reports</u> 18:79-82, 1962.	Leukemia		
?	Evaluation of the comparative effectiveness of myleran and 6-MP in the management of patients with chronic myelocytic leukemia. CC Shullenberger. <u>Cancer Chemotherapy Reports</u> 16:203-207, 1962.	Leukemia		
?	Studies of ACTH, hydrocortisone and 6-mercaptopurine in the treatment of children with acute leukemia. WW Sutow, ME Haggard, RJ Blattner, FS Porter, DE Bergsagel, KM Griffith. <u>J Pediatrics</u> 61(5):693-701, 1962.	Leukemia		
?	Comparative evaluation of ACTH and hydrocortisone used alone and in sequence with 6-mercaptopurine in the treatment of acute leukemia in children. Preliminary report of a cooperative study. WW Sutow. <u>Cancer Chemotherapy Reports</u> 16:431-434, 1962.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1961**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	A method for evaluation of disease and treatment in chronic leukemia. SW Ross, EJ Macdonald, P Davis, J Hammarstei, WC Levin. <u>J Lab Clin Med</u> 58(4):559-579, 1961.	Leukemia		
?	Clinical trials with AB-100 in children with acute leukemia. Preliminary report. WG Thurman, DJ Fernbach, TM Holcomb, WW Sutow, JA Whitaker. <u>Cancer Chemotherapy Reports</u> 12:105-107, 1961.	Leukemia		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1960**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Preliminary report. Clinical trials with cyclophosphamide in children with acute leukemia. DJ Fernbach, WW Sutow, WG Thurman, TJ Vietti. <u>Cancer Chemotherapy Reports</u> 8: 102-105, 1960.	Leukemia		